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"If thou examinest a man for illness in his cardia and he has pains in his arms, and in his 
breast and in one side of his cardia…it is death threatening him"
— Description of cardiac ischemia in the Ebers Papyrus (1,500 B.C.E.)
 General introduction and outline of thesis
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9General introduction & outline thesis
1Cardiovascular Diseases: from mummies to present timeThe Edwin Smith and Ebers Papyri (1,550 B.C.E.) are probably one of the oldest and  rst 
descriptions of atherosclerotic cardiovascular diseases (CVD) in the ancient civilization 
of Egypt. (1, 2) Autopsies of mummies performed by Johann Czermak, (3) Marc Armond 
Ru er, (4) Samuel George Shattock, (5) and Allen Long (6) provided the  rst scienti c evidence 
of atherosclerosis in ancient Egyptians. Using modern imaging techniques (i.e. computed 
tomography), the Horus study (named after Horus, the ancient Egyptian god) extended 
these observations and demonstrated that atherosclerosis was not only present in ancie nt 
Egypt, (7, 8) but also in ancient cultures of Peru, American Southwest, and the Aleutian 
Islands. (9) These observations suggest that the development of atherosclerosis and CVD 
are as old as humankind.
The morbidity burden has shifted from communicable diseases (e.g. infectious diseases) 
to non-communicable diseases (e.g. CVD, cancer, and respiratory diseases) since the 
20th century. (10) Especially the burden of CVD rose to pandemic proportions. (11) Despite 
declining mortality rates of CVD since the 1960s (Figure 1.1), (12) CVD was still accountable 
for more than 17 million deaths worldwide in 2013. (11) This number is expected to grow 
to 22.2 million by 2030. (13) In Europe alone, CVD represents the most common cause of 
mortality with >4 million deaths per year. (14) Ischemic heart diseases represent the most 
prevalent cause (47%) of the total cardiovascular deaths in 2013. (11) The estimated annual 
costs for CVD were $316.6 billion globally in 2012, (11) making CVD costlier than any other 
disease. (11) Lowering the burden of CVD has been a public health priority for more than 
50 years and will continue to be in the near future. (15) 
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Figure 1.1 Since the 1960s, mortality rates of CVD (A) declined in the Netherlands (--) and United States 
of America (—), whilst hospital discharges (B) remained relatively steady in the USA or even 
increased in the Netherlands. Source: Organisation for Economic Cooperation and Development 
(OECD). (12) Age-standardised (death) rates per 100,000 people for selected causes are calculated 
by the OECD.
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Determinants of cardiovascular diseases
In order to prevent CVD, we must understand underlying (risk) factors involved in the 
development of CVD. In general, determinants of CVD can be divided into 1) non-modi able 
factors and 2) modi able factors. (16-19) Non-modi able risk factors are for example sex, 
ethnic origin, and age. From these factors, ageing is considered one of the most important 
risk factors for CVD (Figure 1.2), (18) which is highly relevant in the rapidly ageing population 
in most Western countries. (20) Modi able risk factors include tobacco consumption, 
physical inactivity, unhealthy diet, and being overweight/obese. (17) Contrary to the decline 
in tobacco consumption, (21) the prevalence of overweight and obesity increased (13) from 
921 million in 1980 to 2.1 billion in 2013. (22) Currently, more than 50% of the adult Dutch 
population is overweight or obese. (23) Being overweight or obese can result from several 
factors, such as unhealthy dietary habits and/or physical inactivity. (13, 24) Especially, physical 
inactivity is a major public health problem of the 21st century (25) and represents a strong 
independent risk factor for the development of CVD. (26-30) More than 40% of the American 
population (31) and more than 30% of the Dutch population (32) did not meet the guidelines 
for physical activity in 2014 (Figure 1.2). 
Figure 1.2 A. Proportion of adults not meeting the recommended physical activity guidelines in the United 
States of America (line) and the Netherlands (dashed line). B. Prevalence of cardiovascular 
diseases among di erent age categories in the United States of America (National Health 
and Nutrition Examination Survey: 2009–2012). Source: Research institute TNO, (33) Centers for 
Disease Control and Prevention, (31) and Moza arian et al. (2016). (16)
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Physical activity: the key component for a healthy lifestyle?
Hippocrates (460 – 370 B.C.E.) already observed that a physically active lifestyle is an 
important factor to promote healthy aging. (34) Physical activity lowers the risk for CVD, 
whereas a physical inactive (i.e. sedentary) lifestyle increases the risk for CVD. (34) First 
scienti c evidence that physical activity lowers the risk for CVD, originates from two giants 
11
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1in the  eld of physical activity epidemiology: Profs. Jeremiah Morris (1910 – 2009) and Ralph Pa enbarger (1922 – 2007). The London Transport Workers study by Morris et al. was focussed on the relation between occupational-related physical activity patterns and 
cardiovascular mortality. In this study, Morris and colleagues demonstrated that physically 
active individuals (e.g. bus conductors and postmen) were two times less likely to su er 
from (the consequences of) coronary heart diseases compared to their physically inactive 
peers (e.g. bus drivers and telephonists, Figure 1.3). (35, 36) The studies of Prof. Pa enbarger 
were focussed on the impact of engagement in (leisure time) exercise training and 
(cardiovascular) mortality. Pa enbarger and colleagues initiated the landmark Harvard 
alumni study, (37, 38) which included 16,936 males who enrolled at the Harvard University 
between 1916 and 1950. Using this data set, Pa enbarger found that regular engagement 
in moderate-to-high intensity exercise training lowers the risk for premature mortality 
between 22% and 48% compared to a sedentary lifestyle (Figure 1.3). (38)
The epidemiologic research of Profs. Morris and Pa enbarger provided the  rst rationale 
for health-related (physical) activity recommendations. Controlled exercise training studies 
were used to quantify the frequency, intensity, and duration or the volume of physical 
activities recommended to improve cardiovascular health. (39) Probably the  rst exercise 
study that provided the groundwork for intensity recommendations was conducted 
by Karvonen and colleagues in 1957. Karvonen et al. demonstrated that an exercise 
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Figure 1.3 Landmark studies by A. Prof.  Jeremiah Morris (London Transport Workers) and B. Prof. Ralph 
Pa enbarger (Harvard alumni study). Prof.  Morris investigated the outcome of  rst clinical 
episodes of coronary heart-disease (CHD) in relation to occupational related physical activity 
among drivers and male conductors (aged 35-64) of central buses, trams, and trolleybuses of 
London transport executive in 1949-1950. Prof.  Pa enbarger studied the relative risks of (all 
cause) death among 16,936 Harvard Alumni, 1962 to 1978 according to (leisure-time) physical 
activity. Data adapted from Morris et al. (35) and Pa enbarger et al. (38)
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intensity of >60% of heart rate reserve (i.e. moderate-to-vigorous intensity) improved the 
physical work capacity (i.e.  tness). (40) Many exercise-intervention studies followed and 
indicated that moderate-to-vigorous intensity physical activities are required to improve 
cardiovascular health and lower the risk for future CVD. (39, 41) Physical activity is therefore 
considered an important determinant to promote healthy ageing. (27, 37, 42-46) The World 
Health Organisation (WHO) and most national governments recommend the population 
to perform at least 150 minutes of moderate-intensity exercise or 75 minutes of vigorous-
intensity exercise per week to improve cardiovascular and global health. (47-49) 
Too much exercise hypothesis: can we have too much of a good thing?
 The inverse relation between the amount of physical activity and the risk of CVD suggest 
‘the more, the better’. A recent comprehensive review however, indicated that engaging 
in vigorous intensity exercise training for a prolonged period of time might damage the 
heart. (50) The potential ‘cardiotoxic’ e ects of exercise are controversial with respect to the 
compelling evidence of the exercise bene ts. Whether the potentially detrimental e ects 
of vigorous-intensity exercise training on the heart directly translate to changes in risk for 
development of CVD is unclear. 
Several studies explored the dose-response relation between exercise volume and the CVD 
mortality risk, which has been described as either a ‘J’-, ‘U’-, or ‘S’-shaped curve. (38, 51-56) These 
curves suggest the same: high doses of exercise may abolish (some of) the bene cial health 
e ects (Figure 1.4). (51, 52) One of the  rst studies indicating that higher exercise volumes 
might abolish the bene ts of exercise against premature mortality, is the previously 
mentioned Harvard Alumni study by Pa enbarger et al. (38) The study demonstrated after 
a follow up period of 12-16 years among 16,936 Harvard Alumni, mortality rates declined 
as energy expenditure increased from less than 500 (hazard ratio [HR]:1.00) to 3,500 (HR: 
0.46) kcal/wk. However, compared to 500-3,500 kcal, mortality rates beyond 3,500 kcal 
(i.e. >8 hours/week) slightly increased (HR: 0.46 to 0.62, respectively). (38) Noteworthy, these 
‘extreme’ physically active individuals still had a lower mortality risk compared to physically 
inactive individuals. 
Currently, there is no consensus whether high exercise volumes are deleterious for 
cardiovascular health and increase morbidity risk. One large meta-analysis, (53) pooling 
6 di erent longitudinal studies in total including 661,137 individuals demonstrated 
that meeting the recommended physical activity guidelines was associated with a 31% 
reduction in mortality risk (HR [95%CI]: 0.69 [0.67-0.70]) and further decreased to 39% 
when the guidelines were 3-5 times exceeded (HR [95%CI]: 0.61 [0.59-0.62]). (53) 
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1Interestingly, the study found no evidence of harm at 10 or more times the recommended guidelines (HR [95%CI]: 0.69 [0.59-0.78]). (53) Other studies contradict these data and suggested that at the upper end of physical activity dose, mortality rates did not di er (51) or 
even increased (52) compared to sedentary individuals. The main question remains whether 
extreme forms of exercise abolish none, some, or all bene ts associated with regular 
exercise training and warrants further exploration. 
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Figure 1.4 The relation between the amount of physical activity and risk for cardiovascular diseases. At 
the upper end of the physical activity spectrum, recent studies suggest an increased risk for 
cardiovascular diseases: 'too much exercise hypothesis'
Benefits of exercise: mediating factors
Despite the possible existence of a U-shape relation between exercise and morbidity/
mortality, exercise training is a powerful strategy to lower the risk for future CVD. However, 
athletes are not exempt from atherosclerotic coronary events. (57, 58) Post-mortem studies 
in the sixties demonstrated a signi cant relation between the amount of atherosclerotic 
plaques and age, which was independent of physical activity patterns. (59, 60) In autopsies 
of more than 200 adults aged 30-60 years, it was demonstrated that the degree of 
coronary atherosclerosis increased with age, but did not di er between physically active 
and sedentary subjects. (60) In a recent study, 90% of marathon runners demonstrated 
atherosclerotic plaques in the carotid and coronary arteries. (61) This is quite remarkable 
since one would expect that an active lifestyle prevented or attenuated the development 
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atherosclerosis and these  ndings indicate that the bene ts of exercise training are 
mediated via other (cardiovascular risk) factors or mechanisms. 
Ample evidence suggests that exercise training induces favourable changes in the 
cardiovascular risk factor pro le. (62, 63) Mora et al. demonstrated that approximately 60% 
of the bene cial e ects of exercise are attributed to favourable changes in traditional 
risk factors such as lipid pro le, body weight, and blood pressure. (63) The remaining 40% 
indicates a ‘risk factor gap’ (Figure 1.5). Several authors (64, 65) suggest that the remaining 
exercise bene ts relate to improvement in the vasculature, such as a smaller intima-
media thickness, increased vascular compliance, and improved endothelial function. 
These vascular improvements represent a ‘vascular conditioning’ e ect, which might 
attenuate the risk for cardiovascular morbidity. (64, 66) Other exercise-induced cardiovascular 
adaptations relate to improved cardiac function, (67, 68), reduction in the formation of 
advanced glycation endproducts, (69) increased ischemia reperfusion tolerance, and infarct 
sparing after myocardial infarction. (70-73)
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Figure 1.5 Exercise-induced bene ts are for 60% explained via various cardiovascular risk factors (adapted 
from Mora et al. (63)). The remaining 40% may, in part, relate to improvement in the function and 
structure of the (coronary) vasculature (adapted from Thijssen et al. (66)).
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1General aim of this thesisVeteran athletes (i.e. those who are physically active for the most part of their lives) might 
provide additional insight in the e ects of exercise training on cardiovascular function and 
the prevention of CVD, and are therefore a unique group to investigate. The general aim of 
this thesis was to evaluate the impact of lifelong exercise training on cardiovascular health. 
For this purpose, we have conducted a mixture of epidemiological and physiological 
studies. First, we assessed the relation between extreme doses of lifelong exercise training 
and cardiovascular health. We hypothesized that there will be an inverse relation between 
exercise dose and the risk for adverse cardiovascular events. Second, we assessed whether 
the engagement in lifelong exercise training results in an improvement in cardiovascular 
health parameters beyond traditional cardiovascular risk markers. We hypothesized that 
veteran athletes will have a superior cardiovascular health, which is demonstrated by 
improved ischemic tolerance, vascular function, and antioxidant pro le. 
Outline of this thesis
Despite the well-established bene ts of exercise training, some studies raise concerns 
that extreme volumes of exercise training have detrimental e ects on cardiovascular 
health. (51, 52) In the  rst part of this thesis, the dose-response relation between the volume 
of exercise training and cardiovascular health is examined. First, Chapter 2 discusses 
the relation between exercise training and longevity. Secondly, Chapter 3 explores the 
relation between lifetime exercise dose and the prevalence of cardiovascular risk factors 
and cardiovascular events in a large cohort of Dutch amateur athletes. 
Early detection of people at risk for CVD is of paramount importance to prevent life treating 
events, such as stroke or myocardial infarction. Several guidelines recommend the body 
mass index (BMI) to evaluate the cardiovascular risk pro le in the general population. (74, 75) 
Exercise training, however, does not necessarily lower body weight and using the BMI 
among physically active individuals might overestimate their cardiovascular risk. Chapter 4 
describes whether novel body indices (‘a body shape index’ and ‘body roundness index’) 
may improve disease risk evaluation among physically active individuals. High-resolution 
ultrasound imaging techniques are other popular methods to assess cardiovascular risk by 
evaluating the properties of the arteries. (76) Compound strain imaging is a promising novel 
ultrasound method for the noninvasive assessment of vascular properties. The technique 
has the potential to contribute in an early risk strati cation of the individual patient 
without apparent vascular abnormalities (e.g. stenotic arteries). (77) Chapter 5 describes the 
association between compound strain imaging and cardiovascular diseases.
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Exercise training exerts many favourable cardiovascular health bene ts, which are often 
described as improvements in ‘traditional’ cardiovascular risk factors. The second part of 
this thesis focuses on the bene ts of exercise training from a physiological perspective. 
Advanced glycation endproducts (AGEs) are a complex group of modi ed proteins or 
lipids that are formed by a process of non-enzymatically glycation and oxidation. (78, 79) 
Highly reactive dicarbonyls are involved in the fast formation of AGEs and accumulation 
of dicarbonyls is known as dicarbonyl stress. High dicarbonyl stress and concentration 
of AGEs are linked to the development of diabetes and cardiovascular diseases. (80-82) 
Chapter 6 describes the e ects of exercise on highly reactive dicarbonyl stress and the 
formation of advanced glycation endproducts. 
Ischemic events are the most common cardiovascular events and reperfusion is essential 
for the survival of ischemic tissue, but causes additional damage to the endothelium 
(i.e. ischemia-reperfusion injury). (83) Ischemic preconditioning refers to short repetitive 
episodes of ischemia, which can protect against ischemic-reperfusion injury, (84-86) but the 
e  cacy of ischemic preconditioning is lost at older age. (87) Chapter 7 explores whether 
lifelong exercise training is associated with attenuated endothelial ischemia reperfusion, 
and relates to preservation of the e  cacy of Ischemic preconditioning in veteran athletes.
Despite the fact that exercise training lowers the risk for future events, athletes are not 
exempted from a myocardial infarction. (57, 58) Chapter 8 discusses whether veteran post 
myocardial athletes have an improved vascular function (endothelial function) and reduced 
vascular wall thickness compared to sedentary post-myocardial infarction individuals. 
Directly after a myocardial infarction the pathological left ventricular remodelling begins. 
Chapter  9 assesses the hypothesis that lifelong exercise training is associated with an 
attenuated and/or maintained left ventricular function after myocardial infarction. 
Methods applied in this thesis
Epidemiology, Nijmegen Exercise Study
The Nijmegen Exercise Study (www.nijmegenexercisestudy.com) is an ongoing large-
population based study which was initiated by the Department of Physiology and the 
Department for Health Evidence of the Radboud university medical center in June 2011. 
Each year, participants of the Four Days Marches and the Seven Hills Run receive an invitation 
to  ll in an online questionnaire regarding their medical health and physical activities. The 
overall aim of the Nijmegen Exercise Study is to examine the e ects of physical activity on 
general health and various disease outcomes in the general population. More details can 
be retrieved from Chapters 3 and 4.
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1Physiology, laboratory measurementsMedical screening. A physician screened the participants by taking a detailed medical history, 
physical examination, and 12-lead electrocardiogram. Blood samples were obtained, 
under fasting conditions, from an antecubital vein for the analysis of total cholesterol, 
high-density lipoprotein (HDL), low-density lipoprotein (LDL), triglycerides, glucose, and 
glycated hemoglobin (HbA1c). More details can be retrieved from Chapters 6, 8, and 9.
Incremental maximal cycling test. The maximal oxygen uptake (i.e. cardiorespiratory  tness) 
(VO2peak, mLO2/min/kg) was assessed via an incremental maximal cycling test. During the 
test, heart rate (12 lead-electrocardiogram), oxygen uptake (VO2 [ml/min]), carbon dioxide 
output (VCO2 [ml/min]), and respiratory exchange ratio (RER) were continuously measured 
(CPET, Cosmed v9.1b, Italy). Lactate concentration (mmol/L) was measured via a capillary 
blood sample taken one-and-a-half minute after exercise cessation (Arkray, type LT-1730, 
Japan). More details can be retrieved from Chapters 6, 8, and 9.
Vascular measurements. All vascular measurements were performed in a temperature-
controlled room. Participants followed a ≥6h fasting period, ≥18h abstinence from ca eine, 
alcohol, vitamin supplements, and performed no vigorous physical activity at least 24h 
before the test. Measurements began after a resting period in the supine position for at 
least 15 minutes. (88) Below, short descriptions of the applied vascular measurements can 
be found and more details can be retrieved from Chapters 5, 6, 7, and 8.
Endothelial (in)dependent measurements were performed according to recent guidelines 
for vascular assessment and in a temperature-controlled room (88) using a T3000 ultrasound 
system (Terason Teratech Corporation, Boston, United States) equipped with a 10-MHz 
12L5 linear transducer. As measures for vascular function the following indices were 
evaluated: 1) brachial artery endothelium-dependent  ow-mediated dilatation (FMD; 
an index of endothelial function, 2) brachial artery conduit artery vasodilatory capacity 
(CADC; an index of arterial structure),  and 3) brachial artery endothelium-independent 
dilatation (GTN; an index of vascular smooth muscle function). 
Central and peripheral arterial sti ness were measured using a three-lead electrocardiogram 
and an Echo-Doppler ultrasound machine (Waki Doppler, Atys Medical, Soucieu en Jarrest, 
France) at the left carotid artery, right common femoral artery, and radial artery. (89)
Intima-media thickness (IMT; an index for vascular structure) was measured in left common 
carotid, brachial, and super cial femoral artery using a T3000 ultrasound system (Terason 
Teratech Corporation, Boston, United States) equipped with a 10-MHz 12L5 linear 
transducer. (90, 91)
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Compound strain imaging is a novel non-invasive ultrasound-based technique that 
measures deformations of the arteries in transverse imaging planes using an Accuvix V10 
ultrasound system (Samsung Medison, Seoul South Korea) equipped with a 9 MHz (L5-13) 
linear transducer. (92)
Echocardiographic measurements. Participants underwent an extensive echocardiographic 
assessment. Two-dimensional Doppler and four-dimensional images were obtained by an 
experienced cardiologist using a Vivid E9 ultrasound system (General Electric Healthcare, 
Norway). All measurements were performed according to the American Society of 
Echocardiography (ASE) guidelines. (93) Data were transferred to a workstation for o  ine 
analysis (EchoPac BT113, General Electric Healthcare, Norway). More details can be 
retrieved from Chapter 9.
19
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 TO THE EDITOR
We read, with great interest, the paper by Schnohr et al., (1) who investigated the association 
between jogging and long-term all-cause mortality. The investigators reported that light 
and moderate joggers had lower mortality rates (HR: 0.22, 95%-CI: 0.10 to 0.47 and HR: 0.66, 
95%-CI: 0.32 to 1.38, respectively) compared with sedentary nonjoggers, whereas these 
health bene ts were absent in strenuous joggers (HR: 1.97, CI: 0.48 to 8.14). Hence, the 
investigators concluded that a U-shaped association between exercise dose and all-cause 
mortality was present, which suggested an upper limit of the health bene ts of exercise. 
Interestingly, strenuous exercise was established as >4 hours of jogging per week at a 
fast pace. Although this amount of physical activity clearly exceeded the current exercise 
recommendations, (2) these doses were typically observed in amateur and professional 
athletes. Other studies investigated the life expectancy of athletic populations. Finnish 
skiers (3) and world-class endurance athletes (4) demonstrated an increased life expectancy 
of 2.8 to 6 years compared with reference cohorts. A study including 15,174 Olympic 
medallists con rmed these  ndings, and found 2.8 years of increased life expectancy 
compared to matched cohorts from the general population. (5) Furthermore, a large 
Swedish study reported a 52% reduction of all-cause mortality amongst participants of the 
Vasaloppet cross-country ski-race, with the highest life expectancy for older participants 
and athletes who participated in multiple races. (6) 
These  ndings suggest that high volumes of exercise training improve longevity and 
are in contradiction with the U-shaped association between exercise dose and all-cause 
mortality as suggested by Schnohr et al. The small sample size of the strenuous jogger 
group (n=40), with only 2 deaths during the 12 years of follow-up, may contribute to these 
con icting  ndings. In addition, the lack of insight in the cause of death may confound 
the results; if only one of the 2 death cases is caused by a non-natural death (e.g. accidents, 
suicide), the study outcomes would be completely di erent. Finally, the arbitrarily chosen 
cut-points for classi cation of the light, moderate, and strenuous jogger groups may not 
appropriately re ect the spectrum of light to extreme doses of exercise training.  
Therefore, we believe, that the evidence for an upper limit (>4 hrs/week) of exercise health 
bene ts and associated all-cause mortality is premature. With physical inactivity as one 
of the most in uential risk factors for worldwide morbidity and mortality, (7) we would 
recommend to keep on running.
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"If you do not know where you are going, any road will get you there"
— Cheshire Cat (Alice in Wonderland)
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Objective
To determine the relation between lifelong exercise dose and the 
prevalence of cardiovascular morbidity.
Patients and Methods
From June 1, 2011, through December 31, 2014, 21,266 individuals 
completed an online questionnaire regarding their lifelong exercise 
patterns and cardiovascular health status. Cardiovascular disease (CVD) 
was de ned as a diagnosis of myocardial infarction, stroke, or heart 
failure. Cardiovascular risk factors (CVRF) were de ned as a diagnosis of 
hypertension, hypercholesterolemia, or type 2 diabetes. Lifelong exercise 
patterns were measured over a median of 32 years for 405 patients with 
CVD, 1,379 patients with CVRFs, and 10,656 controls. Participants were 
categorized into nonexercisers and quintiles (Q1 to Q5) of exercise dose 
(metabolic equivalent of task [MET] minutes per week).
Results
The CVD/CVRF prevalence was lower for each exercise quintile compared 
with nonexercisers (CVD: nonexerciser, 9.6% vs. Q1: 4.4%, Q2: 2.8%, Q3: 
2.4%, Q4: 3.6%, Q5: 3.9%; P<0.001; CVRF: nonexercisers, 24.6% vs. Q1: 
13.8%, Q2: 10.2%, Q3: 9.0%, Q4: 9.4%, Q5: 12.0%; P<0.001). The lowest 
exercise dose (Q1) signi cantly reduced CVD and CVRF prevalence, but 
the largest reductions were found at 764-1,091 MET minutes per week 
for CVD (adjusted odds ratio=0.31; 95% CI, 0.20-0.48) and CVRF (adjusted 
odds ratio=0.36; 95% CI, 0.28-0.47). The CVD/CVRF prevalence did not 
further decrease in higher exercise dose groups. Exercise intensity did 
not in uence the relation between exercise patterns and CVD or CVRFs. 
Conclusion
These  ndings demonstrate a curvilinear relation between lifelong 
exercise patterns and cardiovascular morbidity. Low exercise doses can 
e ectively reduce CVD/CVRF prevalence, but engagement of exercise for 
764 to 1,091 MET minutes per week is associated with the lowest CVD/
CVRF prevalence. Higher exercise doses do not yield additional bene ts. 
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INTRODUCTION
Physical inactivity is considered a major modi able risk factor for all-cause mortality, (1, 2) 
whereas habitual physical exercise reduces the risk of cardiovascular morbidity and 
mortality. (3, 4) Regular exercise is also associated with increased survival in the general and 
the athletic populations. (5-7) Therefore, the W orld Health Organization and the Centers for 
Disease Control and Prevention recommend that adults engage in at least 150 minutes 
of moderate-intensity exercise or 75 minutes of vigorous-intensity exercise per week for 
optimal cardiovascular and global health. (8-10) These guidelines also state that there is even 
more bene t from 300 minutes of moderate-intensity exercise or 150 minutes of vigorous-
intensity exercise per week. 
 Such recommendations suggest increasing bene t with increasing exercise dose, but recent 
studies suggest a potential U-shaped association, indicating that high doses of exercise 
may abolish the bene cial health e ects. (11, 12) Results of the Copenhagen  Heart  Study 
indicate that vigorous joggers have similar mortality rates as sedentary nonjoggers (hazard 
ratio: 1.97; 95% CI: 0.48-8.14 and hazard ratio: 0.66; 95% CI: 0.32-1.38, respectively). (11) The 
Million Women Study indicates that d aily s trenuous activities increase the risk for stroke and 
venous thromboembolism compared with strenuous activities performed for 2-3 sessions 
per week. (12) The notion that exercise might increase the risk for cardiovascular morbidity 
is striking, but strong evidence is currently lacking. 
To con rm or reject the U-shaped association between exercise and cardiovascular 
morbidity, this study aimed to determine the relation between lifelong exercise dose 
and the prevalence of cardiovascular morbidity (myocardial infarction, stroke, and heart 
failure) in a physically active population. We collected data from 21,266 participants of the 
Nijmegen Exercise Study and hypothesized that high lifelong exercise doses relate to a 
decrease in the prevalence of cardiovascular morbidity.
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METHODS
St udy design and study population
The Nijmegen Exercise Study is a population-based study of participants in Dutch sport 
events (International Nijmegen Four Days Marches and Seven Hills Run) and their family 
members and friends. The study is designed to examine the impact of a physically active 
lifestyle on health, quality of life, and the development and progression of cardiovascular 
disease (CVD). From June 1, 2011, through December 31, 2014, inactive and active 
participants were recruited via newsletters and internet advertisements. Participants 
completed an online questionnaire about demographic characteristics, anthropometric 
measures, lifestyle factors, lifelong exercise patterns, cardiovascular health status, and 
family history of CV D. To assess the impact of lifelong physical exercise patterns on 
cardiac morbidity, participants age 35 or older were included in the present study. The 
study adhered to the Declaration of Helsinki. The Local Committee on Research Involving 
Human Subjects, region Arnhem-Nijmegen, the Netherlands, approved the study, and all 
participants gave their written informed consent.
Lifestyle factors
Participants were asked about their smoking status (never, former, or current) and the 
highest level of education they completed. Level of education was categorized as low 
(elementary school or basic vocational education), intermediate (secondary vocational 
education), or high/academic (higher professional education or academic education).
History of cardiovascular diseases
Participants were asked whether (yes/no) and when (age) their physician diagnosed CV D 
(myocardial infarction, stroke, or heart failure) or presence of cardiovascular risk factors 
(CVRF) (hypertension, hypercholesterolemia, or diabetes [type 2]). All participants were also 
queried about their (cardiovascular) medication use. To validate the CVD/CVRF diagnosis, 
we performed a cross-check with medication use. Participants with CVD or CVRF, who 
did not report cardiac medication use were excluded from the study. Participants were 
allocated to the control group if they had no cardiac medical history and did not use cardiac 
medication. When both CVD and CVRF were diagnosed, the participant was allocated to 
the CVD group. Participants with congenital heart disease, de ned as diagnosis of CVD 
before the age of 35 years, were excluded from further analysis (Figure 3.1). Participants 
were also asked whether CVD was present in their immediate biological family (de ned as 
the participant’s parents, brothers, and sisters). 
35
Lifelong exercise patterns and cardiovascular health
3
Lifelong exercise patterns
The lifelong exe rcise patterns before CVD/CVRF diagnosis (patients) or before study 
participation (controls) were evaluated via an exercise history questionnaire, distinguishing 
four age-periods: 1) 18 to 29 years, 2) 30 to 49 years, 3) 50 to 64 years, and 4) 65 years 
and older. In these categories, participants were asked per period whether (yes/no) 
they performed exercise with the corresponding 1) exercise time (hours) per week and 
2) self-perceived intensity (light/moderate/vigorous). Participants who did not complete 
the exercise questionnaire were excluded from the  nal analysis. Based on Ainsworth’s 
compendium of physical activities, (13) we assigned a metabolic equivalent of task (MET) 
value of 2.5 for light-, 4.5 for moderate-, and 8.5 for vigorous-intensity exercise. MET minutes 
were calculated by multiplying the exercise time in minutes with the accompanying MET 
score of the self-perceived intensity. (13) 
The average weekly amount of lifelong exercise (MET minutes per week) was calculated 
between age 18 years and age at CVD/CVRF diagnosis for patients. Calculations were 
made for control participants between age 18 years and age at study participation. 
Participants were classi ed into 6 groups: nonexercisers and quintiles of weekly exercise 
dose (MET minutes per week). 
Data analysis
The characteristics of nonexercisers and exercisers are summarized using means ± standard 
deviations or counts and proportions. The  prevalences of CVD and CVRF were determined 
for each exercise dose quintile. Logistic regression was used to calculate the odds ratios 
(ORs) of CVD or CVRFs with nonexercisers as the reference category. In the logistic 
regression analysis, we adjusted for the following potential confounders: age at CVD/CVRF 
diagnosis (patients) or age of study participation (controls), sex, smoking status, level of 
education, and CVD family history. To determine the impact of intensity on CVD or CVRF 
prevalence across exercise dose quintiles, the proportion of light, moderate, and vigorous-
intensity were calculated per exercise dose quintile. The analysis was performed via a two-
way analysis of variance, with factors 1) CVD/CVRF (yes/no) and 2) exercise dose quintiles. 
All statistical analyses were performed using SPSS 21.0 software (IBM Corp. Released 
2012. IBM SPSS Statistics for Windows, Version 21.0. Armonk, NY: IBM Corp.). Statistical 
signi cance was assumed at P<0.05 (two-sided).
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RESULTS
Study population
A total of 21,266 participants completed the online questionnaire. After the exclusion 
of participants with missing data, aged less than 35 years, or with type I diabetes, 
12,440  participants were available for analysis (Figure 3.1). We calculated the average 
weekly lifelong exercise dose over a median of 32 years [interquartile range Q25–Q75: 26–39 
years] for 405 CVD cases, 1,379 CVRF cases, and 10,656 controls. The CVD sample most 
frequently had a myocardial infarction (n=207, 51%), followed by heart failure (n=122, 
30%) and stroke (n=76, 19%) (Table 3.1). 
Excluded CVD cases (n 174, 30%)
- Missing data:
 - Exercise history (n 54)
 - Education  (n 1)
 - Smoking  (n 32)
 - Medication use (n 51)
- Presence CVD < 35 years (n 36)
Excluded CVD cases (n 1,973; 59%)
- Missing data:
 - Exercise history (n 243)
 - Education  (n 8)
 - Smoking  (n 160)
 - Medication use (n 1,135)
- Presence CVRF < 35 years (n 427)
Controls
(n 11,688)
Individuals completed the online questionnaire
n 21,266
2011
n 10,687
2012
n 4,858
2013
n 3,730
2014
n 1,991
Excluded participants (n 5,647; 27%)
- Missing data
 - Data of Birth   (n 13)
 - Cardiovascular history (n 1,700)
- Age < 35 years   (n 3,871)
- Diabetes type 1   (n 63)
CVD cases
(n 579)
CVRF cases
(n 3,352)
Non-exercisers Q1 Q2 Q3 Q5Q4
Participants of the 
Four Days Marches
Participants of the 
Seven Hills Run
Family and friends 
of the participants
n 12,440 included in statistical analysis
Exercise quintilesReference
Study population
(n 15,619; 73%)
Excluded CVD cases (n 1,032; 9%)
- Missing data:
 - Exercise history (n 641)
 - Education  (n 14)
 - Smoking  (n 377)
Controls
(n 10,656; 91%)
CVD cases
(n 405; 70%)
CVRF cases
(n 1,379; 41%)
Figure 3.1 Flowchart for enrollment of the study population. 21,266 participants completed the online 
questionnaire. Initially, 5,647 participants were excluded from the study due to missing data 
(n=1,713), age younger than 35 years (n=3,871), diabetes type 1 (n=63). 15,619 participants 
were divided over three groups: patients with cardiovascular disease (CVD), patients with 
cardiovascular risk factors (CRVFs), and controls. We excluded participants with missing 
data for exercise history (n=938), education level (n=23), smoking status (n=569), cardiac 
medication use (n=1,186), and diagnosis of CVD or CVRFs before 35 years of age (n=463). The 
 nal study consisted of 405 patients with CVD, 1,379 patients with CVRFs, and 10,656 controls. 
CVD = cardiovascular disease, CVRF = cardiovascular risk factors.
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The CVRF sample most frequently had hypertension (n=992, 72%), followed by 
hypercholesterolemia (n=330, 24%) and diabetes (n=57, 4%) (Table 3.2). In general, 
exercisers had a 58% lower risk of CVD (adjusted OR: 0.42 (95% CI: 0.29-0.60) and a 56% 
lower risk of CVRFs (adjusted OR: 0.44 [95% CI: 0.35-0.55]) compared with the nonexercisers. 
These associations were consistent regardless of sex, age, smoking status, family history, 
and level of education (Figure 3.2). 
0.0 0.5 1.0 1.5 0.0 0.5 1.0 1.5
Exercise better Nonexercise better 
Males
Females
Age < 50
Age >= 50
NonSmokers
(Ex)smokers
CVD family history
Positive
Negative
Education
Low
Middle
High
Overall
Subgroup
Exercise better Nonexercise better 
Males
Females
Age < 50
Age >= 50
NonSmokers
(Ex)smokers
CVD family history
Positive
Negative
Education
Low
Middle
High
Overall
SubgroupOdds ratio (95% CI) of CVD Odds ratio (95% CI) of CVRFs
0.33 (0.23-0.48)
0.34 (0.13-0.87)
0.15 (0.09-0.27)
0.53 (0.35-0.83)
0.39 (0.19-0.78)
0.36 (0.24-0.54)
0.33 (0.22-0.49)
0.44 (0.22-0.88)
0.49 (0.24-1.01)
0.34 (0.21-0.55)
0.41 (0.20-0.85)
0.42 (0.29-0.60)
0.33 (0.26-0.43)
0.50 (0.34-0.75)
0.24 (0.18-0.33)
0.55 (0.41-0.73)
0.37 (0.26-0.52)
0.41 (0.31-0.54)
0.44 (0.33-0.59)
0.32 (0.23-0.44)
0.48 (0.31-0.72)
0.53 (0.38-0.74)
0.30 (0.21-0.44)
0.44 (0.35-0.55)
Figure 3.2 Odds ratio of cardiovascular disease (CVD) (A) and cardiovascular risk factors (CVRFs) (B) by subgroup. 
Nonexercisers were set as the reference group.  Exercisers had a 58% lower risk of CVD and a 56% 
lower risk of CVRFs compared with nonexercisers. These associations were consistent regardless 
of sex, age, smoking status, family history, and level of education. The overall odds ratio was 
adjusted for: age, sex, smoking status (never, former, or current smoker), level of education (low, 
middle, or high education), and CVD family history (positive or negative). 
Exercise dose
Compared with nonexercisers, CVD prevalence was lower in all exercise dose quintiles 
(nonexercisers: 9.6% vs. Q1: 4.4%, Q2: 2.8%, Q3: 2.4%, Q4: 3.6%, Q5: 3.9%; P<0.001). After 
adjustment for age, sex, smoking status, level of education, and CVD family history, the 
adjusted ORs of CVD prevalence to lifelong exercise dose were 0.55 [95% CI: 0.36-0.82] for 
Q1, 0.38 [95% CI: 0.25-0.59] for Q2, 0.31 [95% CI: 0.20-0.48] for Q3, 0.41 [95% CI: 0.27-0.62] 
for Q4, 0.43 [95% CI: 0.28-0.65] for Q5 (Figure 3.3A). Participants who exercised at a dose of 
773 to 1,091 MET minutes per week (Q3) reported the lowest CVD prevalence, with a risk 
reduction of 69% compared with the nonexercisers. An exercise dose of 773 to 1,091 MET 
minutes is equal to a weekly run of 13 to 18 km at a speed of approximately 8.0 km/h or a 
weekly walk of 17 to 24 km at a speed of approximately 5.6 km/h.
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Table 3.2 Characteristics of patients with CVRFs and control participants in the nonexercisers and exercisers quintiles of lifelong exercise dose
Group
Nonexercisers Q1 Q2 Q3 Q4 Q5
n 500 n 2,306 n 2,307 n 2,308 n 2,307 n 2,307
Characteristics
n (%males) 301 (60) 1,136 (49) 1,141 (49) 1,282 (56) 1,462 (63) 1,637 (71)
Age at study participation (years) 55±10 52±10 50±9 49±9 51±9 51±9
Positive family history (n (%)) 242 (48) 1,047 (45) 995 (43) 969 (42) 1,019 (44) 983 (43)
Lifelong exercise dose (MET-min/wk) 0±0 290±120 616±80 919±101 1,386±184 2,918±1,331
Cardiovascular medical history
Age diagnosis CVRF (years)* 52±9 51±10 49±9 49±9 50±9 50±9
n total CVRF cases (n (%)) 123 (25) 318 (14) 236 (10) 208 (9) 218 (9) 276 (12)
n hypertension (n (%)) 92 (18) 236 (10) 169 (7) 143 (6) 154 (7) 198 (9)
n hypercholesterolemia (n (%)) 24 (5) 69 (3) 57 (2) 56 (2) 56 (2) 68 (3)
n diabetes type 2 (n (%)) 7 (1) 13 (1) 10 (0) 9 (0) 8 (0) 10 (0)
Level of education
Low (n (%)) 116 (23) 274 (12) 142 (6) 155 (7) 175 (8) 175 (8)
Intermediate (n (%)) 225 (45) 937 (41) 881 (38) 872 (38) 918 (40) 912 (40)
High / academic (n (%)) 159 (32) 1,095 (47) 1,284 (56) 1,281 (56) 1,214 (53) 1,220 (53)
Smoking status
Non-smokers (n (%)) 221 (44) 1,111 (48) 1,222 (53) 1,262 (55) 1,323 (57) 1,402 (61)
Ex-smokers (n (%)) 224 (45) 1,053 (46) 974 (42) 930 (40) 878 (38) 791 (34)
Smokers (n (%)) 55 (11) 142 (6) 111 (5) 116 (5) 106 (5) 114 (5)
CVRF: cardiovascular risk factors; MET:  Metabolic equivalent of task; Q: quintile. *patients with CVRFs only
Table 3.1 Characteristics of patients with CVD and control participants in the nonexercisers and exerciser quintiles of lifelong exercise dose
Group
Nonexercisers Q1 Q2 Q3 Q4 Q5
n 417 n 2,130 n 2,128 n 2,127 n 2,129 n 2,130
Characteristics
n (%males) 243 (58) 1,047 (49) 1,048 (49) 1,177 (55) 1,348 (63) 1,502 (71)
Age at study participation (years) 53±10 52±10 50±9 49±9 50±9 51±9
Positive family history (n (%)) 203 (49) 939 (44) 879 (41) 878 (41) 926 (43) 879 (41)
Lifelong exercise dose (MET-min/wk) 0±0 297±122 623±80 924±101 1,388±181 2,909±1,336
Cardiovascular medical history
Age diagnosis CVD (years)* 53±10 51±10 49±9 49±9 50±9 50±9
n total CVD cases (n (%)) 40 (10) 93 (4) 60 (3) 52 (2) 77 (4) 83 (4)
n myocardial infarction (n (%)) 27 (6) 43 (2) 31 (1) 22 (1) 41 (2) 43 (2)
n stroke (n (%)) 5 (1) 19 (1) 11 (1) 10 (0) 15 (1) 16 (1)
n heart failure (n (%)) 8 (2) 31 (1) 18 (1) 20 (1) 21 (1) 24 (1)
Level of education
Low (n (%)) 88 (21) 225 (11) 126 (6) 133 (6) 165 (8) 146 (7)
Intermediate (n (%)) 200 (48) 856 (40) 799 (38) 804 (38) 840 (39) 831 (39)
High / academic (n (%)) 129 (31) 1,049 (49) 1,203 (57) 1,190 (56) 1,124 (53) 1,153 (54)
Smoking status
Non-smokers (n (%)) 186 (45) 1054 (49) 1137 (53) 1174 (55) 1235 (58) 1307 (61)
Ex-smokers (n (%)) 180 (43) 950 (45) 886 (42) 846 (40) 789 (37) 713 (33)
Smokers (n (%)) 51 (12) 126 (6) 105 (5) 107 (5) 105 (5) 110 (5)
CVD: cardiovascular disease; MET: Metabolic equivalent of task; Q: quintile; *patients with CVD only
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The CVRF prevalence was also lower in all exercise dose quintiles (nonexercisers: 24.6% 
vs. Q1: 13.8%, Q2: 10.2%, Q3: 9.0%, Q4: 9.4%, Q5: 12.0%; P<0.001). After adjustment 
for age, sex, smoking status, level of education, and CVD family history, the adjusted 
ORs of CVRF prevalence to lifelong exercise dose were 0.57 [95% CI: 0.44-0.72] for Q1), 
0.43 [95% CI: 0.33-0.55] for Q2, 0.36 [95% CI: 0.28-0.47] for Q3, 0.36 [95% CI: 0.28-0.47] for 
Q4, and 0.47 [95% CI: 0.37-0.60] for Q5 (Figure 3.3B). Participants who exercised at a dose of 
764 to 1,085 MET minutes per week (Q3) reported the lowest CVRF prevalence, with a risk 
reduction of 64% compared with the nonexercisers. 
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Figure 3.3 The association between the prevalence of cardiovascular morbidity and exercise dose per quintile 
(Q). The proportion of participants with cardiovascular disease (CVD) (A) CVD and cardiovascular 
risk factors (CVRFs) (B) per exercise dose (metabolic equivalent of task [MET] minutes per 
week) in quintiles is shown. Nonexercisers were set as the reference group, where the dotted 
line represents an odds ratio of 1. During the analysis, we adjusted for the following potential 
confounders: age, sex, smoking status, level of education, and CVD family history. 
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Exercise intensity
In general, CVD, CVRF, and control participants exercised mostly at a moderate intensity 
(71%), followed by vigorous intensity (16%) and light intensity (13%). The proportion of 
light- and moderate-intensity exercise decreased with higher exercise dose quintiles 
(P<0.001), whereas the proportion of vigorous-intensity exercise increased with higher 
exercise dose quintiles (P<0.001). Participants with CVD or CVRF performed more light-
intensity exercise compared with controls across quintiles (CVD: Pinteraction=0.028; CVRF 
Pinteraction=0.001). Proportions of moderate-intensity exercise (CVD: P=0.48; CVRF: 0.17) and 
vigorous-intensity exercise (CVD: P=0.20; CVRF: 0.36) did not di er between CVD/CVRF 
and controls participants across quintiles (Figure 3.4). 
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Figure 3.4 Proportion of light-, moderate-, and vigorous-intensity per exercise dose quintile (Q). We categorized 
the total amount of lifelong exercise dose into light, moderate, and vigorous intensity, based on 
self-reported perceived intensity of the participant. The bars represent the proportion intensity 
per exercise dose quintile for control participants (CON) vs. (A) patients with cardiovascular 
diseases (CVD) (A) and patients with cardiovascular risk factors (CVRFs) (B). The proportion of 
light- and moderate-intensity exercise decreased with higher exercise dose quintiles (P<0.001), 
whereas the proportion of vigorous-intensity exercise increased with higher exercise dose 
quintiles (P<0.001). Patients with CVD or CVRFs performed more light-intensity exercise across 
quintiles compared with controls, whereas moderate- and vigorous-intensity exercise did not 
di er between patients with CVD or CVRFs and CONs across quintiles. 
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DISCUSSION
This study presents several major  ndings. First, exercise below the recommended dose is 
associated with reduced cardiovascular morbidity. Second, performing exercise at a dose 
of 764 to 1,091 MET minutes per week is associated with the lowest reduction in CVD/
CVRF prevalence, approximating 69% for CVD and 64% for CVRFs. Third, a higher exercise 
dose does not yield additional cardiovascular bene ts; we observed that CVD and CVRF 
prevalence did not further decrease in the highest exercise dose groups. Fourth, these 
data do not support the presence of the U-shaped association between exercise and CVD 
prevalence, but reinforce the hypothesis that regular exercise performance is a potent 
lifestyle intervention to reduce the cardiovascular burden. 
Several studies reported the favourable health e ects of exercise, (7, 14-16) as evidenced by 
reductions in mortality risk in physically active individuals. The present study focused on 
cardiovascular morbidity only, and found reduced CVD and CVRF prevalences across all 
exercise quintiles. Current exercise guidelines recommended a (minimum) weekly exercise 
dose of 675 MET-min ( ve days per week of moderate-intensity exercise [~4.5 MET] for 
30 minutes per day). (10) We found in the least active quintile signi cant cardiovascular 
bene ts of 45% and 43% reduction in CVD and CVRF prevalence, respectively. The Q1 
participants exercised, on average, 297 MET minutes per week, which is equal to the e ort 
of a weekly 4.8 km run at 8 km/h (~8.3 MET) or 6.4 km walk at 5.6 km/h (~4.3 MET). These 
 ndings reinforce previous observations that low doses of exercise can induce signi cant 
health e ects. (14, 15, 17) The high ‘return on investment’ of low exercise doses could encourage 
inactive and vulnerable populations to start exercise and gain subsequent cardiovascular 
bene ts. 
The quest for identi cation of the optimal exercise dose for cardiovascular health is 
challenging, since it includes exercise time, intensity, or a combination of both. (18) The 
present study found the lowest prevalence of CVD and CVRFs between 764 to 1,091 
MET minutes per week, which is in agreement with the exercise recommendations of 
the World Health Organization. (10) This optimal exercise dose is a feasible goal for many 
individuals and includes 170 to 242 minutes per week of moderate-intensity exercise or 
90 to 128 minutes per week of vigorous-intensity exercise. With a reduction of 69% for CVD 
prevalence and 64% for CVRF prevalence, these exercise doses importantly contribute to 
primary prevention and, hence, the reduction of CVD related healthcare expenses.
Interestingly, few studies revealed an upturn in mortality (11, 19) or morbidity (12) risk with 
higher doses of exercise. The exercise dose of the highest quintile (Q5) is equal to the 
e ort of a weekly 350-minute run at approximately 8 km/h (~8.3 MET) or a total running 
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distance of ~47 km/week. Although these extreme exercisers did not report the lowest 
CVD or CVRF prevalence, a 57% reduction in CVD and 53% reduction in CVRF were found 
compared with nonexercisers. One might argue that the absence of a further decline in 
cardiovascular bene ts at the higher exercise doses could relate to the amount of vigorous-
intensity exercise, which these individuals (Q5) experienced. Vigorous endurance exercise 
is known to induce atherosclerotic plaque rupture, (20-22)  transient cardiac dysfunction, and 
cardiac remodelling. (22-25) Indeed, Q5 participants exercised signi cantly more (P<0.001) 
on a vigorous-intensity level (47%) compared with all other quintiles (Q1: 3%, Q2: 6%, 
Q3: 6%, Q4: 16%). However, the proportion of vigorous-intensity exercise did not di er 
between CVD/CVRF and control participants in Q5 (CVD: 50% vs. control: 44%; P=0.22, 
CVRF: 46% vs. control: 44%; P=0.30). Other studies demonstrated an increased longevity 
of 2.8 to 6  years in elite athletes with high-intensity exercise compared with reference 
cohorts. (6,  26, 27) Likewise, Gebel et al. demonstrated that vigorous-intensity activity was 
associated with a strong inverse relation with mortality in the 45 and Up Study (n=204,542; 
aged 45 to 75 years). (28) Larger doses of vigorous-intensity exercise yielded a larger decline 
in (cardiovascular) mortality compared with exercise at a moderate intensity level alone. 
Although a higher exercise dose does not yield additional health bene ts, it is unlikely that 
the amount of vigorous-intensity exercise contributes to this  nding. 
The present study found a curvilinear relation between exercise and cardiovascular 
health. Hence, our  ndings contradict recent studies suggesting a potential U-shaped 
association.  (11, 12) There are several explanations for these di erent study outcomes. The 
results of the Copenhagen Heart Study (11) are di  cult to interpret because of the low number 
of deaths (n=2) in the vigorous exercise group (n=38). (29) Furthermore, the sedentary 
(reference) group was allowed to bike or walk for a maximum of 120 minutes per week, (11) 
suggesting the possibility that they already gained cardiovascular health bene ts from 
these low exercise doses. (15) Hence, the comparison between the sedentary and vigorous-
intensity exercise group is likely to underestimate the true exercise bene ts. Within 
the Million Women Study by Armstrong et al., (12) the prevalence of current smokers was 
surprisingly higher in the daily strenuous exercises compared with those who did strenuous 
exercise between 1 to 6 times per week (~26% vs. ~15%). The authors acknowledge that 
even after adjusting for smoking, residual confounding may have occurred, which could 
explain the increased cardiovascular morbidity in vigorous exercisers. 
The main strength of this study is the extensive period of exercise history (32 years 
[interquartile range Q25–Q75: 26–39 years]) over which we were able to calculate the 
exercise dose. Other studies comprised shorter periods or only questioned the exercise 
characteristics over a single time point. (11, 12) The primary limitation of this study is that 
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the exercise data were entirely dependent on self-report. This limitation is, however, 
applicable to nearly all epidemiological studies, since virtually no studies have objectively 
measured lifelong exercise. Similarly, CVD/CVRF data were obtained by questionnaires, 
but we con rmed the CVD/CVRF status of each individual via cardiovascular medication 
use. Despite our e ort to correct for all potential confounders, it is possible that residual 
confounding may have occurred in the present study. Another caveat may be a recall 
bias regarding the exercise history of the participants. To reduce this potential error to the 
minimum, participants were blinded to the study hypothesis. (30) 
Conclusion
In the present study, a regular low dose of exercise reduced cardiovascular morbidity, with 
further risk reduction at higher doses. Optimal health bene ts were present with 170 to 
242 minutes per week of moderate-intensity exercise or 90 to 128 minutes per week of 
vigorous-intensity exercise. The CVD/CVRF prevalence did not further decrease among 
higher exercise dose groups. Therefore, our study does not con rm the recently reported 
U-shaped association between exercise and morbidity in healthy individuals, but suggests 
a curvilinear relation between lifelong exercise patterns and cardiovascular health.
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Background
The Body Mass Index (BMI) and Waist Circumference (WC) are well-
used anthropometric predictors for cardiovascular diseases (CVD), but 
their validity is regularly questioned. Recently, A Body Shape Index 
(ABSI) and Body Roundness Index (BRI) were introduced as alternative 
anthropometric indices that may better re ect health status. 
Objective
This study assessed the capacity of ABSI and BRI in identifying 
cardiovascular diseases and cardiovascular risk and determined whether 
they are superior to BMI and WC.
Design and Methods
4627 Participants (54±12 years) of the Nijmegen Exercise Study 
completed an online questionnaire concerning CVD health status 
(de ned as history of CVD or CVD risk factors) and anthropometric 
characteristics. Quintiles of ABSI, BRI, BMI, and WC were used regarding 
CVD prevalence. Odds ratios (OR), adjusted for age, sex, and smoking, 
were calculated per anthropometric index.
Results
1332 participants (27.7%) reported presence of CVD or CVD risk factors. 
The prevalence of CVD increased across quintiles for BMI, ABSI, BRI, 
and WC. Comparing the lowest with the highest quintile, adjusted OR 
(95% CI) for CVD were signi cantly di erent for BRI 3.2   (1.4-7.2), BMI 
2.4 (1.9-3.1), and WC 3.0 (1.6-5.6). The adjusted OR (95% CI) for CVD risk 
factors was for BRI 2.5 (2.0-3.3), BMI 3.3 (1.6-6.8), and WC 2.0 (1.6-2.5). No 
association was observed for ABSI in both groups. 
Conclusions
BRI, BMI, and WC are able to determine CVD presence, while ABSI is 
not capable. Nevertheless, the capacity of BRI as a novel body index to 
identify CVD was not superior compared to established anthropometric 
indices like BMI and WC. 
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INTRODUCTION
Overweight and obesity are the  fth leading cause of global death and are an increasing 
worldwide health problem. In 2008, more than 1.4 billion adults su ered from overweight 
and within this group approximately 36% adults is obese. (1) Overweight and obesity 
are associated with an increased risk for cardiovascular diseases (CVD), type 2 diabetes 
mellitus and premature death. (2-9) Therefore, an early detection of overweight or obesity is 
considered necessary to prevent CVD. (10)
The Body Mass Index (BMI) and Waist Circumference (WC) are currently recommended 
by several guidelines to classify overweight and obesity. (10, 11) Indeed, an increase in BMI 
or WC has been shown to be a risk factor for CVD. (10) However, previous studies also 
demonstrated that the discriminative capacity of BMI is not optimal, as this calculation 
cannot distinguish between adipose tissue and lean body mass. (12-16) WC alternatively, has 
been shown to be a good predictor for abdominal adipose tissue. (17, 18) but currently it is 
unclear to what extent the range of WC depends on body size. (19, 20) This has led to the 
idea that by combining traditional measures (e.g. height, weight, BMI, or WC) a better body 
index could be designed, which takes body shape into account. (21-24)
Recently, two new body indices have been introduced. (22, 23) In 2012, Krakauer et al. 
developed ‘A Body Shape Index’ (ABSI), which is based on waist circumference (m), 
BMI (kg⋅m-2), and height (m).  (22) According to the authors, a high ABSI relates to a greater 
fraction of abdominal adipose tissue and appears to be a signi cant risk factor for premature 
death. (22) Other studies have suggested that ABSI is able to predict the onset of diabetes 
mellitus (25) and that it could be used to evaluate physical health status of adolescents. (26) In 
2013, Thomas et al. developed the Body Roundness Index (BRI), which is a new geometrical 
index that combines height (m) and waist circumference (m) to predict the percentage of 
body fat and to evaluate health status. (23) However, it is unknown whether ABSI and BRI can 
determine the presence or risk of cardiovascular diseases.
Therefore, the aim of this study was to assess the capacity of the novel indices A Body 
Shape Index (ABSI) and Body Roundness Index (BRI) to identify cardiovascular diseases 
and cardiovascular risk in the Dutch population and to determine whether these 
anthropometric indices are superior to the Body Mass Index and Waist Circumference. We 
postulate that ABSI and BRI can better identify CVD than BMI or WC.
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METHODS
Ethics Statement
 The study adhered to the Declaration of Helsinki. The Local Committee on Research 
Involving Human Subjects (CMO) of the region Arnhem and Nijmegen approved the 
study, and all subjects gave their written informed consent.
Study design and study population.
The Nijmegen Exercise Study (www.nijmegenexercisestudy.com) is a large-population 
based study conducted by the Department for Health Evidence and the Department of 
Physiology of the Radboud University Medical Center in June 2011. The overall aim of the 
Nijmegen Exercise Study is to examine the e ects of physical activity on general health 
and various disease outcomes in the general population.
In 2011, participants of the International Nijmegen Four Days Marches, the largest multi-
day walking event in the world, were eligible to participate in the Nijmegen Exercise 
Study. By means of a passive recruitment strategy (Four Days Marches newsletter and 
internet advertisement), Dutch speaking adults were invited to complete an online survey. 
Participants were asked about their date of birth, anthropometric measures (weight, 
height, and WC), and whether they were diagnosed with CVD. In addition, participants 
were questioned about their lifestyle factors (physical activity and smoking habits). 
Anthropometric measures
Self-reported body height, weight, and waist circumference. Participants reported their height 
(centimetre), waist circumference (centimetre), and body weight (kilogram) in the online 
survey. Each anthropometric measurement was accompanied with detailed instructions. 
These data were used to calculate the BMI, ABSI, and BRI according to standardized 
formulas. BMI was based on weight (kg) and height (m) and calculated using formula [1]. (27) 
A body shape index. The ABSI was based on height (m), BMI (kg⋅m-2), and waist 
circumference (m) and calculated using formula [2]. (22)
2/13/2 heightBMI
WCABSI

  [2]
2height
weightBMI   [1]
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The Body Roundness Index. The BRI was based on height (m) and waist circumference (m). 
First, the eccentricity (ε) of the body was determined using formula [3]. Eccentricity (non-
dimensional value) quanti es the degree of circularity of an ellipse, and it ranges between 
zero (perfect circle) to one (a vertical line). (23) 
  
  








 2
2
5.0
2/1
height
WC 
  [3]
)5.365(2.364 BRI  [4]
Subsequently, the BRI was calculated using formula [4]. Described by Thomas et al., values 
closer to 1 are related to leaner individuals, whereas larger values are associated with 
rounder individuals. (23) 
Presence of cardiovascular diseases (CVD) and cardiovascular risk factors (CVRF)
Participants were asked whether their physician diagnosed (yes/no) presence of  CVD 
(1. myocardial infarction and 2. stroke) or CVRF (1. hypertension and 2. hypercholesterolemia). 
Participants were categorized in the CVD or CVRF group if one of these questions were 
replied positively, while they were allocated to the control group if all answers were 
negative. Participants who reported CVD as well as CVRF were allocated to the CVD group.
Lifestyle factors
All participants reported whether they had followed a training program prior to the 
Nijmegen Four Days Marches and/or whether they performed other sport activities (e.g. 
playing soccer, tennis, etc.). Based on the duration (hours/week), frequency, and intensity 
(low, moderate, high) of these exercise activities, the average time and intensity level of 
physical activity per day was calculated. The recommendations of the American Heart 
Association were used to determine if a participant ful lled the physical activity criteria. (28) 
Participants reported whether they were current smoker, ex-smoker or non-smokers and 
categorized as (ex)-smoker or non-smoker.
Calculations and statistical analysis
Group characteristics were analysed using descriptive techniques. Continuous variables 
(age, height, weight, ABSI, BMI, BRI, and WC) were reported in tables as mean and 
di erences between the CVD, CVRF, and control group were analysed using one-way 
analysis of variance (ANOVA) with a Bonferroni post-hoc test. Categorical data were 
reported in proportions and di erences tested by Pearson’s chi-squared test (sex, physical 
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activity, myocardial infarction, stroke, hypertension, hypercholesterolemia, and smoking). 
Statistical signi cance was assumed at P<0.05.
Pairwise correlation coe  cients between the continuous variables height, weight, ABSI, 
BMI, BRI, and WC were assessed by calculating Pearson correlation coe  cients. To examine 
the discriminative power of the anthropometric indices for CVD or CVRF the Area under 
the Receiver Operating Characteristic (AROC) curves were calculated. The AROC represents 
a measure of accuracy of an anthropometric index to discriminate between subjects with 
or without CVD or CVRF. (29) 
Quintiles of BMI and BRI were created and the prevalence of CVD and CVRF was calculated 
in each quintile. Since ABSI is strongly correlated with age and sex, (22) ABSI was strati ed for 
age (per year), after which ABSI quintiles were determined within each age group for males 
and females separately. To calculate the prevalence of CVD and CVRF per ABSI quintile, 
subjects within the same ABSI quintile were merged. For WC the quintiles were strati ed 
by sex and the prevalence of CVD and CVRF in each quintile was calculated. Logistic 
regression was used to estimate the odds ratio for su ering from CVD or CVRF per quintile, 
both unadjusted and adjusted for sex, age, and lifestyle factors (smoking and physical 
activity). For all four anthropometric indices, the lowest quintile was set as reference. All 
statistical analyses were performed using SPSS 20.0 (IBM Corp. Released 2011. IBM SPSS 
Statistics for Windows, Version 20.0. Armonk, NY: IBM Corp) software.
Excluded participants (n=1115; 19.4%)
- Missing data
    • Waist circumference (n=1039)
    • Body height (n=12)
    • Body weight (n=14)
- Pregnancy (n=7)
- BMI < 18.5 (n=43)
Participants included in the 
nal analysis (n=4627; 80.6%)
Participants completed the 
online questionnaire (n=5742)
Figure 4.1 Flowchart enrolment of the study population. 5742 participants completed the online 
questionnaire. 1115 participants were excluded because of missing data (n=1065), 
pregnancy  (n=7), or BMI < 18.5 (n=43). The  nal group sample consisted of 4627 participants.
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RESULTS
5742 participants completed the online questionnaire. After the exclusion of participants 
who were pregnant, had underweight (calculated BMI of <18.5), or with missing data on 
anthropometric measures, the study population consisted of 4627 (80.6%) participants 
(Figure 4.1). This included 2425 men (57.5±11.4 years of age) and  2202 women 
(50.2±12.6 years of age). 1332 (27.7%) participants reported CVD or CVRF, of which 32.9% 
(438) were female. Hypertension and hypercholesterolemia were reported in respectively 
19.5% and 14.6% of the study population. Myocardial infarction and stroke were reported 
in respectively 2.6% and 1.4% of the study population (Table 4.1). 
CVD, CVRF, and control group characteristics
Participants with CVD and CVRF were older (63±8 vs. 60±9 vs. 52±13 year; P<0.001) 
compared the control group. The CVD and CVRF group reported a higher body weight 
(81.6 (±11.5) vs. 78.1 (±13.1) vs. 74.5±12.6 kg; P<0.001) and smoked more often (72% vs. 62% 
vs. 50%; P<0.001). There were more participants physically active within the CVRF group 
compared the control group (67.4 vs. 59.2; P<0.001), whereas the CVD and control group 
were comparable  (66.5 vs. 59.2; P=0.06). Participants with CVD and CVRF demonstrated 
higher ABSI, BMI, BRI, and WC values compared to the control group (Table 4.1).  
Table 4.1 Characteristics of the total study population and according to cardiovascular disease status
Parameter Total group
n 4627
Sex, % females (n) 47.6 (2202)
CVD and risk factors, %yes (n) 23.2 (1332)
MI, %yes (n) 2.6 (121)
Stroke, %yes (n) 1.4 (65)
Hypertension, %yes (n) 19.5 (903)
Hypercholesterolemia, %yes (n) 14.6 (674)
Group CVD CVRF Controls P-value
n 179 1153 3295 –
Sex, % females (n) 9.5 (17)*,** 36.5 (421)* 53.5 (1764) <0.001
Age (years) 63 (±8)*,** 60 (±9)* 52 (±13) <0.001
Height (cm) 176.4 (±7.3)*,** 174.4 (±8.8) 174.5 (±9.1) 0.020
ABSI (m11/6·kg-2/3) 0.084 (±0.005)*,** 0.082 (±0.005)* 0.081 (±0.006) <0.001
BMI (kg·m-2) 26.2 (±3.0)*,** 25.6 (±3.1)* 24.4 (±3.0) <0.001
BRI 4.5 (±1.1)*,** 4.2 (±1.1)* 3.7 (±1.2) <0.001
Weight (kg) 81.6 (±11.5)*,** 78.1 (±13.1)* 74.5 (±12.6) <0.001
WC (cm) 97.9 (±9.0)*,** 94.4 (±10.3)* 89.8 (±11.0) <0.001
Norm PA (%yes [n]) 66.5 (119) 67.4 (777)* 59.2 (1949) <0.001
Smoking (%yes [n]) 71.5 (128)*,** 61.6 (710)* 49.5 (1631) <0.001
Abbreviations: ABSI, A Body Shape Index; BRI, Body Roundness Index; BMI, Body Mass Index; MI, Myocardial Infarction; norm PA, norm 
physical activity. Data presented as mean (SD) or proportion (number). *signi cantly di erent from controls; ** signi cantly di erent 
from CVRF
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Correlation and AROC scores
ABSI and BRI were positively and signi cantly correlated to height, weight, BMI and WC 
(Table 4.2; Figure 4.2). Within the CVD group, the AROC scores were 0.63 for ABSI, 0.68 for 
BRI, 0.64 for BMI, and 0.69 for WC (Figure 4.3A). Within the CVRF group, the AROC scores 
were 0.57 for ABSI, 0.63 for BRI, 0.60 for BMI, and 0.61 for WC (Figure 4.3B).
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B. ABSI versus WC
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Figure 4.2 A. Correlation between ABSI and BMI. Increase in ABSI and increase in BMI show a poor yet 
signi cant correlation (r = 0.087, P<0.001). B. Correlation between ABSI and WC. Increase in ABSI 
and increase in WC show a signi cant correlation (r = 0.678, P<0.001). C. Correlation between BRI 
and BMI. Increase in BRI and increase in BMI show a signi cant correlation (r = 0.780, P<0.001). 
D. Correlation between BRI and WC. Increase in BRI and increase in WC show a signi cant 
correlation (r = 0.898, P<0.001). E. Correlation between BRI and ABSI. Increase in BRI and increase 
in ABSI show a signi cant correlation (r = 0.642, P<0.001).
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Prevalence of CVD and CVRF
Prevalence of CVD increased per quintile for all four anthropometric indices (Q1 vs. Q5): ABSI 
3.9% vs. 4.3%, BRI 0.8% vs. 6.5%, BMI 1.0% vs. 6.1%, WC 1.0% vs. 6.1% (P<0.05) (Table 4.3A). 
The prevalence of CVRF increased per quintile for all four anthropometric indices (Q1 vs. 
Q5): ABSI 23.2% vs. 24.1%, BRI 11.6% vs. 36.9%, BMI 15.0% vs. 34.2%, WC 15.0% vs. 34.2% 
(P<0.05) (Table 4.3B).
 Odds of cardiovascular diseases
Unadjusted odds of CVD prevalence increased with increasing quintiles for (ORunadjusted  [95%-
CI]) ABSI (1.1 [0.7 to1.8]), BRI (9.1 [4.1 to 20.1]), BMI (6.7 [3.3 to 13.5]), and WC (3.4 [1.9 to 6.3]) 
(Table 4.4A). Physical activity was non-signi cant in the logistic regression analysis and was 
therefore excluded from further analysis. After adjustment for age, sex, and smoking, the 
odds ratio of CVD remained signi cant for (ORadjusted  [95%-CI]) BRI (3.2 [1.4 to 7.2]), BMI (3.3 
[1.6 to 6.8]), and WC (3.0 [1.6 to 5.6]), but not for ABSI (1.1 [0.7 to 1.8]) (Table 4.4A).
Table 4.2 Correlations between body size and shape
Height Weight WC ABSI BRI BMI
Height 1 0.69** 0.40** 0.18** -0.04* 0.11**
Weight 1 0.79** 0.18** 0.54** 0.79**
WC 1 0.68** 0.90** 0.75**
ABSI 1 0.64** 0.09**
BRI 1 0.77**
BMI 1 
ABSI: A Body Shape Index; BRI: Body Roundness Index; BMI: Body Mass Index; WC; Waist 
Circumference.  Correlation coe  cients between height, weight, ABSI, BMI, BRI, and WC 
among the NES study population (n=4627). **Correlation is signi cant at the 0.01 level 
(2-tailed). *Correlation is signi cant at the 0.05 level (2-tailed).
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Figure 4.3 A. Area under the Receiver Operating Characteristic curve of BRI, WC, BMI, and ABSI to identify 
subjects with cardiovascular diseases. B. Area under the Receiver Operating Characteristic curve 
of BRI, WC, BMI, and ABSI to identify subjects with cardiovascular disease risk factors.
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Odds of cardiovascular disease risk factors
Unadjusted odds of CVRF prevalence increased with increasing quintiles for (ORunadjusted 
[95%-CI]) ABSI (1.1 [0.8 to 1.3]), BRI (4.5 [3.5 to 5.7]), BMI (2.9 [2.3 to 3.7]), and WC (2.4 [2.0 
to 3.0]) (Table 4.4B). After adjustment for age, sex, and smoking, the odds ratio of CVD 
remained signi cant for (ORadjusted  [95%-CI]) BRI (2.5 [2.0 to 3.3]), BMI (2.4 [1.9 to 3.1]), and 
WC (2.0 [1.6 to 2.5), but not for ABSI (1.1 [0.9 to 1.3]) (Table 4.4B).
A. Cardiovascular diseases
Quintile ABSI BRI BMI WC
1 (%CVD [n]) 3.9 (34) 0.8 (7) 1.0 (9) 1.0 (9)
2 (%CVD [n]) 3.4 (31) 1.9 (18) 2.4 (22) 2.4 (22)
3 (%CVD [n]) 3.8 (35) 3.8 (35) 4.4 (41) 4.4 (41)
4 (%CVD [n]) 4.0 (37) 6.4 (59) 5.4 (50) 5.4 (50)
5 (%CVD [n]) 4.3 (42) 6.5 (60) 6.1 (57) 6.1 (57)
B. Cardiovascular risk factors
Quintile ABSI BRI BMI WC
1 (%CVRFs [n]) 23.2 (204) 11.6 (107) 15.0 (139) 15.0 (139)
2 (%CVRFs [n]) 25.9 (239) 20.1 (186) 21.4 (198) 21.4 (198)
3 (%CVRFs [n]) 25.8 (239) 29.7 (275) 25.6 (237) 25.6 (237)
4 (%CVRFs [n]) 25.5 (235) 26.4 (244) 28.4 (262) 28.4 (262)
5 (%CVRFs [n]) 24.1 (236) 36.9 (341) 34.2 (317) 34.2 (317)
Table 4.3 Prevalence of CVD and CVRF in quintiles of ABSI, BRI, BMI, and WC
ABSI: A Body Shape Index; BRI: Body Roundness Index; BMI: Body Mass Index; WC; Waist Circumference. Data presented as mean (SD) or 
proportion (number).
A. Cardiovascular diseases
Quintile ABSI BRI BMI WC
1 (ref) 1 1 1 1
2
0.9 (0.5 - 1.4) 2.6 (1.1 - 6.3) 2.5 (1.1 - 5.4) 2.6 (1.4 - 4.9)
0.8 (0.5 - 1.4) 1.3 (0.5 - 3.2) 1.5 (0.7 - 3.4) 2.5 (1.3 - 4.8)
3
1.0 (0.6 - 1.6) 5.2 (2.3 - 11.7) 4.7 (2.3 - 9.8) 2.7 (1.5 - 5.0)
1.0 (0.6 - 1.6) 2.1 (0.9 - 4.8) 2.5 (1.2 - 5.2) 2.3 (1.2 - 4.4)
4
1.0 (0.6 - 1.7) 8.9 (4.1 - 19.7) 5.8 (2.9 - 12.0) 3.4 (1.9 - 6.3)
1.0 (0.6 - 1.7) 3.1 (1.4 - 6.9) 2.8 (1.3 - 5.8) 3.0 (1.6 - 5.7)
5
1.1 (0.7 - 1.8) 9.1 (4.1 - 20.1) 6.7 (3.3 - 13.5) 3.4 (1.9 - 6.3)
1.1 (0.7 - 1.8) 3.2 (1.4 - 7.2) 3.3 (1.6 - 6.8) 3.0 (1.6 - 5.6)
B. Cardiovascular risk factors
ABSI BRI BMI WC
1 1 1 1
1.2 (0.9 - 1.4) 1.9 (1.5 - 2.5) 1.5 (1.2 - 2.0) 1.4 (1.1 - 1.8)
1.2 (0.9 - 1.5) 1.3 (1.0 - 1.7) 1.3 (1.0 - 1.7) 1.3 (1.0 - 1.6)
1.1 (0.9 - 1.4) 3.2 (2.5 - 4.1) 1.9 (1.5 - 2.5) 1.7 (1.3 - 2.1)
1.2 (0.9 - 1.5) 2.0 (1.6 - 2.6) 1.6 (1.2 - 2.0) 1.4 (1.1 - 1.7)
1.1 (0.9 - 1.4) 2.7 (2.1 - 3.5) 2.2 (1.8 - 2.8) 1.8 (1.5 - 2.3)
1.2 (0.9 - 1.4) 1.6 (1.2 - 2.1) 1.7 (1.4 - 2.2) 1.5 (1.2 - 1.9)
1.1 (0.8 - 1.3) 4.5 (3.5 - 5.7) 2.9 (2.3 - 3.7) 2.4 (2.0 - 3.0)
1.1 (0.9 - 1.3) 2.5 (2.0 - 3.3) 2.4 (1.9 - 3.1) 2.0 (1.6 - 2.5)
ABSI: A Body Shape Index; BRI: Body Roundness Index; BMI: Body Mass Index; WC; Waist Circumference. Unadjusted (white rows) and 
adjusted (grey rows). Ranges in parentheses are 95% con dence intervals.
The between cut points for CVD (A) are 0.077, 0.080, 0.083, and 0.086 for ABSI; 2.8, 3.5, 3.9, 4.7 for BRI; 22.1, 23.7, 25.2, and 27.1 for BMI; 
0.89, 0.94, 0.98, 1.04 for WC (males); 0.78, 0.82, 0.87, 0.94 for WC (females). The between cut points for CVRF (B) are 0.077, 0.080, 0.083, 
and 0.086 for ABSI; 2.8, 3.5, 3.9, 4.7 for BRI; 22.1, 23.7, 25.2, and 27.1 for BMI; 0.89, 0.94, 0.98, 1.04 for WC (males); 0.78, 0.82, 0.87, 0.94 
for WC (females).  *Signi cant at P<0.05; фSigni cant at P<0.01.
Table 4.4 CVD risk in quintiles of ABSI, BRI, BMI, and WC unadjusted and adjusted for sex, age, and smoking to predict the prevalence of CVD 
or CVD risk factors.
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DISCUSSION
We demonstrated that the prevalence of CVD and CVRF signi cantly increased across the 
quintiles for ABSI, BRI, BMI, and WC. However, after adjusting for age, sex, and smoking only 
BRI, BMI, and WC could identify CVD or CVRF and not ABSI. In contrast to our hypothesis, 
neither ABSI nor BRI are superior measures compared to BMI and WC to determine the 
presence of CVD or CVRF. Our  ndings indicate that the novel index ABSI is not suitable for 
identifying CVD or CVRF, while the BRI showed similar capabilities as BMI and WC.
A Body Shape Index
The ABSI was created to produce a quantitative measure to estimate the health of 
body shape independently of body size (height, weight, and BMI). (22) While  Krakauer et 
al. demonstrated that ABSI predicts premature mortality better than BMI or WC, (22) our 
results suggest that ABSI cannot be used to distinguish between individuals with and 
without CVD or CVRF. Compared with BRI, BMI, and WC, the ABSI demonstrated the lowest 
predictive power and had no signi cant association with CVD or CVRF prevalence after 
adjustment for age, sex, and smoking. Thus, ABSI is not a suitable measurement to identify 
CVD and CVRF. 
A possible explanation for the contrasting  ndings between our data and  Krakauer et al., 
is the endpoint variable, namely the prevalence of CVD and CVRF vs. premature death. 
Alternatively, subject characteristics may explain the dissimilarities between our study and 
the one of  Krakauer et al. (30) Our study population has approximately the same ABSI values 
as  Krakauer et al. (0.081±0.0058 m11/6 ⋅kg-2/3 vs. 0.081±0.0053 m11/6⋅kg-2/3), but surprisingly 
our study population had a lower BMI (3rd quintile: 23.7-25.2 vs. 25.6-28.4) and lower WC 
(3rd quintile females: 82-87 vs. 88-97; males: 94-98 vs. 94-101). The explanation why ABSI 
is similar is that our study population comprising Dutch subjects were taller compared to 
the American study population of  Krakauer et al. The estimated average body height is 
1.70 meters in the study of  Krakauer et al., whereas our study population had an average 
body height of 1.75 meters. This suggests that body height might confound the capacity 
of ABSI to identify CVD in our study population. Future studies should further investigate 
the limits of ABSI and especially study the impact of body height on the calculation of ABSI. 
Body Roundness Index
We are the  rst to study the capacity of BRI to identify CVD and CVRF. The BRI was developed 
to predict both body fat and the percentage visceral adipose tissue by using WC in relation 
to height, which allows estimation of the shape of the human body  gure as an ellipse or 
oval. (23) We demonstrated that the BRI is capable to identify CVD and CVRF (Table 4.3). This 
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is in agreement with previous studies, (21, 24) which also related WC to body height (i.e. waist-
to-height ratio [WtH-ratio]). The spearman rank test revealed a perfect nonlinear relation 
between BRI and WtH-ratio (r = 1; P=0.00). This indicates that both body indices are related 
by an one-to-one nonlinear transformation and strictly means that it does not matter what 
index (BRI or WtH-ratio) is used to determine CVD. However, as demonstrated by Thomas 
et al., the advantage of the BRI over the WtH-ratio is that it also can be used to estimate the 
amount of body fat percentage and gives therefore a better impression of physical health 
status. Although the adjusted OR of the BRI was higher compared to BMI and WC, this did 
not reach statistical signi cance. Nevertheless, we recommend that future studies should 
study the sensitivity of BRI to determine cardiovascular health risks in a clinical setting. With 
the development of computerized software that is accessible via internet websites, Tablets 
or Smartphone applications, novel body measures with complex algorithms can easily 
be used by physicians. (22, 23) Therefore, the BRI has the potential to improve the detection, 
evaluation, and progression of CVD and CVRF.
Methodological considerations
Our study compared the ABSI and BRI mutually and against the BMI and WC in a large 
heterogeneous study population. In our study, participants self-reported their weight and 
WC using our written instructions, whilst in the study of  Krakauer et al. trained personnel 
measured WC. Although it is likely that participants made some measurement errors, 
prior studies demonstrated that self-report of body weight and waist circumference is 
a validated and feasible method. (31, 32) We therefore suppose that self-reporting has had 
a minor in uence on our  ndings. Additionally, the outcome variable (CVD) was self-
reported; participants were only allowed to report CVD or CVRF if they were diagnosed 
by a physician. Possibly some participants had a history of CVD and did not report this. 
This could have led to an underestimation of our results. Therefore, the capacity of BRI, 
BMI, and WC to identify CVD or CVRF could somewhat be higher. Finally, one might argue 
that the cross-sectional nature of our study is suboptimal to study the predictive capacity 
of anthropometric characteristics. However, in our study design we demonstrated that 
the BRI as well as BMI and WC were able to identify participants with CVD. It is a  rst step 
in validating BRI in relation to CVD and therefore we believe that the used method is 
appropriate. In future studies, the longitudinal relation between BRI and CVD incidence 
should be studied.
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Conclusion
In the current study, we demonstrated that CVD and CVRF prevalence increased per 
quintile across a heterogeneous population for ABSI, BRI, BMI, and WC. Nonetheless, only 
BRI, BMI, WC, and not ABSI, could signi cantly determine the presence of CVD and CVRF 
after correction for sex, age and smoking. The capacity of BRI to mathematically model the 
human body shape gives an adequate impression of the cardiovascular health status, but 
was not superior to BMI or WC. 
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Albert: 'Oh, yes, sir. But alcohol sort of compensates for not getting them"
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Background
Compound strain imaging is a novel method to noninvasively evaluate arterial 
wall deformation which has recently shown to enable di erentiation between 
 brous and ( bro-)atheromatous plaques in patients with severe stenosis. 
We tested the hypothesis that compound strain imaging is feasible in non-
stenotic arteries and provides incremental discriminative power to traditional 
measures of vascular health (i.e. distensibility coe  cient (DC), central pulse 
wave velocity [cPWV], and intima-media thickness [IMT]) for di erentiating 
between participants with and without a history of cardiovascular diseases 
(CVD).
Methods
72 participants (60±7 years) with non-stenotic arteries (IMT < 1.1 mm) were 
categorized in healthy participants (CON, n=36) and CVD patients (n=36) 
based on CVD history. Participants underwent standardised ultrasound-
based assessment (DC, cPWV, and IMT) and compound strain imaging (radial 
[RS] and circumferential [CS] strain) in left common carotid artery. Area under 
receiver operating characteristics (AROC)-curve was used to determine the 
discriminatory power between CVD and CON of the various measures.
Results
CON had a signi cantly (P<0.05) smaller carotid IMT (0.68 [0.58 to 0.76] mm) 
than CVD patients (0.76 [0.68 to 0.80] mm). DC, cPWV, RS, and CS did not 
signi cantly di er between groups (P>0.05). A higher CS or RS was associated 
with a higher DC (CS: r=-0.32;P<0.05 and RS: r=0.24;P<0.05) and lower cPWV 
(CS: r=0.24;P<0.05 and RS: r=-0.25;P<0.05). IMT could identify CVD (AROC: 0.66, 
95%-CI: 0.53 to 0.79), whilst the other measurements, alone or in combination, 
did not signi cantly increase the discriminatory power compared to IMT. 
Conclusions
In non-stenotic arteries, compound strain imaging is feasible, but does not 
seem to provide incremental discriminative power to traditional measures 
of vascular health for di erentiation between individuals with and without a 
history of CVD.
A
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INTRODUCTION
Atherosclerosis is a multifactorial disease, which a ects the vasculature and usually 
develops in humans over the course of years to decades. (1) Early detection of people at risk 
for CVD is of paramount importance to prevent life threatening events, such as stroke or 
myocardial infarction. Results from large cohort studies (2, 3) indicate that several vascular 
markers obtained via ultrasound techniques, such as the distensibility coe  cient (DC), 
central pulse wave velocity (cPWV), or intima-media thickness (IMT), improve cardiovascular 
risk strati cation. Recent studies also investigated the performance of carotid artery wall 
strain parameters by commercially available speckle tracking techniques for CVD risk 
strati cation. (4-6) Park et al. observed a signi cant correlation between circumferential 
strain, the amount of cardiovascular risk factors and the Framingham Risk Score. (4) 
Catalano et al. found that peak systolic circumferential strain adjusted for pulse pressure 
could di erentiate between three cardiovascular risk groups, whereas for instance IMT 
could not. (6) Although these results are very promising, these commercial techniques were 
initially developed for myocardial strain estimation. All commercially available packages 
for myocardial strain estimation use either B-mode data or the envelope signal of the raw 
radiofrequency data for tracking. (7) It is known that more accurate strain estimation can be 
performed when using the underlying raw ultrasound radiofrequency (RF) data, because it 
contains the phase information of the ultrasound signal. (8, 9) Recently, several RF-based strain 
techniques speci cally designed to evaluate arterial wall strain have been developed. (10-15) 
Some of these techniques have already been validated against post-endarterectomy 
histology and/or magnetic resonance imaging derived plaque composition. (16-19) In all of 
these validation studies patients with severe amounts of stenosis (>50%) were included. 
Whether these RF-based techniques are also feasible in non-stenotic arteries and provide 
information that can discriminate between healthy, asymptomatic subjects and those with 
a history of cardiovascular disease, needs to be explored. Despite the promising  ndings 
for speckle-tracking-based strain analysis, it is also still unclear if the information provided 
by RF-based strain imaging has additional value for cardiovascular risk strati cation over 
traditional measures of conduit arteries, such as cPWV or IMT.
In this study, we tested whether compound strain imaging, an in house built and validated 
RF-based strain imaging technique designed for transverse imaging planes, is feasible 
in non-stenotic arteries and provides information that has additional value compared to 
traditional measures of conduit arteries (i.e. cPWV, DC or IMT) for discrimination between 
participants with and without a history of CVD.
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METHODS
Participants
A total of 72 male participants aged 46 to 77 years with non-stenotic arteries were included. 
Based on CVD history the participants were categorized in healthy, asymptomatic 
controls (CON, n=36) and CVD patients (CVD, n=36). CVD participants su ered from a 
myocardial infarction in the past and used cardiovascular medication (anticoagulants, 
antihypertensive, or lipid lowering agents). Smokers and diabetics were excluded from the 
study. The Local Committee on Research Involving Human Subjects of the region Arnhem 
and Nijmegen approved the study. All participants gave their written informed consent.
Study design
During this cross-sectional study, participants underwent comprehensive vascular 
assessment including traditional measures (DC, cPWV, and IMT) and compound strain 
imaging. 
Vascular measurements
All measurements were performed in supine position, in a temperature-controlled room, 
and following a ≥6h fast, ≥18h abstinence from ca eine, alcohol and vitamin supplements, 
and at least 24h after strenuous physical activity by the participant. Measurements began 
after a resting period in the supine position for at least 15 minutes. (20)
Traditional vascular measurement: distensibility coefficient, central pulse wave velocity, and IMT
Distensibility coe  cient. DC was assessed with a 9 MHz (L5-13) linear transducer connected 
to an Accuvix V10 ultrasound system (Samsung Medison, Seoul South Korea) in a transverse 
plane. Blood pressure was obtained in the right arm (21) and measured twice using a 
sphygmomanometer. Distensibility was measured twice in the left common carotid artery 
1.5 and 2.0 centimetres upstream of the bulbous in the transverse plane. 
Central pulse wave velocity. cPWV was measured using a three-lead electrocardiogram and 
an Echo-Doppler ultrasound machine (Waki Doppler, Atys Medical, Soucieu en Jarrest, 
France) at the left carotid artery and right common femoral artery. (2) The distances were 
measured between sternal notch and site of measurement for the carotid artery and 
common femoral artery via the umbilicus. (2) To estimate the travel distance between the 
carotid and femoral site, we subtracted the distance between the carotid location to the 
suprasternal notch from the distance between the suprasternal notch and the femoral 
site. (22) At least 10 cardiac cycles were recorded for the analysis. 
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Intima-media thickness. IMT of the left common carotid was recorded using a T3000 
ultrasound system (Terason Teratech Corporation, Boston, United States) equipped with 
an 8.5 MHz 12L5 linear transducer. To normalize vascular tonus the participants received 
400 µg of sublingual glyceryl trinitrate (nitric oxide donor) before the IMT measurement. (23) 
Therefore, the IMT measurement took place after DC and compound strain imaging. Image 
sequences of ≥10 seconds were recorded 1.5 to 2.0 cm distally of the bifurcation of the 
common carotid, while having the vessel in a longitudinal imaging plane. Wall thickness 
were collected from two distinct angles and the mean value is presented
Compound strain imaging
Vascular radial strain was assessed with a 9 MHz (L5-13) linear transducer connected to an 
Accuvix V10 ultrasound system (Samsung Medison, Seoul South Korea) equipped with a 
dedicated multi-angle acquisition mode for compound strain imaging and with an interface 
providing ultrasound RF data. The subject was lying in supine position, with no pillow 
beneath the head. Blood pressure was manually measured using a sphygmomanometer 
in the right arm before each recording. Cumulative radial (RS) and circumferential (CS) 
strains from peak systole to end diastole were determined in the left common carotid. The 
end-diastolic phase was based on the carotid distention (pressure) waveform and de ned 
as the time at which minimal lumen diameter was measured. The probe was placed at the 
location where the IMT was the thickest in the left common carotid artery. Whenever there 
was no location with a thicker IMT, the probe was placed between 1.5 and 2.0 centimetres 
upstream of the bulbous. Radiofrequency datasets of the carotid artery in a transverse 
plane were recorded twice for three seconds.
Data analysis
Traditional vascular measurement: distensibility coefficient, cPWV, and IMT
DC was calculated from M-mode using formula [1] (2) and derived from a diameter curve 
that was obtained by manually indicating the lumen-intima interfaces for the near and 
far wall at peak systole, after which the software automatically traced the interfaces from 
systole to systole. DC values of measurement 1 and 2 were averaged per artery. 
Pulse Pressure [2] 






 PP2
22
diastolediameter 
diastolediameter  - systolediameter 
 [1] 
PP = Systolic Blood Pressure – Diastolic Blood Pressure 
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cPWV was calculated in Matlab (MATLAB and Statistics Toolbox Release R2014, The 
MathWorks, Inc., Natick, United States) and was based on the interval between the R-wave 
on the electrocardiogram and onset of the Doppler waveform. The onset of the Doppler 
waveform was semi-automatically detected by the software and only major deviations 
were operator corrected.
Intima-media thickness of the left common carotid artery was examined using custom-
designed o -line edge-detection and wall-tracking software written in LabVIEW 
(LabVIEW  6.02, National Instruments, Austin, TX, USA). This DICOM-based software is 
largely independent of investigator bias and has been previously described in detail. (24, 25) 
Brie y, each recording was converted to a DICOM  le at a frame rate of 30 Hz. Detection of 
the far wall media-adventitia interface was performed on every frame selected. The mean 
intima-media thickness was calculated via: (1/3 × systolic wall thickness) + (2/3 × diastolic 
wall thickness). (26) All  les were analyzed blinded by an independent researcher.
Compound strain imaging
Strain parameters (RS and CS) were calculated from the radiofrequency data using custom 
made software written in Matlab R2014 (The MathWorks Inc., USA). (10, 19) First ultrasonic 
frames were identi ed that corresponded to the systolic and diastolic phases (maximum 
and minimum lumen diameter, respectively) in an M-mode view of the image line that 
crossed the vessel lumen center. For each systolic frame a region-of-interest corresponding 
to the upper half segment of the vessel wall was manually selected for which strains were 
to be computed, tracked and accumulated from systole to diastole. Strain calculation was 
performed using a 2D cross-correlation based coarse-to- ne strain estimation strategy 
followed by displacement compounding, tracking, rotation and 2D least squares strain 
estimation, see Table 5.1 for detailed settings of the compound strain estimation. (8, 10, 27, 28) 
The algorithm provided strain values for every 62.5 μm (vertically) by 200 μm (horizontally) 
of tissue. Of all strain values in the region-of-interest, the 90th percentile of the maximal 
strain was de ned as the  nal result of the strain analysis. Strain was normalized with 
respect to a reference pulse pressure of 40 mmHg. Strain values of measurement 1 and 2 
were averaged. 
Statistical analysis
This study was exploratory by design, since we had no information about RF-based strain in 
patients with cardiovascular diseases in non-stenotic arteries. Participants’ characteristics 
as well as vascular characteristics (DC, cPWV, IMT, RS, and CS) of the left common carotid 
of the participants were summarized with means and standard deviations or median and 
interquartile range (IQR). Parameters were checked for normality using a Shapiro-Wilk test 
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and Q-Q plots. An independent Student’s t in case of normal distribution or Mann-Whitney U 
test for all other cases was used to analyse di erences in participant characteristics and 
di erences in compound strain imaging of non-stenotic carotid arteries between CVD and 
CON. To determine the coherence between traditional vascular measurements (DC, cPWV, 
IMT, RS, and CS) and compound strain imaging, correlation coe  cients were calculated 
via Spearman’s Rank test for the total group and subgroups (CVD and CON). The Holm-
Bonferoni method was used to correct for multiple pairwise testing. (29)  Area under receiver 
operating characteristics (AROC)-curve was used to determine the discriminatory power 
of DC, cPWV, IMT, RS and CS. The di erent vascular measurements were combined to 
determine whether this increased the discriminatory power to detect CVD. All statistical 
analyses were performed using SPSS 22.0 software (IBM Corp. Released 2013. IBM SPSS 
Statistics for Windows, Version 22.0. Armonk, NY: IBM Corp.). Statistical signi cance was 
assumed at P<0.05 (two-sided).
Table 5.1 Settings of the strain estimation algorithm
Iteration 1 Iteration 2 Iteration 3 Iteration 4y Strain Estimation
Data input Envelope RF data RF data RF data Radial displacements
Pre-kernel size (mm x mm) 1.3 x 0.6* 0.6 x 0.6* 0.3 x 0.6* 0.3 x 0.6* -
Post-kernel size (mm x mm)
Axial kernel overlap (%)
1.9 x 1.8*
80
0.9 x 1.8*
80
0.5 x 1.8*
80
0.5 x 1.8*
80
-
-
Lateral kernel overlap (%) 67 67 67 67 -
Median  lter size (mm x mm) 2.2 x 1.8* 1.1 x 1.8* 0.6 x 1.8* 0.9 x 0.6*
z
0.6 x 0.6*z 21° x 0.5 mm
x
2D least squares strain estimator size (° x mm) - - - - 9° x 0.5 mmx
*Axial x lateral direction; y with sub-sample aligning; z- lter settings after compounding for the cumulated horizontal and vertical 
displacements, respectively; x- lter sizes de ned in circumferential x radial direction, because of conversion to polar grid with a spacing 
of 1° circumferentially and 100 µm radially. 
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Table 5.2 Participant characteristics of total and according to presence cardiovascular diseases. P-value refers to an 
independent Student’s t or Mann-Whitney U test (two-sided) between controls and CVD patients. Data is presented 
as mean and standard deviation (normal distribution) or median and interquartile range (non-normal distribution).
Total group
n=72
Controls
n=36
CVD patients
n=36 P-value
CHARACTERISTICS
Age (years) 60±7 59±7 61±6 0.41
Body height (cm) 178±7 180±7 176±6 0.011
Body mass (kg) 81±11 81±11 81±12 0.98
Body Mass Index (kg/m2) * 25.3 [23.6 to 27.0] 24.9 [23.3 to 26.9] 25.6 [24.2 to 27.9] 0.20
Mean arterial pressure (mmHg)* 97 [91 to 105] 100 [93 to 106] 94 [90 to 100] 0.035
Diastolic blood pressure (mmHg)* 79 [75 to 88] 83 [77 to 91] 77 [73 to 82] 0.011
Systolic blood pressure (mmHg) 131 [123 to 142] 136 [124 to 142] 128 [120 to 139] 0.19
CARIOVASCULAR MEDICATION USE
Anticoagulant (n) - 35 (97%)
Antihypertensive agents (n) - 29 (81%)
Lipid lowering agents (n) - 32 (89%)
VASCULAR MEASUREMENTS
Radial strain (%) * 4.2 [3.2 to 6.5] 4.2 [3.2 to 6.4] 4.8 [3.6 to 6.5] 0.50
Circumferential strain (%)* -10.0 [-13.6 to -6.5] -10.2 [-14.9 to -7.0] -8.8 [-13.2 to -6.2] 0.29
Distensibility * 0.27 [0.19 to 0.37] 0.27 [0.20 to 0.35] 0.29 [0.18 to 0.40] 0.77
Central pulse wave velocity * 8.0 [6.8 to 10.1] 7.8 [6.5 to 10.0] 8.0 [7.2 to 10.2] 0.22
Intima to media thickness (mm) * 0.72 [0.61 to 0.78] 0.68 [0.58 to 0.76] 0.76 [0.68 to 0.80] 0.023
*Mann-Whitney U test
RESULTS
Characteristics participants
Age, weight, and body mass index did not signi cantly di er between CVD and CON 
(Table  5.2). CON were taller compared to CVD (CON: 180±7 cm vs. CVD: 176±6 cm; 
P=0.011) and had a higher mean arterial pressure (CON: 100 mmHg [IQR: 93-106] vs. CVD: 
94 mmHg [IQR: 90-100] mmHg; P=0.035) (Table 5.2). Within the CVD group, anticoagulant 
(n=35 [97%]) medications were used most frequently, followed by lipid lowering (n=32 
[89%]) and antihypertensive agents (n=29 [81%]), whereas the control group did not use 
medications (Table 5.2).
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Table 5.3 Spearman rank correlations between vascular measurements. 
RS CS DC cPWV IMT group
RS
-0.72** 0.28 -0.34* -0.05 CON
-0.75** 0.23 -0.26 -0.15 CVD
CS -0.73**
-0.34* 0.42* 0.07 CON
-0.24 0.04 0.24 CVD
DC 0.27* -0.32**
-0.26 0.14 CON
-0.30 -0.17 CVD
cPWV -0.25* 0.24* -0.28*
0.28 CON
-0.38* CVD
IMT -0.08 0.19 0.01 0.01
RS: radial strain; CS: circumferential strain; DC: distensibility coe  cient; CON: controls; 
CVD: patients with history of cardiovascular disease. *P<0.05 **P<0.01; numbers in bold 
remain statistical signi cant after correcting for multiple testing with the Holm-Bonferroni 
method (29)
Vascular measures 
The participants did not show visible atherosclerotic plaques during the vascular 
measurements. All compound strain measures took place approximately 1.5 to 2.0  cm 
below the bifurcation of the carotid artery. DC and cPWV did not signi cantly di er 
between CON and CVD (Table 5.2). CON demonstrated a smaller intima-media thickness 
of carotid artery compared to CVD (Table 5.2). RS and CS not signi cantly di er between 
CON and CVD, respectively (Table 5.2).
Pairwise comparison: traditional measures vs. compound strain imaging
Spearman rank analysis revealed that a higher CS or RS was associated with a higher DC 
and lower cPWV in the total group (Table 5.3). A higher DC was associated with a lower 
cPWV. IMT did not correlate with DC, cPWV, CS, and RS (Table 5.3).
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Table 5.4 Area under the Receiver Operator Curve to determine the discriminatory power to detect 
patients with cardiovascular diseases for Radial Strain (RS), Circumferential Strain (CS), Distensibility 
Coe  cient (DC), central Pulse Wave Velocity (cPWV), Intima-Media Thickness (IMT).
Parameter AUC (95% CI) P-value
RS 0.57 (0.44 to 0.71) 0.28
CS 0.55 (0.41 to 0.68) 0.50
DC 0.48 (0.34 to 0.62) 0.76
cPWV 0.58 (0.45 to 0.72) 0.22
IMT 0.66 (0.53 to 0.79) 0.023
Combinations
IMT+RS 0.64 (0.51 to 0.78) 0.04
IMT+CS 0.66 (0.53 to 0.79) 0.02
IMT+DC 0.65 (0.52 to 0.78) 0.03
IMT+cPWV 0.66 (0.53 to 0.79) 0.02
IMT+RS+CS 0.71 (0.59 to 0.84) 0.002
IMT+RS+CS+DC 0.71 (0.59 to 0.84) 0.002
IMT+RS+CS+DC+pPWV 0.71 (0.59 to 0.84) 0.003
RS: radial strain; CS: circumferential strain; DC: distensibility coe  cient; IMT: intima-media thickness
Area under receiver operating characteristic curve
DC, cPWV, RS, and could not discriminate between CVD or CON (Table 5.4). The IMT was 
able to identify CVD with a best cut-o  for the carotid IMT of 0.70 mm (sensitivity: 74%, 
speci city: 58%). Although combinations of IMT and RS, CS, DC, or cPWV increased the 
AUC, this was not statistically di erent from IMT only (Table 5.4).
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Discussion
The present study revealed that compound strain imaging is coherent to traditional 
measures of vascular sti ness (DC and cPWV). Compound strain imaging seems a feasible 
technique to measure carotid wall deformation, which are indirectly related to wall sti ness. 
However, compound strain imaging does not provide an incremental discriminative value 
to traditional measures of vascular health to discriminate between CVD and asymptomatic 
controls with non-stenotic arteries. 
Measuring vascular strain in non-stenotic arteries
Strain estimation in the arterial wall is challenging because of the small structure of the 
arterial wall. Compound strain imaging was validated in severely stenotic arteries (>70% 
stenosis) (30) and demonstrated good correlation with local plaque composition. A larger 
area to calculate strain was present in these stenotic plaques than in the present study where 
none of the participants had severely stenotic arteries (IMTtotal group: 0.73 [0.61-0.78] mm), 
making a correct estimation of strain more challenging and probably more susceptible 
for errors. We can speculate that strain could provide additional information on changes 
of arterial elastic properties. The cPWV (carotid-fermoral) is considered the gold standard 
measurement to determine arterial sti ness. (2) Our results indicate that strain, DC, and 
cPWV are related measurements, since we observed a statistically signi cant correlation. 
Compound strain imaging seems technically feasible to measure in non-stenotic arteries. 
It is however questionable what additional information strain provides next to DC or 
cPWV when there is no or hardly any plaque present. Given the fact that compound strain 
imaging requires complex and intensive calculations, whereas DC and cPWV are relatively 
straightforward to determine and calculate, we would recommend using the DC or cPWV 
instead of strain to obtain an (indirect) measure for arterial sti ness in non-stenotic arteries. 
Vascular stiffness vs. vascular structure
Elastic and structural properties of the arteries are in uenced by di erent (lifestyle) 
factors. (31-36) In general, elasticity parameters seem to adjust in week-months by changing 
lifestyle (i.e. physical activity) (35, 36) or medication usage. (32) Possibly, the reason why strain 
and distensibility could not discriminate between CVD or CON relates to the use of 
antihypertensive agents within the CVD group (Table 5.2). Antihypertensive agents are 
known to improve vascular compliance, (31, 32) which may have reduced the arterial sti ness 
of the participants with CVD.
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In the present study IMT was signi cantly larger among CVD patients compared to 
controls, despite that participants with CVD used (lipid lowering) medication. These results 
align with other studies, which demonstrated participants with prevalent CVD have an 
increased IMT compared to disease-free controls. (37-40) Lifestyle interventions (e.g. diet, 
physical activity) and usage of lipid lowering agents after myocardial infarction reduces 
the progression of the IMT. (33, 34) IMT is therefore considered a more chronic stable index 
for the evaluation of vascular health. Care should be taken when evaluating vascular 
health in patients with CVD, since (lifestyle) interventions may reduce vascular sti ness, 
whereas structural measures may be better to evaluate long-term arterial properties and 
discriminate between chronically diseased and control participants.
Limitations
A few methodological considerations should be taken into account to the present study. 
This study was cross-sectional by design and is subject to the inherent limitations of that 
approach. During this study, we could not evaluate the predictive value of compound 
strain imaging, since our CVD patient group already had the disease. Secondly, the o  ine 
analysis of the strain data is semi-automatic. The arterial wall was not always detected by 
the program and had to be retraced by the researcher. However, each measurement was 
evaluated by two researchers to determine whether the arterial wall was correctly traced. 
After consensus was met, the measurement was included in the statistical analysis. Third, 
DC was calculated using the pulse pressure of the right brachial artery instead of the local 
pulse pressure of the carotid artery. Due to pressure ampli cation (41) it is possible that we 
overestimated the pulse pressure in the carotid artery, since the amplitude of a pressure 
wave is higher in peripheral arteries than central arteries. However, with natural ageing the 
di erence in arterial sti ness between central and peripheral arteries declines, (41) which 
causes a fall in pressure ampli cation. Fourth, in the present study, we used a Doppler 
device to measure the cPWV. However, applanation tonometry is generally recognized as 
a more reliable technique to measure cPWV. (42) Fifth, in the past, we have gone through 
extensive e orts to improve the analysis (24, 25) and procedures to examine carotid IMT. (23) 
Nonetheless, we understand this approach may be slightly di erent compared to typically 
adopted protocols in the literature (including large cohort studies). We emphasize that, 
due to our protocol, generalizability against larger epidemiologic studies is inappropriate. 
Finally, all the participants of the study were men, which limits the generalizability of the 
present study.
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Conclusion
In non-stenotic arteries, compound strain imaging is a feasible technique to determine 
arterial wall deformation, but did not shown an incremental discriminative value next to 
DC, cPWV, or IMT in this study. This suggests that, in patients with non-stenotic arteries, 
compound strain imaging provides limited additional insight next to traditional measures 
of vascular health (DC, cPWV, or IMT) when di erentiating between CVD patients and 
asymptomatic controls.
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Objectives
Dicarbonyl stress and high concentrations of advanced glycation endproducts 
(AGEs) relate to an elevated risk for cardiovascular diseases (CVD). Exercise training 
lowers the risk for future CVD. We tested the hypothesis that lifelong endurance 
athletes have lower dicarbonyl stress and AGEs compared to sedentary controls 
and that these di erences relate to a better cardiovascular health pro le. 
Design
Cross-sectional study
Methods
We included 18 lifelong endurance athletes (ATH, 61±7 years) and 18 sedentary 
controls (SED, 58±7 years) and measured circulating glyoxal (GO), methylglyoxal 
(MGO) and 3-deoxyglucosone (3DG) as markers of dicarbonyl stress. Furthermore, 
we measured serum levels of protein-bound AGEs Nε-(carboxymethyl)lysine 
(CML), Nε-(carboxyethyl)lysine (CEL), methylglyoxal-derived hydroimidazolone-1 
(MG-H1), and pentosidine. Additionally, we measured cardiorespiratory  tness 
(VO2peak) and cardiovascular health markers. 
Results
ATH had lower concentrations of MGO (196 [180-246] vs. 242 [207-292] nmol/mmol 
lysine, P=0.043) and 3DG (927 [868-972] vs. 1061 [982-1114] nmol/mmol lysine, 
P<0.01), but no GO compared to SED. ATH demonstrated higher concentrations 
CML and CEL compared to SED. Pentosidine did not di er across groups and MG-
H1 was signi cantly lower in ATH compared to SED. Concentrations of MGO en 3DG 
were inversely correlated with cardiovascular health markers, whereas CML and 
CEL were positively correlated with VO2peak and cardiovascular health markers. 
Conclusion
Lifelong exercise training relates to lower dicarbonyl stress (MGO and 3DG) and 
the AGE MG-H1. The underlying mechanism and (clinical) relevance of higher CML 
and CEL concentrations among lifelong athletes warrants future research, since it 
con icts with the idea that higher AGE concentrations relate to poor cardiovascular 
health outcomes.
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 Introduction
Advanced glycation endproducts (AGEs) are a complex group of modi ed proteins or lipids 
that are formed by a process of non-enzymatically glycation and oxidation. AGEs formation 
is a slow process (i.e. weeks to months) and depends on the extent of oxidative stress, degree 
of hyperglycemia, and turnover rate of proteins. (1, 2) The formation of AGEs is irreversible 
and AGEs accumulate with increasing age. Highly reactive dicarbonyls (α-oxoaldehydes) 
are involved in the fast formation of AGEs and accumulation of dicarbonyls is known 
as dicarbonyl stress. (1, 2) Dicarbonyls are precursors for AGEs (3) and the most important 
dicarbonyl marker is the highly reactive methylglyoxal (MGO). (4) Dicarbonyl stress and a 
high concentration of AGEs are linked to the development of cardiovascular diseases. (4-6) 
Higher levels of circulating AGEs are also related to higher vascular sti ness. (7-9) There 
are several mechanisms proposed how AGEs may a ect the vascular wall properties, 
such as binding to receptor AGEs (RAGEs) and cross-linking matrix proteins in the vessel 
wall. (2, 10) AGE-binding to RAGEs leads to an upregulation of in ammation and production 
of reactive oxygen species. (11, 12) These processes augment vascular dysfunction and may 
promote vascular sti ness. (11, 12) Alternatively, AGEs can also bind to collagen and elastin 
to form crosslinks with matrix proteins, which promotes vascular sti ness. (12) Strategies to 
lower the burden of high levels of AGEs may improve cardiovascular health and need to 
be explored.
Regular exercise training is part of a healthy lifestyle and is an e ective strategy to reduce 
the risk for cardiovascular morbidity and mortality. (13, 14) Exercise training attenuates 
the age-associated decline in cardiovascular function, (15, 16) and improves glucose  (17) 
and lipid metabolism. (18) Findings from animal studies suggest that these health 
bene ts of exercise training may relate to a reduction of dicarbonyl stress and AGEs 
concentrations. (19, 20) Clinical studies linking exercise training with dicarbonyl stress or AGEs 
are, however, sparse and con icting. (21-23) A previous study demonstrated that 12 months 
of tai chi training for 2 sessions/week signi cantly reduced serum AGEs concentrations in 
asymptomatic middle-aged adults. (23) However, another study found no e ect on serum 
AGEs concentrations in middle-aged overweight or obese men after a 3-month aerobic 
moderate intensity exercise training program. (21) Variation in study outcomes may partially 
relate to the training duration (3 vs. 12 months), exercise intensity (light vs. moderate), or 
study population (asymptomatic vs. overweight/obese). Lifelong endurance athletes may 
provide better insight to what extent exercise is related to attenuated AGEs formation. 
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Therefore, we tested the hypothesis that lifelong endurance athletes have lower dicarbonyl 
stress and a lower concentration of AGEs compared to sedentary controls. Additionally, 
we explored whether lower dicarbonyl stress and lower concentration of AGEs relate to a 
better cardiovascular health pro le.
Methods
Thirty-six male participants aged >45 years were included and strati ed into 2 groups based 
on their lifelong exercise patterns: 1) lifelong endurance athletes (ATH, n=18), 2) sedentary 
controls (SED, n=18). ATH had to perform ≥20 years of endurance exercise training (e.g. 
running or cycling) for ≥4 hours/week, whereas SED had to report ≥20 years of habitual 
physical activity <2 hours/week. Current smokers, participants with a history of diabetes 
mellitus or cardiovascular disease, or participants not able to perform an incremental 
maximal cycling test were not included in the study. The Local Committee on Research 
Involving Human Subjects of the region Arnhem and Nijmegen approved the study. All 
participants gave their written informed consent prior to study participation.
Study design
During this cross-sectional study, participants visited our laboratory on 2 separate days. 
On day 1, participants were medically screened for eligibility, followed by an incremental 
maximal cycling test to determine their physical  tness. On day 2, pulse wave velocity was 
measured as an index of vascular sti ness and blood samples were obtained under fasting 
conditions. Both testing days were scheduled within a 14-day time-frame, with at least 
1 recovery day between measurement day 1 and 2.
Medical screening and Incremental maximal cycling test
A physician medically screened the participants by taking a detailed medical history, physical 
examination, and 12-lead electrocardiogram. After screening, participants performed 
an incremental maximal cycling test to determine the cardiorespiratory  tness and peak 
oxygen uptake (VO2peak, mLO2/min). The test took place in a temperature-controlled 
room (18-19˚C) and under the supervision of a physician. Participants cycled with 60-80 
rotations per minute while the workload increased with 20 Watt/min for ATH and 10 Watt/
min for CON. Heart rate was continuously measured via a 12 lead-electrocardiogram. 
Oxygen uptake (VO2 [mL/min]), carbon dioxide output (VCO2 [mL/min]), and respiratory 
exchange ratio (RER) were continuously measured via a gas analyser (CPET, Cosmed v9.1b, 
Rome, Italy). Lactate concentration (mmol/L) was measured (Lactate Pro™ 2, Arkray, type 
LT-1730, Kyoto, Japan) via a capillary blood sample taken 1.5 minute after cessation of 
the exercise test. The incremental maximal cycling test was considered successful when 
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2 of the 4 criteria were met: I) RER ≥ 1.05, II) achievement of at least 85% of age-predicted 
maximal heart rate (220 – age), III) blood lactate ≥ 6.00 mmol/L, or IV)  attening of VO2 
uptake curve (≤ 150 mL increase during the last minute). (24, 25)
Lifelong exercise history
Lifelong exercise patterns were queried via an exercise history questionnaire, distinguishing 
5 age-periods: I) 20-29 years, II) 30-39 years, III) 40-49 years, IV) 50-59 years and V) >60 years. 
Each category consisted of 2 queries: 1) type of activity (e.g. running, cycling, etc., or 
nothing) and 2) exercise time (hours) per activity per week. Based on the Compendium 
of Physical Activities, (26) the corresponding metabolic equivalent of task (MET) score 
per exercise activity was determined. Vigorous exercise activities were de ned as a MET 
score >6. Subsequently, exercise volume (MET-hours/week) was calculated by multiplying 
exercise time with accompanying MET score. The average exercise time and dose were 
calculated over the last 2 decades. 
Pulse wave velocity
Before the second testing day, participants were asked to abstain from I) (vigorous) 
physical activities for 24 hours, II) ca eine, alcohol, or vitamin supplement intake for at least 
18 hours, and III) food intake for ≥6 hours. Central and peripheral pulse wave velocity was 
assessed with a three-lead electrocardiogram and an echo-Doppler ultrasound machine 
(WakiLoki Doppler, 4 MHz, Atys) at the left carotid artery, right common femoral artery, 
and radial artery. The distances between sternal notch and site of measurement for the 
carotid artery and between radial artery and common femoral artery via the umbilicus 
were measured. (27) At least 10 cardiac cycles were recorded for analyses. Based on the R-R 
interval and onset of the Doppler waveform, central and peripheral pulse wave velocities 
were calculated in Matlab R2014 (The MathWorks Inc., United States).
Traditional cardiovascular risk markers
Following vascular measurements, a fasting blood sample (8 mL) was obtained from 
an antecubital vein for the assessment of concentrations of dicarbonyl stress and AGEs. 
Additionally, lysine and traditional cardiovascular risk factors (total-, high-density 
lipoproteins [HDL]-, low-density lipoproteins [LDL]-cholesterol, triglycerides, glycated 
hemoglobin [HbA1C], and glucose) were determined. Homeostasis model assessment of 
insulin resistance (HOMA-IR) was calculated based on glucose and insulin concentrations 
(IR = (fasting insulin [mU/L] X fasting glucose [mmol/L])/22.5). (28) To gain insight in the 
cardiovascular (risk) pro le of ATH and SED, the 10-year CVD risk was calculated via the 
Framingham Risk Score (FRS). (29) 
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Dicarbonyl stress
For measurement of serum levels of diarbonyl components and AGEs, we used ultra-
performance liquid chromatography tandem mass spectrometry (UPLC-MS/MS, Waters, 
Milford Massachusetts, USA). UPLC-MS/MS combines liquid chromatography for separation 
and tandem mass spectrometry for speci c detection.
Whole blood samples in serum-separating tubes were centrifuged after collection (10 min, 
4°C, 3,000 g) and supernatant was stored at –80°C until analysis. Serum levels of dicarbonyl 
compounds glyoxal (GO), MGO, and 3-deoxyglucosone (3DG) were analysed following 
a previously described protocol. (3) Brie y, serum samples were deproteinized using 
perchloric acid and subsequently derivatized with o-phenylenediamine. GO, MGO, and 
3DG concentrations were measured using stable isotope-dilution UPLC-MS/MS (Waters, 
Milford Massachusetts, USA) with a run-to-run time of 8 min. Intra-run and inter-run 
variations were 4.3% and 14.3% for GO, 2.9% and 7.3% for MGO, and 2.4% and 12.0% for 
3DG, respectively. 3
Advanced glycation endproducts
Protein-bound serum AGEs Nε-(carboxymethyl)lysine (CML), Nε-(carboxyethyl)lysine 
(CEL), methylglyoxal-derived hydroimidazolone-1 (MG-H1), and lysine were measured 
with UPLC-MS/MS (Waters, Milford Massachusetts, USA), as previously described. (30, 31) 
Pentosidine was measured with high-performance liquid chromatography and  uorescent 
detection. (31) Intra-run and inter-run variations were 2.8% and 7.1% for CML, 3.7% and 6.4% 
for CEL, 3.7% and 5.1% for MG-H1, and 2.0% and 3.1% for pentosidine. (30, 31) All serum AGEs 
were adjusted for lysine concentrations as a marker of total protein concentration.
Statistical analysis
Participant characteristics were summarized with means and standard deviations or median 
and interquartile range (IQR), when appropriate. Categorical data were analysed using the 
Fisher’s exact test. Parameters were checked for normality using a Shapiro-Wilk test and Q-Q 
plots. Skewed variables were loge-transformed before statistical analyses were conducted. 
Di erences in participant characteristics, lifelong exercise patterns, and cardiovascular 
health markers between ATH and SED were analysed using an independent Student’s t 
test. As an overall measure of pulse wave velocity, z-scores of central and peripheral pulse 
wave velocities were averaged. Correlations between markers for dicarbonyl stress or AGEs 
and markers for cardiovascular health (BMI, pulse wave velocity, cardiorespiratory  tness, 
Framingham risk score, and glucose metabolism) were evaluated using Spearman’s rank 
test. All statistical analyses were performed using SPSS 21.0 software (SPSS 21.0. Armonk, 
NY: IBM Corp.). Statistical signi cance was assumed at P<0.05 (two-sided).
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Results
Age, height, mean arterial pressure, and smoking history did not di er between groups, 
but ATH demonstrated a lower body weight and Body Mass Index compared to SED 
(Table 6.1). HbA1c, total cholesterol, and glucose concentrations did not di er between 
groups, but ATH demonstrated a higher HDL cholesterol concentration and lower LDL 
cholesterol, triglycerides, and HOMA-IR compared to SED (Table 6.1). The median time 
between smoking cessation and study participation was 28 years (Q25: 12 to Q75: 40) in ATH 
vs. 25 years (Q25: 15 to Q75: 37) in SED (P=0.78).
ATH showed a signi cantly higher weekly exercise time and dose compared to SED 
(Table  6.1). ATH mostly performed vigorous-intensity exercise activities (e.g. running or 
road cycling). We observed a higher VO2peak in ATH (3544±651 mL/min) compared to 
SED (2843±519 mL/min, P<0.01). Likewise, ATH reached a higher power output during the 
incremental exercise test compared to SED (P<0.01, Table 6.2). 
Table 6.1 Participants’ characteristics of lifelong endurance athletes (ATH, n=18) and sedentary controls 
(SED, n=18). Data is presented as mean and standard deviation or median and interquartile range (IQR). 
P-value refers to an independent Student’s t test or Mann-Whitney U test.
ATH SED P-value
n 18 18
CHARACTERISTICS
Age (years) 61±7 58±7 0.29
Height (m) 179±8 181±6 0.31
Weight (kg) 74±8 87±10 <0.01
Body Mass Index (kg/m2) ¥ 23.6 (21.1-24.9) 26.7 (25.0-27.4) <0.01
Mean arterial pressure (mmHg) * 98 (90-106) 103 (93-107) 0.70
Systolic blood pressure (mmHg) 134±17 137±16 0.53
Diastolic blood pressure (mmHg) 84±10 84±10 0.92
Smoking history (%yes [n]) 10 (56) 15 (83) 0.15
FASTING BLOOD SAMPLES
HbA1c (mmol/mol) ¥ 35.5 (34.4-38.3) 35.5 (35.5-38.3) 0.53
Cholesterol (mmol/L) 5.4±0.8 5.9±0.9 0.07
LDL (mmol/L) 3.3±0.8 4.0±0.8 0.012
HDL (mmol/L) 1.8±0.3 1.4±0.3 <0.01
Triglycerides (mmol/L) * 0.8 (0.7-1.2) 1.3 (1.0-2.4) <0.01
Glucose (mmol/L) * 4.6 (4.4-5.0) 4.7 (4.4-4.9) 0.66
Insulin (mU/L) 2.8±1.8 6.8±2.9 <0.01
HOMA-IR * 0.5 (0.3-0.9) 1.3 (0.8-2.2) <0.01
LIFELONG EXERCISE PATTERNS
Exercise time (hours/week) ¥ 7.1 (5.8-11.9) 0.5 (0.0-1.4) <0.01
Exercise dose (MET-hours/week) ¥ 60 (47-110) 4 (0-12) <0.01
HbA1c: Glycated haemoglobin; HDL: High-density lipoprotein; HOMA-IR: homeostasis model 
assessment of insulin resistance; LDL: low-density lipoprotein; MET: Metabolic Equivalent of Task; 
* Data were loge-transformed before statistical analysis; ¥ non-parametrically tested via Mann-Whitney U
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Central pulse wave velocity was signi cantly lower in ATH (7.0±2.2 m/s) compared to 
SED (9.2±2.3 m/s, P<0.01). Peripheral pulse wave velocity was signi cantly lower in ATH 
(8.1±1.5 m/s) compared to SED (9.4±1.6 m/s, P=0.017).
MGO (196 [180-246] vs. 242 [207-292] nmol/mmol lysine, P=0.043) and 3DG (927 [868-
972] vs. 1061 [982-1114] nmol/mmol lysine, P<0.01) concentrations were lower in ATH 
compared to SED (Figure 6.1). Glyoxal concentrations did not di er between ATH vs. SED 
(314 [202-451] vs. 342 [266-388] nmol/mmol lysine, P=0.86, Figure 6.1). 
CML was signi cantly higher in ATH (80 [73-89] nmol/mmol lysine) vs. SED (68 
[56-76] nmol/mmol lysine, P<0.01, Figure 6.1). Similarly, CEL was signi cantly higher in ATH 
(35 [28-41] nmol/mmol lysine) compared to SED (28 [24-34] nmol/mmol lysine, P=0.035). 
Pentosidine (0.63 [0.59-0.86] vs. 0.56 [0.48-0.67] nmol/mmol lysine, P=0.11) did not di er 
between groups (Figure 6.1). MG-H1 concentration was signi cantly lower in ATH (363 
[288-468] nmol/mmol lysine) compared to SED (460 [340-536] nmol/mmol lysine, P=0.043, 
Figure 6.1).
Table 6.2 Participants’ characteristics of lifelong endurance athletes (ATH, n=18) and sedentary controls 
(SED, n=18). Data is presented as mean and standard deviation or median and interquartile range (IQR). 
P-value refers to an independent Student’s t test or Mann-Whitney U test.
ATH SED P-value
n 18 18
CARDIOVASCULAR HEALTH PARAMETERS
Pulse Wave Velocity
Central PWV (m/s) 7.0±2.2 9.2±2.3 <0.01
Peripheral PWV (m/s) 8.1±1.5 9.4±1.6 0.017
Framingham Risk Score (%) * 10.1 (7.5-20.3) 16.5 (10.1-19.5) 0.12
VO2peak (mL/min) 3544±651 2843±519 <0.01
INCREMENTAL EXERCISE TEST
Maximal heart rate (beats/min) 165±13 171±15 0.29
RER (ratio: VCO2 / VO2) * 1.13 (1.06-1.17) 1.08 (1.05-1.14) 0.029
Lactate (mmol/L) * 11.6 (8.9-12.3) 11.1 (9.4-12.8) 0.77
Power Output (W) 319±58 209±46 <0.01
PWV: pulse wave velocity; RER: respiratory exchange ratio; VO2peak: peak oxygen uptake; 
* Data were loge-transformed before statistical analysis; ¥ non-parametrically tested via Mann-Whitney U
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A. Markers for dicarbonyl stress
B. Markers for advanced glycation endproducts
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Figure 6.1 Individual and average values of markers for (A) dicarbonyl stress and (B) advanced glycation 
endproducts in lifelong athletes (circles) and sedentary controls (squares). For dicarbonyl 
markers, GO concentrations did not di er between groups, whereas MGO and 3DG were 
signi cantly lower in athletes compared to controls. For advanced glycation endproducts, 
CML and CEL concentrations were higher in athletes compared to controls. Concentrations of 
pentosidine did not di er between groups. Concentrations of MG-H1 were lower in athletes 
compared to controls. P-value refers to an independent Student’s t or Mann-Whitney U (¥) test. 
Group averages are presented as median and interquartile range.
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MGO was positively correlated with BMI, central PWV, and FRS (Table 6.3). 3DG was 
negatively correlated with VO2peak, but positively correlated with BMI, central and 
peripheral PWV, FRS, and glucose (Table 6.3). GO did not correlate with cardiovascular 
health parameters (Table 6.3). 
CML was negatively correlated with BMI and peripheral PWV, but positively correlated 
with VO2peak. MG-H1 was negatively correlated with VO2peak (Table 6.3). Pentosidine was 
negatively correlated with peripheral PWV and glucose (Table 6.3). CEL did not correlate 
with cardiovascular health parameters (Table 6.3). 
Discussion
This study aimed to compare markers of dicarbonyl stress and circulating AGEs between 
lifelong endurance athletes and sedentary controls. MGO and 3DG were signi cantly 
lower in ATH compared to SED, and were related to a better cardiovascular health pro le. 
However, we also found that CML and CEL were signi cantly higher in ATH compared to 
SED. 
The bene ts of exercise training on cardiovascular health are indisputable, (14-16) but 
underlying mechanisms explaining the lower risk for cardiovascular events in physically 
active individuals are not fully understood. (16) Our results suggest that bene ts of exercise 
training relate to a lower concentration of MGO and 3DG. These  ndings are in line with 
Dicarbonyl stress
GO MGO 3DG
CARDIOVASCULAR HEALTH MARKERS
BMI 0.02 0.35* 0.40*
Average PWV 0.12 0.35* 0.55**
Central PWV 0.24 0.51** 0.46**
Peripheral PWV -0.05 0.10 0.44**
VO2peak (mL/min) 0.01 -0.32 -0.47**
FRS 0.24 0.52** 0.43**
Glucose -0.19 0.15 0.46**
Insulin 0.04 0.36* 0.44**
HOMA-IR -0.01 0.34 0.49**
LIFELONG EXERCISE PATTERNS
Exercise time -0.04 -0.34* -0.53**
Exercise dose -0.04 -0.34* -0.53**
3DG: 3-deoxyglucosone; CEL: Nε-(carboxyethyl)lysine; CML: Nε-(carboxymethyl)lysine; FRS: Framingham risk score; GO: glyoxal; HOMA-IR: 
homeostasis model assessment of insulin resistance; MG-H1: Methylglyoxal-derived hydroimidazolone-1; MGO: methylglyoxal; VO2peak: 
peak oxygen uptake (cardiorespiratory  tness); Average PWV: average pulse wave velocity, the average of the z-scores of central and 
peripheral PWV; Correlation is signi cant at *0.05 or **0.01 level (two-sided).
Table 6.3 Spearman’s Rank (ρ) correlations between dicarbonyl stress, advanced glycation endproducts, and cardiovascular health parameters
Advanced glycation endproducts
CML CEL Pentosidine MG-H1
-0.53** -0.13 -0.31 0.19
-0.54** 0.10 -0.31 0.04
-0.30 0.07 -0.10 0.03
-0.58** 0.11 -0.43* 0.02
0.34* 0.33 0.18 -0.55**
-0.23 -0.06 -0.09 0.11
-0.13 0.13 -0.41* -0.09
-0.36* -0.24 -0.12 0.35*
-0.36* -0.21 -0.16 0.33
0.46** 0.32 0.28 -0.36*
0.45** 0.36* 0.30 -0.37*
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a recent study in rats, which demonstrated that running exercise was associated with a 
reduction in dicarbonyl stress. (19) In general, we found that markers of dicarbonyl stress 
showed a moderate, yet signi cant correlation with cardiovascular health or metabolic 
markers. For example, lower concentration MGO and 3DG were correlated to low 
Framingham risk score, lower insulin concentration, and better HOMA-IR. Reducing 
hyperglycaemia and improving insulin sensitivity may be a  rst step to reduce accumulation 
of MGO (4, 32) and 3DG. (32) High levels of dicarbonyl stress, and especially MGO, increase 
morbidity risk. (4-6) MGO is highly reactive and is mainly catabolized via glyoxalase I of the 
glyoxalase system. The activity of the glyoxalase system depends on concentrations of 
reduced glutathione (GSH). (4, 33) Biosynthesis of GSH is heavily dependent of the antioxidant 
response element-nuclear respiratory factor (ARE-Nrf) pathway. Animal and human studies 
demonstrated that an acute bout of swimming or moderate intensity endurance exercise 
training upregulate the ARE-Nrf pathway and GSH biosynthesis. This led to the hypothesis 
that exercise training enhances the glyoxalase system and may lower MGO and MG-H1 
concentrations. (34) Based on our data, it can be speculated that exercise training possibly 
lowers the levels of MGO and MG-H1 via an upregulation of the glyoxalase system. Further 
research is warranted to explore these pathways. Taken together, our data demonstrated 
that exercise training is related to lower levels of MGO, 3DG, and MG-H1.
In contrast to our hypothesis, we found that 2 of the 4 AGEs (CML and CEL) were signi cantly 
higher in ATH, whereas MG-H1 was signi cantly lower in ATH compared to SED. Although 
MG-H1 is a AGE, it is produced in a much shorter timeframe and is less stable than CML, 
CEL or pentosidine. (35) MG-H1 may, therefore, better relate to abnormal accumulation of 
dicarbonyl stress. (35) This could explain why MG-H1 showed opposite results compared to 
the other AGEs, since dicarbonyl stress was lower in ATH compared to SED.
Previous studies indicated that an increase in AGEs concentration relates to poor health 
outcomes. (4-6) Our  ndings are contradictory to this concept, as we found an inverse 
relation between circulating CML and pulse wave velocity, BMI, and cardiorespiratory 
 tness. A potential explanation for this  nding could be that exercise enhances collagen 
turnover rate, which breaks and prevents AGE cross-links in the vessel wall. (12, 36, 37) This may 
contribute to higher levels of circulating AGEs, but this hypothesis needs to be reinforced 
with future studies. Alternatively, a recent animal study demonstrated that a 12-week 
running exercise training leads to suppressed RAGEs activation in the aorta of aged rats. (38) 
It could be speculated that attenuated RAGEs activity limits the uptake of AGEs from the 
circulation to the surrounding tissue, (39) leading to increased levels of circulating AGEs. 
Thus, the observation of higher AGEs in lifelong endurance athletes may relate to a higher 
collagen turnover and/or suppression of RAGEs due to long-term exercise training.
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Another possible explanation for the higher AGEs concentrations in ATH vs. SED may 
relate to the (vigorous) exercise training regimes of our lifelong endurance athletes. Acute 
exercise induces a transient increase in oxidative stress, (40) which upregulates the formation 
of AGEs. (1, 2) Mice de cient in NADPH (nicotinamide adenine dinucleotide phosphate) 
oxidase, a pathway involved in the generation of reactive oxygen species, showed an 
impaired CML generation, which suggests that oxidative stress is a potential stimulus to 
generate CML. (41) Although the sudden increase in oxidative stress is a necessary stimulus 
to enhance the anti-oxidative defence mechanism (i.e. glyoxalase system), (42) it is possible 
that the formation of AGEs is simultaneously upregulated. The positive relation between 
exercise dose / time and CML concentrations found in the present study (Table 6.3) may 
relate to the e ects of sustained exposure to vigorous exercise training. Hence, lifelong 
and repetitive exposure to vigorous exercise increases oxidative stress and may boost 
the accumulation of circulating AGEs in the blood. Future research is warranted to 
elucidate the underlying mechanisms and (clinical) impact of higher AGEs (CML and CEL) 
concentrations in athletes, as this observation contradicts with the general believe that 
high concentrations of circulating AGEs relate to CVD.
This cross-sectional study is inherent to some limitations. First, the comparison between 
athletes and sedentary individuals does not prove that exercise can attenuate the formation 
of dicarbonyl stress. A randomized clinical trial would be needed to con rm causation. 
However, our results indicate that exercise training is related to lower dicarbonyl stress. 
Unfortunately, we do not have information about the dietary habits of the participants. The 
absorption, bioavailability, and e ects of dietary AGEs are poorly understood in vivo, (43) and 
it could be that diet patterns may contribute to the di erences in AGEs between ATH and 
SED. AGE-rich food intake has been associated with higher levels of serum AGEs, whereas 
an AGE-restricted diet has been associated with lower serum AGEs. (21) However, whether 
food AGEs in uence protein bound AGEs, as measured in this study, is not clear. Free AGEs 
may be relatively quickly absorbed, biotransformed, and excreted. On the other hand, 
high molecule weight AGEs, such as protein bound AGEs, may not be very extensively 
absorbed due to insu  cient degradation by gastrointestinal enzymes. (43) Further research 
is warranted to establish a direct relation between dietary AGEs and protein-bound AGEs. 
Finally, all the participants of the study were men and the lifelong athletes performed 
endurance exercise activities only, which limits the generalizability of the present study.
93
Exercise, dicarbonyl stress, and AGEs
6
Conclusion
Findings of the present study indicate that lifelong exercise training is associated with 
lower dicarbonyl stress (MGO and 3DG), which is related to improved cardiovascular health. 
Although MG-H1 was lower in lifelong endurance athletes compared to sedentary controls, 
AGEs concentrations of CML and CEL were signi cantly higher in athletes compared to 
sedentary controls. The underlying mechanism and (clinical) relevance of higher CML and 
CEL concentrations among lifelong athletes warrants future research, since it con icts with 
the idea that higher AGEs concentrations relate to poor cardiovascular health.
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"The beginning of wisdom is the statement 'I do not know.' The person who cannot make 
that statement is one who will never learn anything"
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Objective
Reperfusion is essential for ischemic tissue survival, but causes 
additional damage to the endothelium (i.e. ischemia-reperfusion [IR] 
injury). Ischemic preconditioning (IPC) refers to short repetitive episodes 
of ischemia that can protect against IR. However, IPC e  cacy attenuates 
with older age. Whether physical inactivity contributes to the attenuated 
e  cacy of IPC to protect against IR injury in older humans is unclear. 
We tested the hypotheses that lifelong exercise training relates to 1) 
attenuated endothelial IR and 2) maintained IPC e  cacy that protects 
veteran athletes against endothelial IR.
Methods
 In 18 sedentary male individuals (SED, <1 exercise hour/week for 
>20 years, 63±7 years) and 20 veteran male athletes (ATH, >5 exercise 
hours/week for >20 years, 63±6 years), we measured brachial artery 
endothelial function with  ow-mediated dilation (FMD) before and after 
IR. We induced IR by 20-minutes of ischemia followed by 20-minutes of 
reperfusion. Randomized over 2 days, participants underwent either 
35-minute rest or IPC (3 cycles of 5-minutes cu  in ation to 220 mmHg 
with 5-minutes of rest) before IR. 
Results
In SED, FMD decreased after IR (median [interquartile range]): 
(3.0% [2.0-4.7] to 2.1% [1.5-3.9], P=0.046) and IPC did not prevent this 
decline (4.1% [2.6-5.2] to 2.8% [2.2-3.6], P=0.012). In ATH, FMD was 
preserved after IR (3.0% [1.7-5.4] to 3.0% [1.9-4.1], P=0.82) and when IPC 
preceded IR (3.2% [1.9-4.2] to 2.8% [1.4-4.6], P=0.18). 
Discussion
These  ndings indicate that lifelong exercise training is associated 
with increased tolerance against endothelial IR. These protective, 
preconditioning e ects of lifelong exercise against endothelial ischemia-
reperfusion may contribute to the cardio-protective e ects of exercise 
training.
A
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T
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 Introduction
Cardiovascular disease is the world’s leading cause of mortality, with ischemic disease 
representing the most prevalent cause (47%) of cardiovascular death. (1) Reperfusion 
therapy (e.g. percutaneous coronary intervention) is a common and e ective strategy 
to restore blood  ow to ischemic tissue after coronary artery occlusion. (2) Paradoxically, 
reperfusion causes signi cant additional damage (i.e. ischemia-reperfusion [IR] injury) to 
the endothelium, which may limit the prognosis after myocardial infarction. (3) Although 
reperfusion therapy induces damage, it is mandatory in order to prevent further tissue 
damage. Attenuating the deleterious e ects of IR is therefore of utmost importance to 
further improve outcomes after myocardial infarction.
Ischemic preconditioning (IPC; i.e. short repetitive episodes of non-injurious ischemia 
and reperfusion) has been recognized as a potent strategy to reduce the severity of 
endothelium IR. (4-6) The majority of research on IPC is conducted in healthy animals or young 
healthy humans, whereas ischemic heart diseases generally occur in older humans with 
di erent comorbidities that may interfere with the e  cacy of IPC. (7, 8) Various traditional 
cardiovascular risk factors may a ect the e  cacy of IPC and/or the magnitude of IR. (7-9) 
Lifestyle changes and appropriate pharmacotherapy can modify some risk factors such as 
smoking, obesity, hyperlipidemia, and type 2 diabetes mellitus. However, some risk factors 
cannot be modi ed, such as ageing. A recent in vivo study compared the e ectiveness of 
IPC between 15 young (20–25 years) vs. 15 older (68–77 years) men, and demonstrated 
that older age was associated with an attenuated protective e ect of IPC against IR. (10) It is 
unclear whether this attenuated e  cacy in older humans results from the ageing process 
per se, or whether physical inactivity contributes to these observations. (11) 
Regular exercise training is one of the most potent strategies to improve the cardiovascular 
risk pro le, (12) lower the risk for cardiovascular diseases, (12-15) and promote longevity. 
Whether exercise training also in uences the magnitude of IR and/or maintains the 
e  cacy of IPC is less frequently studied. DeVan et al. suggested that habitual resistance 
exercise protects against IR in young, asymptomatic adults. (16) Other studies found that 
exercise mimics the e ects of IPC in young healthy individuals, (17, 18) and attenuates the 
magnitude of IR on endothelial function. Animal studies demonstrated that exercise 
training can restore the attenuated e  cacy of IPC in aged rat hearts. (11, 19) To date, no 
previous study explored the impact of exercise training on IR and IPC in older individuals. 
Examining veteran athletes, i.e. those who exercised a large part of their lives, may provide 
novel insight to understand whether exercise training is associated with protection against 
IR and/or maintained e  cacy of IPC in older humans. 
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Therefore, by comparing veteran athletes vs. older sedentary individuals, we tested the 
hypothesis that lifelong exercise training relates to an attenuated endothelial IR. Secondly, 
we evaluated whether lifelong exercise training relates to a maintained IPC e  cacy that 
protects veteran athletes against endothelial IR.
Methods
Ethical approval
This study was approved by the local Ethics committee of the region Arnhem-Nijmegen 
(CMO no. 2011-079) and conducted in accordance with the standards set by the Declaration 
of Helsinki. All participants gave their written informed consent before study participation. 
The study was registered at ClinicalTrials.gov (NCT01606410).
Participants
We included 20 veteran male athletes (ATH, >5 exercise hours/week for more than 
20 years, 63±6 years) and 18 sedentary male individuals (SED, <1 exercise hour/week for 
more than 20 years, 63±7 years. We assessed exercise history of the athletes over 5 age-
periods: I) 20-29 years, II) 30-39 years, III) 40-49 years, IV) 50-59 years, and V) >60 years. Each 
period consisted of 2 queries: 1) type of activity (e.g. running, cycling, etc., or nothing) and 
2) exercise time (hours) per activity per week. Veteran athletes performed mostly lower 
limb endurance exercise activities (e.g. running and cycling). All participants were non-
smokers, free of any cardiovascular disease, diabetes mellitus, and were not treated for 
hypertension or hypercholesterolemia. 
Experimental design
Participants visited our laboratory twice on the same time of day to study the e ect of 
forearm ischemia and reperfusion on endothelial function in the presence and absence 
of preceding preconditioning by short periods of forearm ischemia and reperfusion. A 
washout period of at least 7 days and a maximum of 30 days was set between day 1 and 
day 2 to eliminate any residual e ects of IPC (20). During each visit, participants underwent 
vascular measurements. Brachial artery endothelial vasodilator function was quanti ed 
before and after IR using  ow-mediated dilation (FMD), measured with ultrasound. We 
induced IR by 20 minutes of forearm ischemia by upper arm cu  in ation to 220 mmHg, 
followed by 20 minutes of reperfusion. In a randomized order, each participant underwent 
either 35-minute rest or IPC (3 cycles of 5-minute cu  in ation to 220 mmHg with 5 minutes 
of reperfusion) before the prolonged period of ischemia and reperfusion (Figure 7.1). The 
randomization procedure was programmed via a random-number generator in Microsoft 
Excel 2016. 
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Screening. Participants were medically screened for eligibility during the  rst visit. 
Height (cm), body mass (kg), and waist circumference (cm) were assessed. Blood pressure 
was measured twice after 15 minutes of rest in supine position followed by assessment 
of cholesterol and glucose levels via a capillary blood sample (35µL blood, Mission, ACON 
Laboratories, Inc., San Diego, USA). The Framingham Risk Score was calculated to obtain 
insight in the cardiovascular risk pro le of the participants. (21)
Vascular measurements. Participants were asked to abstain from high intensity exercise 
for 24 hours, any food intake for ≥6 hours, and from dietary products known to alter 
endothelial function for ≥18 hours before the testing sessions (i.e. ca eine, vitamin C, 
alcohol) according to guidelines to assess peripheral vascular function. (22) Measurements 
were performed in a temperature-controlled room (22°C) with the participants in the 
supine position. 
Brachial artery  ow mediated dilation (FMD). Assessment of the FMD as measure of 
endothelial function is a validated model to explore the potential protective e ects of 
several strategies on IR in humans in vivo [1]. (23, 24) FMD was measured by positioning the 
Echo-Doppler probe on the brachial artery using a T3000 ultrasound system (Terason 
Teratech Corporation, Boston, United States) equipped with a 10-MHz 12L5 linear 
transducer. A rapid in ating/de ating pneumatic cu  (E20 rapid cu  in ator, Hokanson, 
Bellevue, USA) was placed on the right forearm, distally from the imaged artery. Diameter 
and  ow velocity were recorded at the baseline during 1-minute, followed by 5 minutes 
of ischemia by in ating the pneumatic cu  to 220 mmHg. Diameter and  ow velocity 
recordings resumed 30 seconds before de ating the cu , and continued for 3 minutes 
during the reperfusion. (22) All FMD measurements were taken by a single experienced 
sonographer to reduce variation. (25) 
A. Rest
20-MIN ISCHEMIA 20-MIN REPERFUSION
0 5 10 15 20 25 30 35 40 45 50 55 60 65 70 75 80 85 90 95 100
REST FMDPROCEDURE
FMD
PROCEDURE35 MINUTES OF REST
5-min
rest
5-min
ischemia
5-min
rest
5-min
ischemia
5-min
rest
5-min
rest
5-min
ischemia 20-MIN ISCHEMIA 20-MIN REPERFUSION
35 minutes ischemic preconditioning
B. Ischemic preconditioning
0 5 10 15 20 25 30 35 40 45 50 55 60 65 70 75 80 85 90 95 100
REST FMDPROCEDURE
FMD
PROCEDURE
Figure 7.1 Study design. In randomized order, each participant underwent either A) 35-minute rest or B) 
IPC (3 cycles of 5-minute cu  in ation to 220 mmHg with 5 minutes of reperfusion) before the 
prolonged period of ischemia and reperfusion. A washout period of at least 7 days and with a 
maximum of 30 days was set between day 1 and day 2 to eliminate any residual e ects of IPC.
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Intervention: rest or IPC before IR. In randomized order, 5 minutes after baseline FMD 
measurement, participants received either a) 35-minute rest or b) IPC, which were both 
followed by 20 minutes of ischemia and 20 minutes of reperfusion. When the participant 
received IPC, the pneumatic cu  was positioned proximally around the upper arm. Thus, 
the brachial artery was within the ischemic zone and was exposed to IR. IPC was performed 
by applying of 3 cycles of 5 minutes of upper arm ischemia by in ating the pneumatic cu  
to 220 mmHg, followed by 5 minutes of rest (in total covering 35-min). 
Ischemia reperfusion (IR). Five minutes after either a) 35-minute rest or b) IPC stimulus, 
participants received upper arm ischemia, which was induced by in ating the pneumatic 
cu  on the upper arm to 220 mmHg for 20 minutes, followed by 20 minutes of reperfusion. 
Finally, brachial artery endothelial function was re-examined using the FMD.
Experimental analyses
Brachial artery diameter,  ow velocity, and shear analyses. Analysis of the FMD was performed 
with a custom-designed edge-detection and wall tracking software written in LabVIEW 
(LabVIEW 6.02, National Instruments, Austin, United States) as described elsewhere. (26) 
Brie y, from B-mode a region of interest (ROI) was drawn to calibrate the artery diameter. 
Within this ROI a pixel-density algorithm automatically identi ed the vessel wall. For the 
calibration of the  ow velocity another ROI was drawn around the Doppler waveform. 
Baseline diameter was calculated as the mean of data acquired during 1-minute baseline 
recording, preceding cu  in ation. Peak diameter and peak  ow velocity were detected 
during 3 minutes of reperfusion. FMD was calculated as the relative di erence in peak 
diameter and baseline diameter. Post de ation shear rate data, derived from velocity and 
diameter measures, were used to calculate the area under the shear rate curve (SRAUC). (26) 
Analyses were performed by a single, blinded researcher and analyses were subsequently 
checked by a second blinded researcher. A recent analysis of 672 repeated measures 
(between multiple laboratories) showed an average reproducibility of the FMD% of 9.3% 
(coe  cient of variation) when measuring asymptomatic volunteers. (25)
Power analysis & statistics
In order to assess whether IPC protects against IR, we assumed that a change <1% in 
FMD after IR (when preceded by IPC) can be regarded as a negligible or absent change 
and suggests that IPC can e ectively prevent a change in FMD. A previous study of our 
laboratory (10) revealed a signi cant decrease in %FMD after reperfusion from 3.7%±2.1 
to 2.2%±1.1 (Δ1.5% FMD) in older participants. Based on a power of 80% and alpha 5% 
signi cance level, we calculated that 20 subjects per group should be included to detect 
a relevant e ect.
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Data are presented as mean with standard deviation (SD) unless stated otherwise. 
Parameters were checked for normality using a Shapiro-Wilk test and Q-Q plots. Group 
characteristics were analyzed using independent Student’s t or Mann-Whitney U test, 
when appropriate. Within the groups, di erences between baseline measurements and 
after IR were analyzed using linear mixed models with factors time (before vs. after IR) and 
group (athletes vs. sedentary) or the nonparametric Friedman test, when appropriate. In 
the present study, FMD data were non-normal distributed and we used the non-parametric 
Friedman test. This statistical approach limited the possibility to co-vary for potentially 
confounding factors. Data were analyzed using SPSS 22.0 software (IBM Corp. Released 
2012. IBM SPSS Statistics for Windows, Version 21.0. Armonk, NY: IBM Corp.). Statistical 
signi cance was assumed at P<0.05 (two-sided).
Results
Characteristics
ATH demonstrated a lower body mass and waist circumference compared to SED, whilst 
age, height, body mass index, and mean arterial pressure did not di er between groups 
(Table 7.1). ATH showed lower levels of total cholesterol and LDL cholesterol compared to 
SED, whilst no di erences were found for HDL cholesterol, triglyceride, and glucose levels 
between groups (Table 7.1). Framingham Risk Score was lower in ATH compared to SED 
(Table 7.1).
Table 7.1 Characteristics and cardiovascular risk pro le of veteran athletes (n=20) and sedentary individuals (n=18). P-value refers to Mann-Whitney U 
test. Data is presented as median [interquartile range].
Veteran athletes
n = 20
Sedentary individuals
n = 18
CHARACTERISTICS
Age (years) 64 [58-67] 63 [57-67] 0.78
Height (cm) 179 [178-183] 182 [176-184] 0.39
Body mass (kg) 77 [72-82] 85 [79-87] 0.009
Body mass index (kg/m2) 24.5 [22.1-25.7] 25.4 [24.2-25.7] 0.16
Waist circumference (cm) 86 [83-91] 98 [93-103] <0.01
Mean Arterial Pressure (mmHg) 92 [88-96] 92 [87-98] 0.90
Systolic Blood Pressure (mmHg) 121 [117-131] 123 [117-136] 0.70
Diastolic Blood Pressure (mmHg) 77 [72-80] 76 [71-81] 0.92
CARDIOVASCULAR RISK PROFILE
Framingham Risk Score (%) 14.1 [9.7-15.5] 18.3 [13.0-23.2] 0.017
Total Cholesterol (mmol/L) 5.4 [4.8-5.8] 6.1 [5.6-6.5] 0.030
HDL (mmol/L) 1.5 [1.4-1.9] 1.3 [1.2-1.5] 0.06
LDL (mmol/L) 3.1 [2.5-3.8] 4.0 [3.3-4.5] 0.033
Triglycerides (mmol/L) 1.1 [0.9-1.5] 1.3 [1.1-1.9] 0.14
Glucose (mmol/L) 4.5 [3.8-4.8] 4.7 [3.8-5.2] 0.30
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IR and IPC: sedentary individuals
Baseline diameter of the brachial artery did not di er before and after prolonged IR, whilst 
baseline diameter of the brachial artery signi cantly increased after prolonged IR when 
preceded by IPC (Table 7.2). FMD% signi cantly decreased after prolonged IR in SED (3.0% 
[2.0-4.7] to 2.1% [1.5-3.9], P=0.046) (Table 7.2, Figure 7.2). A similar decrease in FMD% was 
found after prolonged IR when preceded by IPC (4.1% [2.6-5.2] to 2.8% [2.2-3.6], P=0.012) 
(Table 7.2, Figure 7.2). SRAUC, and time-to-peak did not di er before and after IR under both 
conditions (i.e. a. 35-minute rest or b. IPC) (Table 7.2).
IR and IPC: veteran athletes
A signi cant increase in baseline brachial artery diameter was observed after prolonged IR 
when preceded by 35-minute rest or the IPC intervention (Table 7.2). The FMD% did not 
signi cantly di er after IR in ATH (3.0% [1.7-5.4] vs. 3.0% [1.9-4.1], P=0.80) (Table 7.2, Figure 
7.2). Likewise, the FMD% did not di er after prolonged IR when preceded by IPC (3.2% [1.9-
4.2] vs. 2.8% [1.4-4.6], P=0.18) (Table 7.2, Figure 7.2). SRAUC, and time-to-peak did not di er 
after IR under both conditions (i.e. rest or IPC) (Table 7.2).
Table 7.2 Brachial artery characteristics before and after ischemia reperfusion (IR) when preceded, in randomized order, by either a) 35-minutes of rest or 
b) ischemic preconditioning (IPC) in asymptomatic veteran athletes (n=20) and sedentary individuals (n=18). P-value refers to Friedman test for di erence 
in change from baseline (rest vs. IPC). Data is presented as median [IQR].
35-minutes of rest IPC rest vs. IPC
Baseline Post IR P-value Baseline Post IR P-value P-value
ATHLETES
Baseline diameter (mm) 4.5 [4.2-5] 4.8 [4.3-5.2] <0.01 4.5 [4.3-4.8] 4.9 [4.7-5.1] <0.01 0.25
FMD (%) 3.0 [1.7-5.4] 3.0 [1.9-4.1] 0.82 3.2 [1.9-4.2] 2.8 [1.4-4.6] 0.18 0.49
Time-to-Peak (sec) 68 [42-116] 56 [29-89] 0.11 51 [25-71] 52 [34-95] 0.66 0.11
SRAUC (x103) 12.6 [11.3-18.8] 12.8 [7.3-16.2] 0.49 14.9 [10.7-19.8] 11.6 [7.9-15.3] 0.18 0.49
SEDENTARY AGED INDIVIDUALS
Baseline diameter (mm) 4.9 [4.4-5.2] 4.7 [4.4-5.8] 0.44 4.6 [4.2-5.1] 5.2 [4.5-5.7] 0.012 0.020
FMD (%) 3.0 [2.0-4.7] 2.1 [1.5-3.9] 0.046 4.1 [2.6-5.2] 2.8 [2.2-3.6] 0.012 0.80
Time-to-Peak (sec) 68 [45-81] 52 [44-62] 0.62 60 [39-86] 66 [42-76] 0.62 0.43
SRAUC (x103) 15.8 [12.7-18.4] 11.5 [8.9-18.8] 0.62 15.6 [11.1-19.2] 13.7 [8.3-18.9] 0.62 0.62
FMD:  ow-mediated dilation; SRAUC: Shear Rate Area Under the Curve
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Discussion
The purpose of this study was to test the hypotheses that lifelong exercise training is 
associated with attenuated endothelial IR in humans in vivo, and that lifelong exercise 
training is associated with maintained e  cacy of IPC in veteran athletes. Our study presents 
the following  ndings. First, we found that brachial artery endothelial function decreases 
after forearm IR in older sedentary individuals and IPC was unable to prevent this decline 
in endothelial function. Second, in marked contrast to the sedentary individuals, we found 
that endothelial function did not decrease after IR in veteran athletes. Furthermore, when 
preceded by IPC, we found no further attenuation of endothelial function after IR in veteran 
athletes. These data suggest that lifelong exercise training protects against the detrimental 
e ects of ischemia reperfusion on endothelial function.
We did not observe a signi cant di erence in baseline %FMD between veteran athletes 
and sedentary controls. This  nding is in line with previous work, (27, 28) which demonstrated 
that trained individuals do not necessarily have a superior %FMD compared to their 
non-athletic peers. Exact mechanisms are not completely understood. Nitric oxide is 
an important regulator of basal vasodilator tone of the blood vessels. (29) Studies found 
that exercise promotes the bioavailability of nitric oxide. (14, 30) However, athletes do not 
necessarily demonstrate an elevated basal limb blood  ow (31) or basal coronary  ow. (32) 
Some evidence suggests that exercise training also increases sympathetic vasoconstrictor 
tone. (33, 34) It is hypothesized that this increased sympathetic vasoconstrictor tone 
counterbalances the training-induced increase in nitric oxide bioavailability, leading to 
a preserved basal limb blood  ow. (31, 32, 35) Similarly, this interaction may also contribute 
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Figure 7.2 Individual (circles) and group values (median [IRQ]) of brachial artery FMD before and after 
ischemia reperfusion (IR) when preceded, in randomized order, by 35-minutes of rest or ischemic 
preconditioning (IPC) in A. sedentary individuals (n=18) and B. asymptomatic veteran athletes 
(n=20). FMD of sedentary individuals decreased after 35-min rest as well as IPC, whilst veteran 
athletes had no change in FMD after either 35-min rest or IPC. P-value refers to Friedman test.
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to preservation of the conduit artery endothelium-dependent responses to increased 
shear during the  ow-mediated dilation. Future studies are needed to further explore this 
hypothesis.
Endothelial Ischemia Reperfusion: impact of a sedentary lifestyle
Endothelial function was signi cantly lower after IR in sedentary older individuals, which 
is in line with previous research. (10) Despite the fact that previous studies in animals (6) and 
preclinical work in humans (5, 23) found that IPC attenuates the magnitude of IR, translation 
of IPC to clinical practice is often challenging. (36-38) This might relate to the inclusion of 
young, healthy animals/humans, whereas clinical studies mostly include aged individuals 
with (co)morbidities, (38) which may interfere with the e  cacy of IPC. Indeed, a recent 
study found an impaired ability of IPC to prevent the decline in endothelial function after 
IR in heart failure patients (n=15, 67±10 years). (37) In the current study, we found that 
IPC could not prevent the decline in endothelial function after IR in asymptomatic aged 
sedentary individuals. These data reinforce  ndings of previous work from our laboratory, 
in which we found that IPC could not prevent the decrease in endothelial function after 
IR in older individuals (72±4 years). (10) Taken together, our results are in line with previous 
work, indicating that IR impairs endothelial function and cannot be prevented by IPC in 
sedentary older individuals.
Endothelial Ischemia Reperfusion: impact of lifelong exercise training
In contrast to the decline in FMD in sedentary older humans, we found no signi cant 
change in FMD after IR among veteran athletes. This novel  nding suggests that lifelong 
exercise training is associated with preconditioning-like e ects. DeVan et al. explored 
whether endothelial IR is present in middle-aged endurance trained athletes, but found a 
signi cant decline in endothelial function after IR. (39) Di erences in methodological design 
(i.e. longer reperfusion in the present study), group characteristics (i.e. age) and exercise 
history may contribute to the di erent observations between studies. Furthermore, the 
absence of a decrease in endothelial function after prolonged IR also implies that we could 
not determine whether lifelong exercise training a ected the e  cacy of IPC. At least, our 
results indicated that lifelong exercise training is associated with maintained endothelial 
function after IR in older humans. 
Several previous studies support the hypothesis that exercise possesses preconditioning 
e ects against endothelial IR. (17, 40) The similarity of IPC and exercise could relate to the 
repeated short periods of ischemia/hypoxia. (41) These short episodes of ischemia activate 
signaling pathways involved in the increased tolerance against IR, such as adenosine, 
bradykinin and opioids. (18, 20) Michelsen et al. found that this exercise-preconditioning may 
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be driven by a systemic, blood-borne factor that works through opioid receptors. (18) The 
existence of a systemic preconditioning e ect of exercise training is supported by our 
results, as our veteran athletes performed most of the time lower limb exercise training 
(e.g. running or cycling), whilst we observed no signi cant decrease in brachial artery 
endothelial function after IR. 
Another explanation for vascular protection against IR due to lifelong exercise training in 
the older participants included in our study may relate to upregulation of nitric oxide. (20, 41) 
In healthy endothelium, an increased blood  ow causes release of nitric oxide, leading to 
dilation of the vessel. (42) However, older age is associated with endothelial dysfunction and 
reduced nitric oxide bioavailability. (43) This latter observation may relate to lower production 
of nitric oxide, but also to the presence of increased oxidative stress (43) (possibly caused 
by relatively higher levels of reactive oxygen species). (44) Potentially, regular endurance 
exercise training lowers oxidative stress (45) and prevents the age-related decline in nitric 
oxide bioavailability. (45, 46) Collectively, our study indicates that lifelong endurance exercise 
training increases IR tolerance.
Benefits of exercise training: beyond traditional cardiovascular risk factors?
The positive e ects of regular endurance training on cardiovascular risk factor pro le are 
widely accepted. (12) Additional bene ts of exercise training may be mediated via improved 
vasculature. (47) Interestingly, endothelial function did not di er at baseline between 
veteran athletes and their sedentary peers, which seem contradictory as previous studies 
provided solid evidence that exercise training may enhance endothelial function.  (46) 
However, potential bene ts of exercise in the lifelong athletes become apparent after 
the endothelium is exposed to challenging conditions that immediately a ect the 
endothelium (i.e. after 20 minutes of ischemia and 20 minutes of reperfusion). Our  ndings 
suggest that exercise training may o er cardioprotective e ects, in addition to favorable 
changes in cardiovascular risk pro le, through increased tolerance against IR. 
Methodological considerations
Strengths of our study include the homogenous asymptomatic sedentary and 
physically active individuals, blinded observer independent analyses, and we adhered 
to expert-consensus FMD guidelines (22) to obtain a high reproducibility of the vascular 
measurements.  (25, 48) However, our study was inherent to some limitations. There was 
a high variation in baseline FMD within the groups, which may relate to inter-individual 
variation between the participants. (25) However, primary comparisons were performed 
within participants, i.e. a strong methodological approach and linked to good day-to-day 
reproducibility. (25) Furthermore, FMD data were non-normally distributed. Therefore, we 
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used nonparametric statistical tests to analyze the data. As a consequence of using non-
parametric tests we were unable to co-vary for factors, such as SRAUC and baseline diameter, 
an approach that is recommended to control for potential within- or between-subject 
di erences in these variables. (49) However, SRAUC did not di er between the pre- and post-
measurement of both conditions in both groups, which makes it unlikely that individual 
di erences in SRAUC explain or may alter our main observations. Regarding baseline 
diameter, we found diameter to signi cantly increase after IR in both conditions in the 
ATH group. Although a larger baseline diameter is typically associated with a smaller FMD 
response, (50) FMD% after IR was preserved in both conditions in ATH. On the contrary, we 
observed that baseline diameter of the sedentary controls decreased after IR during the 
IPC-condition. Although a smaller diameter is typically associated with a higher FMD, (50) 
the FMD signi cantly decreased in sedentary controls. Despite these observations, our 
inability to statistically correct for potential variations in baseline diameter is a limitation of 
our study and should be taken into consideration.
Another potential limitation is that we included a healthy (asymptomatic) study 
population, whilst ischemic events mostly occur in individuals with cardiovascular risk 
factors. However, we focused on asymptomatic individuals to study the potential e ects of 
exercise and IPC against IR. Whether comparable e ects can be found in participants that 
undergo exercise training after an ischemic event or in those with risk factors is a logical 
next step. Furthermore, due to the absence of a decline in endothelial function after IR 
in veteran athletes, we were unable to determine whether IPC could prevent endothelial 
IR in veteran athletes. However, care should be taken when generalizing our  ndings to 
other stimuli or arteries, since a stronger ischemic stimulus or di erent vascular bed may 
demonstrate di erent results. Finally, since we did not test endothelium-independent 
vasodilation, we cannot exclude that our  ndings are possibly mediated by changes in 
vascular smooth muscle cell function.
Conclusion
The results of our study indicated that, in marked contrast to the characteristic reduction 
in endothelial function after IR in older sedentary humans, lifelong exercise training was 
associated with maintained endothelial function after IR. These  ndings suggest that 
veteran athletes have an increased tolerance against IR compared to sedentary individuals. 
Therefore, lifelong exercise training has protective preconditioning e ects against 
endothelial ischemia-reperfusion that may partially contribute to the cardio-protective 
e ects of exercise training during physiological ageing.
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Chapter 8
Purpose
Despite athletes demonstrate a lower cardiovascular risk and superior 
vascular function compared to sedentary peers, they are not exempted 
from cardiac events (i.e. myocardial infarction [MI]). The presence of a MI 
is associated with increased cardiovascular risk and impaired vascular 
function. We tested the hypothesis that lifelong exercise training in post-
MI athletes, similar as in healthy controls, is associated with a superior 
peripheral vascular function and structure compared to a sedentary 
lifestyle in post-MI individuals.
Methods
We included 18 veteran (>20 years) athletes (ATH) and 18 sedentary controls 
(SED). To understand the impact of lifelong exercise training after MI, we 
included 20 veteran post-MI athletes (ATH+MI) and 19 sedentary post-MI 
controls (SED+MI). Participants underwent comprehensive assessment 
using vascular ultrasound (vascular sti ness, intima-media thickness 
(IMT), and endothelium (in)dependent mediated dilation). Lifetime Risk 
Score was calculated for a 30-year risk prediction of cardiovascular disease 
mortality of the participants.
Results
ATH demonstrated a lower vascular sti ness, and smaller femoral IMT 
compared to SED. Vascular function and structure did not di er between 
ATH+MI and SED+MI. ATH (4.0%±5.1) and ATH+MI (6.1%±3.7) had a 
signi cantly better lifetime risk score compared to their sedentary peers 
(SED: 6.9%±3.7 and SED+MI: 9.3%±4.8). ATH+MI had no secondary events 
vs. two recurrent MI and six elective percutaneous coronary interventions 
within SED+MI (P<0.05).
Conclusion
Although veteran post-MI athletes did not have a superior peripheral 
vascular function and structure compared to their sedentary post-MI peers, 
bene ts of lifelong exercise training in veteran post-MI athletes relate to a 
better cardiovascular risk pro le and lower occurrence of secondary events. 
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 Introduction
Exercise training is an e ective strategy to lower the risk for cardiovascular diseases. (1-3) The 
marked cardio-protective e ects of exercise are in part explained via traditional risk factors, 
such as a lower cholesterol level, blood pressure, and body mass index. (4, 5) Additional 
bene ts of regular exercise training may relate to a direct e ect on the arterial wall, leading 
to remodeling of the arteries and improvement of endothelial function. (6) For example, 
exercise training exerts its bene ts on the artery wall through repeated elevation in blood 
 ow and vascular laminar shear stress, which results in increased nitric oxide bioavailability, 
promotion of an antioxidant state, and improvement in vascular function and structure. (7, 8) 
Previous studies comparing athletes and sedentary controls consistently found that 
athletes have higher vascular compliance and better vascular wall structure compared to 
sedentary controls. (6, 9) Younger athletes also typically demonstrate outward remodelling, 
as evidenced by larger conduit artery diameters and a larger resistance artery vascular 
bed. (10) Some controversy is present around the e ects of regular exercise training on 
endothelial function of conduit arteries measured with the  ow-mediated dilation 
(FMD). (11-15) Variation in FMD between these studies may, at least partly, relate to structural 
remodelling in athletes (i.e. larger diameter in athletes), that may contribute to a lower 
FMD. (11) Exercise training is a widely accepted powerful strategy to lower risk for future 
cardiovascular events, which is at least partly related to improved vascular function. (16) 
Despite the vascular health bene ts and reduction of cardiovascular risk with regular 
exercise, (1, 2, 4, 5) veteran athletes are not exempted from acute coronary syndromes or 
myocardial infarction. (17, 18) Previous work demonstrated that post-myocardial infarction 
(post-MI) patients have an impaired vascular function and structure compared to healthy 
peers. (19, 20) Whether lifelong exercise training in post-MI patients may be associated with a 
preserved vascular function and structure is currently unknown. Therefore, we tested the 
hypothesis that lifelong exercise training in post-MI athletes, similar as in healthy controls, 
is associated with a superior peripheral vascular function and structure compared to a 
sedentary lifestyle in post-MI individuals. 
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Methods
Participants
In total, we included 75 middle-aged men. We included 36 healthy, asymptomatic men who 
were divided over two groups: a) 18 veteran (>20 years) athletes (ATH) and b) 18 sedentary 
controls (SED). To understand the role of a MI on the impact of lifelong exercise, we included 
39 participants who were divided into: a) 20 veteran (>20 years) post-MI athletes (ATH+MI) 
and b) 19 sedentary post-MI controls (SED+MI). Athletes performed regular moderate or 
vigorous endurance exercise training (e.g. running or cycling) for ≥3.5 hours per week for 
≥20 years. Sedentary individuals performed habitual physical activities for ≤2 hours per 
week for ≥20 years. Smokers, participants with diabetes mellitus type 1 or 2, and those 
not able to perform an incremental maximal cycling test were excluded from participation 
in our study. The Local Committee on Research Involving Human Subjects of the region 
Arnhem and Nijmegen approved the study and the study protocol conformed to the 
ethical guidelines of the 1975 Declaration of Helsinki. All participants gave their written 
informed consent.
Lifelong exercise history
We asked the participants about their lifelong exercise history over  ve age-periods: 
I) 20-29 years, II) 30-39 years, III) 40-49 years, IV) 50-59 years, and V) >60 years. Three queries 
were asked per period: 1) type of activity (e.g. running, cycling, etc., or nothing), 2) exercise 
time (hours) per activity per week, and (3) self-perceived exercise intensity (light, moderate, 
or vigorous) per activity. Based on Ainsworth’s compendium of physical activities, (21) we 
determined the corresponding metabolic equivalent of task (MET) score per activity. Based 
on the ACSM position stand, (22) we de ned moderate intensity activities between 3 and 
5.9  MET, and vigorous intensity activities as ≥6 MET. Weekly exercise time was de ned 
as the amount of time (in hours) spent on moderate and/or vigorous intensity exercise 
activities per week. The average weekly exercise time and intensity (i.e. percentage of time 
spent on light, moderate, and vigorous intensity) were calculated over the last 20 years 
before study participation.
Experimental design
Participants visited our laboratory on two separate days during this cross-sectional study. 
On Day 1, participants were medically screened for eligibility, followed by an incremental 
maximal cycling test. On Day 2, participants underwent a comprehensive assessment of 
vascular function and structure using non-invasive echo-Doppler ultrasound techniques.
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Experimental measures
Day 1: Screening + Incremental maximal cycling test
Screening. A physician medically screened participants by taking a detailed medical history, 
physical examination, and 12-lead electrocardiogram. Cardiac medical history of the post-
MI participants was retrieved from their medical history reports, which encompassed 
the clinical diagnosis of the MI, details of the size and location of the MI, and treatment 
strategy. To gain insight in the cardiovascular risk pro le of the participants, we calculated 
the Lifetime Risk Score (LRS) for a 30-year risk prediction of cardiovascular disease 
mortality. (23) Parameters taken into account for the LRS were age, systolic blood pressure, 
total cholesterol, physical  tness level, and body mass index.
Incremental maximal cycling test. Peak oxygen uptake (VO2peak, mLO2/min/kg) of the 
participants was determined via an incremental maximal cycling test. Heart rate was 
continuously measured via a 12 lead-electrocardiogram. Oxygen uptake (VO2 [ml/
min]), carbon dioxide output (VCO2 [ml/min]), and respiratory exchange ratio (RER) were 
measured via a gas analyser (CPET, Cosmed v9.1b, Rome, Italy). Lactate concentration 
(mmol/L) was measured via a capillary blood sample taken one-and-a-half minute after 
cessation of the test with the Lactate Pro™ 2 (Arkray, type LT-1730, Kyoto, Japan).
Day 2: Vascular function and structure
All measurements were performed according to recent guidelines for vascular assessment 
and in a temperature-controlled room (24) using a T3000 ultrasound system (Terason 
Teratech Corporation, Boston, United States) equipped with a 10-MHz 12L5 linear 
transducer. Continuous Doppler velocity was obtained using a position insoni cation 
angle of <60°. (12) Participants followed a ≥6h fasting period, ≥18h abstinence from ca eine, 
alcohol, vitamin supplements, and performed no vigorous physical activity at least 24h 
before the test. Measurements began after a resting period in the supine position for at least 
15 minutes. (24) Subsequently, heart rate and blood pressure were manually assessed using 
a sphygmomanometer. Blood samples were obtained after the vascular measurements 
from the antecubital vein for the analysis of blood glucose, and traditional cardiovascular 
risk markers (cholesterol, HDL, LDL, triglycerides, and glycated hemoglobin [HbA1c]). 
Brachial artery endothelium-dependent  ow-mediated dilatation (FMD). The FMD (an index 
of endothelial function) of the brachial artery was measured by positioning the Echo-
Doppler probe on the brachial artery. A pneumatic cu  (E20 rapid cu  in ator, Hokanson, 
Bellevue, United States) was placed on the right forearm, distally from the imaged artery. 
Diameter and  ow velocity were recorded at the baseline during one-minute, followed 
by 5 minutes of ischemia by in ating the pneumatic cu  at 220 mmHg. Diameter and 
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blood velocity recordings resumed 30 seconds before de ating the cu  and continued for 
3 minutes thereafter, during the reperfusion. (24)
Brachial artery conduit artery vasodilatory capacity (CADC). After a 20-minute resting period, 
the CADC (an index of arterial structure) was measured using the same equipment. The 
pneumatic cu  was in ated to 220 mmHg on the right upper arm, proximal from the 
imaged artery, for 5 minutes. Participants performed handgrip exercise from minute 1 
until minute 4 (one-second contraction/one-second relaxation) at ~30 newton during 
the ischemic period. Diameter and blood velocity recordings resumed 30 seconds before 
de ating the cu  and continued for 3 minutes thereafter, to detect peak  ow and peak 
diameter. (25)
 Brachial artery endothelium-independent dilatation. After another 20-minute rest, the 
vasodilator response to glyceryl trinitrate mediated vasodilatation (GTN; an index of 
vascular smooth muscle function) was measured. After recording baseline brachial artery 
diameter across 1-min, a single dose (400 µg) sublingual GTN (nitric oxide donor) was 
administered. Recording of diameter and blood velocity of the artery continuous 8 minute 
thereafter. (26)
FMD, CADC, and GTN dilation were analyzed by custom-designed edge-detection and wall 
tracking software written in LabVIEW (LabVIEW 6.02, National Instruments, Austin, United 
States) as described elsewhere. (27) Brie y, from B-mode a region of interest (ROI) was drawn 
to calibrate the artery diameter. Within this ROI a pixel-density algorithm automatically 
identi ed the vessel wall. For the calibration of the blood  ow velocity another ROI was 
drawn around the Doppler waveform. Baseline diameter was calculated as the mean of data 
acquired during one-minute baseline recording, preceding cu  in ation. Peak diameter 
and peak of blood  ow velocity was detected during three minutes of reperfusion. Brachial 
artery FMD, CADC, and GTN response were calculated as the relative di erence in peak 
diameter and baseline diameter. 
Pulse wave velocity. As an index for vascular sti ness, central and peripheral pulse wave 
velocity were measured using a three-lead electrocardiogram and an Echo-Doppler 
ultrasound machine (Waki Doppler, Atys Medical, Soucieu en Jarrest, France) at the left 
carotid artery, right common femoral artery, and radial artery. The distances were measured 
between sternal notch and site of measurement for the carotid artery and between radial 
artery and common femoral artery via the umbilicus. (28) At least 10 cardiac cycles were 
recorded for analyses. Based on the interval between the R-wave on the electrocardiogram 
and onset of the Doppler waveform, central and peripheral pulse wave velocities were 
calculated in Matlab (MATLAB Release R2014, The MathWorks, Inc., Natick, United States).
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Conduit artery intima-media thickness. Intima-media thickness (IMT) of the left common 
carotid, brachial, and super cial femoral artery were recorded using the same ultrasound 
machine. Image sequences of ≥10 seconds were recorded 1.5 to 2.5 cm distally of the 
bifurcation of the common carotid and super cial artery, while having the vessel in a 
longitudinal imaging plane. Diameter and wall thickness were collected from two distinct 
angles. Analysis was performed using custom-designed o -line edge-detection and wall-
tracking software written in LabVIEW (LabVIEW 6.02, National Instruments, Austin, United 
States). This DICOM-based software is largely independent of investigator bias and has been 
previously described in detail. (29, 30) Brie y, each recording was converted to a DICOM  le at 
a frame rate of 30 Hz. Detection of the far wall media-adventitia interface was performed 
on every frame selected. The mean diameter and wall thickness were calculated by using 
the formula: (1/3 x systolic diameter or wall thickness) + (2/3 x diastolic diameter or wall 
thickness). Additionally, to correct for di erences in vascular tone between measurements 
wall:lumen-ratio was calculated. All  les were analyzed blinded by an independent 
researcher.
Power calculation and statistical analysis
Based on anticipated di erence in %FMD between study groups of 3.5% with a SD 
of 2.4, (12, 19) a power of 90% and alpha 5% signi cance level, we calculated that 18 subjects 
per group should be included. To correct for possible drop-out, we included 20 subjects 
per study group. 
Characteristics of the participants and vascular function and vascular structure were 
summarized with means and standard deviations or median and interquartile range (IQR), 
when appropriate. Categorical data were analysed using the Fisher’s exact test. Parameters 
were checked for normality using a Shapiro-Wilk test. Non-normal data were Ln-transformed 
before the statistical analysis. Data that could not be transformed into Gaussian distribution 
were analysed using nonparametric tests. For aim 1 and 2, di erences between veteran 
athletes and sedentary peers, either with or without a history of MI, were assessed using an 
independent Student’s t or Mann-Whitney U test, when appropriate. All statistical analyses 
were performed using SPSS 21.0 software (IBM Corp. Released 2012. IBM SPSS Statistics 
for Windows, Version 21.0. Armonk, NY: IBM Corp.). Statistical signi cance was assumed at 
P<0.05 (two-sided).
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RESULTS
Veteran athletes vs. sedentary controls
ATH had a lower body weight and body mass index compared to SED, whilst no di erences 
were present for age, height, and mean arterial pressure (Table 8.1). ATH performed 
signi cantly more exercise per week compared to SED (7.1 hours/weeks [5.8-11.9] vs. 
0.5 hours/weeks [0.0-1.4], P<0.01), respectively. ATH performed most of their activities at a 
moderate intensity (66%), followed by vigorous (33%) and light intensity (1%). ATH reached 
a higher VO2peak and power output during the incremental exercise test compared to 
SED (Table 8.1). ATH showed higher HDL and lower LDL and triglyceride levels compared 
to SED, whilst no di erences were found for HbA1c and cholesterol (Table 8.1). As a 
consequence of these di erences, ATH demonstrated a lower lifetime risk score compared 
to SED (Table 8.1). Participants with a positive family history of cardiovascular diseases did 
not di er between ATH (n=8, 44%) and SED (n=6, 33%), P=0.73.
Table 8.1 Characteristics of the athletes (ATH) vs. sedentary (SED) controls. Data is presented as mean and standard deviation or median 
and interquartile range. P-value refers to an independent Student’s t test or Mann-Whitney U test (*).
ATH
n=18
SED
n=18 P-value
CHARACTERISTICS
Age (years) 61±7 58±7 0.29
Height (cm) 179±8 181±6 0.31
Weight (kg) 74±8 87±10 <0.01
Body Mass Index (kg/m2)* 23.6 (21.1-24.9) 26.7 (25.0-27.4) <0.01
Mean arterial pressure (mmHg)* 98 (90-106) 103 (93-107) 0.70
Systolic Blood Pressure (mmHg)* 134 (122-142) 136 (124-146) 0.53
Diastolic Blood Pressure (mmHg) 84±10 84±10 0.92
Resting Heart Rate (beats/min) 52±6 64±11 <0.01
Exercise time (hours/week)* 7.1 (5.8-11.9) 0.5 (0.0-1.4) <0.01
INCREMENTAL EXERCISE TEST
VO2peak (mL/min/kg) 48.0±8.5 32.8±5.2 <0.01
Maximal heart rate (beats/min) 165±13 171±15 0.29
RER (ratio: VCO2 / VO2)* 1.13 (1.06-1.17) 1.08 (1.05-1.14) 0.020
Lactate (mmol/L)* 8.9 (11.6-12.3) 11.1 (9.4-12.8) 0.77
Power Output (W) 319±58 209±46 <0.01
CARDIOVASCULAR RISK PROFILE
Lifetime risk score* 4.0 (1.7-7.0) 6.9 (4.4-10.2) <0.05
Glucose (mmol/L)* 4.6 (4.4-5.0) 4.7 (4.4-4.9) 0.66
HbA1c (mmol/mol)* 35.5 (34.4-38.3) 35.5 (35.5-38.3) 0.53
Cholesterol (mmol/L) 5.4±0.8 5.9±0.9 0.07
HDL (mmol/L) 1.8±0.3 1.4±0.3 <0.01
LDL (mmol/L) 3.3±0.8 4.0±0.8 <0.05
Triglycerides (mmol/L)* 0.8 (0.7-1.2) 1.3 (1.0-2.4) <0.01
RER: Respiratory Exchange Ratio; HbA1c: Glycated haemoglobin; HDL: High-density lipoprotein; LDL: low-density lipoprotein.
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Vascular function + structure. Whilst ATH and SED did not di er in brachial diameter and 
SRAUC, the FMD was lower in ATH compared to SED (Table 8.2). We found no di erences 
between ATH and SED for CADC or GTN response, whereas FMD/GTN ratio was signi cantly 
lower in ATH compared to SED (Table 8.2). ATH demonstrated a lower central and peripheral 
pulse wave velocity (i.e. higher vascular compliance) compared to SED (Figure  8.1). No 
di erences between groups were found for IMT, diameter, and wall:lumen-ratio of the 
carotid and brachial artery, whilst femoral artery IMT and wall:-lumen-ratio was smaller in 
ATH compared to SED (Table 8.2).
Table 8.2 Vascular function and structure of the athletes (ATH) and sedentary (SED) controls. Data is presented as mean 
and standard deviation or median and interquartile range (IQR). P-value refers to an independent Student’s t test or 
Mann-Whitney U test (*).
ATH
n=18
SED
n=18 P-value
Vascular function
FLOW MEDIATED DILATION
Baseline diameter (mm) 4.3 (3.9-4.9) 4.4 (4.3-4.5) 0.65
Peak dilation (%) 3.8±1.7 6.4±2.8 <0.01
Shear Rate (AUC)* 21177 (14041-31869) 18251 (12830-23160) 0.34
CONDUIT ARTERY VASODILATORY CAPACITY
Baseline diameter (mm) 4.4±0.6 4.3±0.6 0.84
Peak dilation (%) 16.0±4.9 15.2±8.9 0.75
 Shear Rate (AUC)* 32380±10375 34566±13973 0.61
GLYCERYL TRINITRATE DILATATION
Baseline diameter (mm) 4.2±0.6 4.4±0.8 0.43
Peak dilation (%) 17.1±6.7 15.1±5.4 0.33
FMD / GTN ratio* 0.23 (0.15-0.30) 0.40 (0.25-0.69) <0.01
Vascular structure
CAROTID ARTERY
IMT (mm)* 0.69 (0.58-0.81) 0.71 (0.65-0.86) 0.16
Diameter (mm) 6.4 (5.8-6.7) 6.8 (6.4-7.3) 0.07
wall:lumen-ratio* 0.11 (0.09-0.13) 0.11 (0.10-0.12) 0.79
BRACHIAL ARTERY
IMT (mm) 0.44±0.11 0.47±0.11 0.41
Diameter (mm)* 4.0 (3.8-4.3) 4.4 (3.8-4.8) 0.13
wall:lumen-ratio* 0.11 (0.09-0.13) 0.10 (0.09-0.11) 0.84
FEMORAL ARTERY
IMT (mm)* 0.59 (0.52-0.65) 0.64 (0.58-0.71) <0.05
Diameter (mm) 7.3±1.4 6.9±0.7 0.23
wall:lumen-ratio* 0.08 (0.06-0.09) 0.09 (0.08-0.11) 0.01
AUC: area under the curve; IMT: Intima-media thickness
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Veteran post-MI athletes vs. sedentary post-MI controls
ATH+MI had a lower body weight and body mass index compared to SED+MI (Table 8.3). 
ATH+MI performed signi cantly more exercise per week compared to SED+MI (5.7 hours/
week [4.9-9.4] vs. 0.2 hours/week [0.0-1.2], P<0.01), respectively. ATH+MI performed most 
of their activities at a moderate intensity (63%), followed by vigorous (34%) and light 
intensity (3%). Intensity patterns did not di er between ATH and ATH+MI. ATH+MI reached 
a higher VO2peak and power output during the incremental exercise test compared to 
SED+MI (Table 8.3). Cholesterol, HDL, and LDL levels did not di er between ATH+MI and 
SED+MI, but ATH+MI had lower triglyceride levels compared to SED+MI (Table 8.3). ATH+MI 
demonstrated a lower lifetime risk score compared to SED+MI (Table 8.3). Participants 
with a positive family history of cardiovascular diseases did not di er between ATH+MI 
(n=15, 07.5%) and SED+MI (n=15, 79%), P=1.00.
Table 8.3 Characteristics of the post-MI athletes (ATH+MI) vs. sedentary post-MI (SED+MI) controls. Data is presented as mean and 
standard deviation or median and interquartile range. P-value refers to an independent Student’s t test, Mann-Whitney U test (*), or 
Fisher’s exact test.
ATH+MI
n=20
SED+MI
n=19 P-value
CHARACTERISTICS
Age (years) 60±6 61±5 0.44
Height (cm) 176±5 176±6 0.72
Weight (kg) 77±7 84±13 <0.05
Body Mass Index (kg/m2)* 24.5 (23.9-26.0) 26.8 (24.3-28.6) <0.05
Mean arterial pressure (mmHg)* 95 (93-100) 92 (88-101) 0.17
Systolic Blood Pressure (mmHg)* 131 (126-142) 124 (114-136) 0.051
Diastolic Blood Pressure (mmHg) 79±9 77±11 0.49
Resting Heart rate (beats/min) 57±7 60±9 0.26
Exercise time (hours/week)* 5.7 (4.9-9.4) 0.2 (0.0-1.2) <0.01
Post-MI time before study participation (years) 5 (3-10) 7 (4-10) 0.73
INCREMENTAL EXERCISE TEST
VO2peak (mL/min/kg) 40.9±5.5 29.7±6.0 <0.01
Maximal heart rate (beats/min) 164±15 146±18 <0.01
RER (ratio: VCO2 / VO2)* 1.10 (1.07-1.15) 1.08 (1.05-1.14) 0.31
Lactate (mmol/L)* 10.5 (9.2-11.2) 11.5 (9.4-12.4) 0.19
Power Output (W) 274±40 190±49 <0.01
CARDIOVASCULAR RISK PROFILE
Lifetime risk score* 5.4 (3.3-8.6) 8.6 (6.2-12.8) <0.05
Glucose (mmol/L)* 4.6 (4.5-5.0) 4.8 (4.4-5.0) 0.95
HbA1c (mmol/mol)* 36.6 (35.5-37.7) 37.7 (37.4-40.2) <0.01
Cholesterol (mmol/L) 4.5±0.9 4.2±0.9 0.25
HDL (mmol/L) 1.6±0.4 1.4±0.3 0.08
LDL (mmol/L) 2.6±0.8 2.3±0.7 0.22
Triglycerides (mmol/L)* 0.9 (0.8-1.1) 1.2 (1.0-2.0) <0.05
RER: Respiratory Exchange Ratio; HbA1c: Glycated haemoglobin; HDL: High-density lipoprotein; LDL: low-density lipoprotein.
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No di erences were observed in extent and location of the MI between groups (Table 8.4). 
Treatment strategy (surgical and rehabilitation) did not di er between groups (Table 8.4). 
Six SED+MI needed an elective percutaneous coronary intervention (PCI) and two reported 
a recurrent MI, whereas none of the ATH+MI needed an elective PCI or reported a recurrent 
MI. The use of anticoagulants, lipid lowering and antihypertensive agents did not di er 
between groups, whilst fewer ATH+MI used ACE-inhibitors (Table 8.4).
Table 8.4 Cardiac medical history data of post-MI athletes (ATH+MI) vs. sedentary post-MI (SED+MI) controls. P-value refers to 
an independent Student’s t, Mann-Whitney U (*), or Fisher’s exact test (two-sided). Data is presented as mean and standard 
deviation or median and interquartile range.
ATH+MI SED+MI P-value
Post-MI time before study (years) 5 (3-10) 7 (4-10) 0.73
ENZYME MARKERS¥
CK (u/L)* n=17 775 (251-2029) n=17 871 (422-2467) 0.45
CREAT (umol/L)* n=14 87 (78-103) n=16 89 (77-93) 0.70
AST (u/L)* n=14 38 (26-135) n=15 84 (36-208) 0.22
LDH (u/L)* n=13 407 (335-638) n=14 422 (178-537) 0.52
INFARCT LOCATION
Anterior (n) 7 (35%) 10 (53%) 0.34
Inferior (n) 7 (35%) 8 (42%) 0.75
Non-STEMI (n) 6 (30%) 1 (5%) 0.09
TREATMENT¥
PCI (n [%]) 18 (95%) 16 (94%)
1.00
Thrombolytic therapy (n [%]) 1 (5%) 1 (6%)
CARDIAC REHABILITATION
Cardiac rehabilitation (n [%]) 13 (65%) 11 (79%) 0.47
Secondary events
Elective PCI (n) 0 (0%) 6 (32%) <0.01
Recurrent MI (n) 0 (0%) 2 (11%) 0.23
MEDICATION
Anticoagulant (n) 19 (95%) 19 (100%) 1.00
Anti-platelet (n) 18 (90%) 17 (89%) 1.00
Vitamin K antagonist (n) 1 (5%) 2 (11%) 0.61
Antihypertensive agents (n) 14 (70%) 18 (95%) 0.09
ACE-inhibitor (n) 5 (25%) 14 (74%) <0.01
AT1-antagonist (n) 3 (15%) 3 (16%) 1.00
Beta-blocker (n) 8 (40%) 14 (74%) 0.05
Diuretic (n) 1 (5%) 4 (21%) 0.18
Calcium channel blockers (n) 1 (5%) 0 (0%) 1.00
Lipid lowering agents (n) 16 (80%) 19 (100%) 0.11
Statins (n) 16 (80%) 18 (95%) 0.34
¥Based on a sub sample; hospital data not available. MI: myocardial infarction; PCI: Percutaneous coronary intervention; CK: Creatine kinase; 
CREAT: Creatinine; ASAT: Aspartate transaminase; LDH: Lactate dehydrogenase; Non-STEMI: non-ST elevation acute coronary syndrome; ACE: 
angiotensin converting enzyme; AT: angiotensin.
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Figure 8.1 Arterial sti ness of (A) athletes (circles) vs. sedentary controls 
(squares) and (B) athletes+MI (triangles) and sedentary 
controls+MI (diamonds) of the central pulse wave velocity and 
peripheral pulse wave velocity. Athletes had lower central and 
peripheral pulse wave velocity, indicating that athletes had 
decreased vascular sti ness (i.e. higher vascular compliance) 
compared to sedentary controls. No di erences were observed 
in vascular sti ness between post-MI groups. Data is presented 
as median and interquartile range. cPWV: central pulse wave 
velocity, pPWV: peripheral pulse wave velocity
Vascular function + structure. We found no signi cant di erences between ATH+MI and 
SED+MI for brachial artery diameter, FMD, CADC, GTN, or GTN/FMD ratio (Table 8.5). We 
also found no di erences between groups for central or peripheral pulse wave velocity 
(Figure 8.1). We found no signi cant di erences in carotid, brachial and femoral artery IMT, 
diameter and wall:lumen-ratio between groups (Table 8.5).
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Table 8.5 Vascular function and structure of the post-MI athletes (ATH+MI) and sedentary post-MI (SED+MI) controls. 
Data is presented as mean and standard deviation or median and interquartile range (IQR). P-value refers to an 
independent Student’s t test or Mann-Whitney U test (*).
ATH+MI
n=20
SED+MI
n=19 P-value
VASCULAR FUNCTION
Flow mediated dilation
Baseline diameter (mm)* 4.5 (4.1-4.8) 4.2 (3.7-4.6) 0.42
Peak dilation (%) 4.0±1.9 5.3±3.3 0.16
Shear Rate (AUC)* 16646 (9987-23701) 16837 (12395-19196) 0.89
Conduit artery vasodilatory capacity
Baseline diameter (mm) 4.4±0.5 4.3±0.6 0.77
Peak dilation (%) 14.0±6.2 13.1±5.2 0.65
Shear Rate (AUC)* 31593±9054 31394±9546 0.95
Glyceryl trinitrate dilatation
Baseline diameter (mm) 4.3±0.6 4.4±0.6 0.82
Peak dilation (%) 16.0±6.2 13.8±4.8 0.23
FMD / GTN ratio* 0.23 (0.18-0.41) 0.35 (0.19-0.49) 0.19
VASCULAR STRUCTURE
Carotid artery
IMT (mm)* 0.79 (0.64-0.86) 0.77 (0.69-0.80) 0.64
Diameter (mm)* 6.9 (6.5-7.2) 6.5 (6.2-7.1) 0.17
wall:lumen-ratio* 0.11 (0.09-0.13) 0.12 (0.10-0.13) 0.26
Brachial artery
IMT (mm) 0.48±0.1 0.46±0.11 0.47
Diameter (mm)* 4.2 (3.6-5.1) 4.2 (3.8-4.6) 0.69
wall:lumen-ratio* 0.11 (0.10-0.12) 0.11 (0.10-0.12) 0.71
Femoral artery
IMT (mm)* 0.70 (0.65-0.82) 0.65 (0.56-0.71) 0.05
Diameter (mm) 7.4±0.8 6.9±0.9 0.10
wall:lumen-ratio* 0.10 (0.09-0.11) 0.10 (0.08-0.11) 0.60
AUC: area under the curve; IMT: Intima-media thickness
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DISCUSSION
We present the following  ndings. First, in line with our hypothesis, some markers of 
vascular function (i.e. pulse wave velocity) and structure (i.e. femoral IMT and wall:lumen-
ratio) were signi cantly better in asymptomatic veteran athletes compared to their 
sedentary peers, potentially contributing to the bene ts of lifelong exercise. Second, in 
contrast with our hypothesis, we found no di erences in vascular function or structure 
between veteran post-MI athletes and sedentary post-MI controls, which may be a 
consequence of pharmaceutical strategies. Third, veteran athletes with or without a history 
of MI had a signi cantly better cardiovascular risk pro le compared to their sedentary 
peers. Furthermore, veteran post-MI athletes reported no secondary events, which 
contrasts the 8 events that occurred in the sedentary post-MI controls. Taken together, our 
 ndings indicate that veteran post-MI athletes do not have a superior vascular function 
and structure compared to their sedentary peers, whilst bene ts of lifelong exercise relate 
to better cardiovascular risk pro le and a lower occurrence in secondary events. 
Impact of lifelong exercise on vascular function and structure: asymptomatic individuals
Our results support the hypothesis that bene ts of lifelong exercise training go beyond 
traditional risk factors (5) and improves functional and structural aspects of the vascular 
system. For example, femoral IMT was signi cantly smaller in veteran athletes compared 
to sedentary controls, which is in line with previous studies that report that regular exercise 
training is associated with a smaller conduit artery wall thickness. (31, 32) Related to functional 
characteristics of the vasculature, we found that veteran athletes have a higher central 
and peripheral vascular compliance compared to sedentary controls. This observation 
con rms previous studies which demonstrated that exercise training improves arterial 
compliance. (9, 33) 
Somewhat con icting with the observations related to central and peripheral compliance, 
we observed a signi cantly lower FMD in veteran athletes compared to their sedentary 
peers. A previous study demonstrated that young healthy athletes had a lower FMD 
compared to their sedentary peers (5.1% vs. 6.0% respectively). (11) The authors suggested 
that the lower FMD in young athletes might relate to inherent structural changes in the 
artery and the interaction between artery structure and function. (11) In the present study, 
however, baseline diameter did not di er between athletes and sedentary controls. It is 
therefore unlikely that structural di erences explain the lower FMD responses among 
athletes. Also di erences in smooth muscle cell sensitivity for nitric oxide cannot explain 
our results, since the GTN response did not di er between groups (ATH: 17.1%±6.7 vs. 
SED: 15.1±5.4, P=0.33). Alternatively, an interaction between vasodilator mechanisms and 
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the autonomic sympathetic nervous system may contribute to a lower FMD in athletes. (11) 
Athletes typically exhibit altered autonomic balance, which may contribute to attenuated 
conduit artery endothelium-dependent responses to elevation in shear. (11) However, future 
studies are necessary to explore this hypothesis. Our  ndings indicate that endothelial 
 ow-mediated vasodilation is lower in veteran athletes compared to their sedentary peers, 
whereas di erences are not simply related to structural di erences or smooth muscle 
sensitivity between groups. 
Impact of lifelong exercise on vascular function and structure: post-MI individuals
Although a history of MI is associated with impairment in cardiovascular risk and 
vascular function, regular exercise training is known to improve cardiovascular risk and 
vascular function. However, in the present study no di erences in vascular function and 
structure were found between veteran post-MI athletes and sedentary post-MI peers. A 
possible explanation for these unexpected observations may relate to the extent of the 
MI. However, we observed no di erences in cardiac enzyme markers, location of the MI 
and duration since MI between ATH-MI and SED-MI. Alternatively, previous studies that 
revealed an impaired endothelial function in post-MI patients observed these e ects 
within 1-12 months after MI, (19, 20) whereas we measured the endothelial function after 
7±5 years after MI. Since the endothelium recovers during the  rst months post-MI,  (34) 
our results may be partly explained by the long time since MI and/or bias in selecting 
‘healthy’ post-MI patients given the long time since MI. Finally, prescription of medication 
after MI may contribute to our observations, especially since several cardiac medications 
directly improve endothelial function. (35, 36) Antihypertensive agents most likely decrease 
in oxidative stress and increase nitric oxide bioavailability, (35) whereas statins are associated 
with an improvement in endothelial function and FMD. (36) Therefore, the combination of 
the prolonged post-MI period and use of cardiac medications may ameliorate endothelial 
function and structure in both post-MI groups. This might explain absence of di erences in 
vascular function and structure between post-MI athletes and sedentary peers.
Despite the absence of di erences in vascular function and marginal di erences in 
cardiovascular risk factors, veteran post-MI athletes showed a better cardiovascular 
lifetime risk score compared to their sedentary post-MI peers. The higher cardiorespiratory 
 tness in athletes was the major contributor to the better risk score among athletes. 
Cardiorespiratory  tness is strongly related with reduced risk for morbidity and mortality 
as well it mitigates the risk of a second cardiac event. (37, 38) Although our study was not 
powered to investigate the relation between lifelong exercise and secondary events after 
MI, our results indicated that post-MI athletes reported fewer complications (elective PCI or 
recurrent MI) after the MI compared to their sedentary post-MI peers. Alternative bene ts 
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of regular exercise training may relate to an improvement in circulating hormones, 
endothelial progenitor cells, and/or (exercise) preconditioning of the vasculature. (39-41) 
Future research is warranted to elucidate bene ts of exercise training in more detail to 
close the ‘risk factor gap’ in cardiovascular disease. (5) 
Limitations
This study was inherent to some limitations. First, the cross-sectional design of our study 
makes it di  cult to give detailed view of the development of vascular function and 
structure across time and study the impact of a MI. Second, post-MI participants were 
allowed to take their medication before the measurements due to ethical considerations. 
Medication usage might in uence the results of the vasculature. However, since both 
post-MI groups took their medication, we believe it likely that the medication e ect on 
the vasculature did not in uenced our major observations regarding the comparison 
between post-MI groups. Finally, most of our veteran athletes performed primarily lower 
limb endurance exercises, such as running and cycling. Therefore, it is di  cult to translate 
our results to other types of exercise training, especially since resistance exercise training 
may be of special interest in older populations.
CONCLUSION
The present study indicates that some markers of vascular function (i.e. compliance) and 
structure (i.e. femoral IMT and wall:lumen-ratio) were signi cantly better in asymptomatic 
veteran athletes compared to their sedentary peers. Whilst these observations are in line 
with previous reports and emphasise the bene ts of regular exercise, we unexpectedly 
found no di erences in vascular function and structure between veteran post-MI athletes 
and sedentary post-MI controls. Whilst medication use may contribute to these  ndings, 
regular exercise training in veteran post-MI athletes was still associated with signi cantly 
better cardiovascular risk pro le and lower occurrence of secondary events compared to 
sedentary post-MI controls. 
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BACKGROUND
Endurance exercise training induces cardio-protective e ects, but athletes are 
not exempted from a myocardial infarction (MI). Evidence from animal studies 
suggests that exercise training attenuates pathological left ventricular (LV) 
remodelling after MI. We tested the hypothesis that lifelong exercise training is 
related to an attenuated pathological LV remodelling after MI as evidenced by 
a better LV systolic function in veteran athletes compared to sedentary peers.
DESIGN
Cross-sectional study
METHODS
Sixty- ve males (60±6 years) were included and allocated to four groups based 
on lifelong exercise training volumes: 1) athletes (ATH, n=18), 2) post-MI athletes 
(ATH+MI, n=20), 3) sedentary controls (SED, n=13), and 4) post-MI controls 
(SED+MI, n=14). Athletes were lifelong (≥20 years) highly physically active 
(≥30 MET-hours/week), whereas sedentary controls did not meet the exercise 
guidelines (<10 MET-hours/week) for the past 20 years. LV systolic function, 
diastolic function, and wall strain were measured using echocardiography. 
RESULTS
Cardiac enzyme markers (creatine-kinase, creatinine, aspartate transaminase, 
and lactate dehydrogenase) after MI and infarct location did not di er between 
ATH+MI and SED+MI. LV ejection fraction was signi cantly higher in ATH 
(61%±4), ATH+MI (58%±4), and SED (57%±6) compared to SED+MI (51%±7; 
P<0.01). LV circumferential strain was superior in ATH (-19% [-21% to -17%], 
ATH+MI (-16% [-20% to -12%]), and SED [-15% [-18% to -14%] compared to 
SED+MI (-13% [-15% to -8%], P<0.01). Diastolic function parameters did not 
di er across groups.
CONCLUSION
These  ndings suggest that lifelong exercise training may preserve LV systolic 
function and possibly attenuates or minimizes the deleterious e ects of 
pathological post-MI LV remodelling in veteran athletes.
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 Introduction
Regular exercise training leads to a favourable cardiovascular risk factor pro le, (1) improves 
cardiovascular function, (2, 3) and lowers the risk for cardiovascular disease. (4) Despite 
the cardio-protective e ects of exercise training, athletes are not exempted from acute 
coronary syndromes or myocardial infarction. (5, 6)
After a myocardial infarction, the pathological LV remodelling starts within hours. (7, 8) This 
process is characterized by LV wall thinning, LV wall dilatation, reduced ejection fraction, 
and scar formation (7, 8) and eventually leads to impaired LV function. Preventing or reversing 
these maladaptations is of utmost importance to recover and maintain LV function. Animal 
studies demonstrated that exercise training before a myocardial infarction attenuates 
pathological LV remodelling. (9-12) Trained rats had less cardiac damage after ligation of the 
left anterior descending artery and fewer changes in cardiomyocyte function. (9-12) These 
results suggest that a physically active lifestyle before a myocardial infarction may attenuate 
pathological LV remodelling. Con rmation of these  ndings in humans is lacking.
The primary aim of the study was to determine whether lifelong exercise training is related 
to an attenuated pathological left ventricular remodelling after myocardial infarction. For 
this purpose, we collected echocardiographic images in veteran athletes with and without 
a myocardial infarction and sedentary controls with and without a myocardial infarction. 
We hypothesized that veteran athletes will have a better LV systolic function compared to 
their sedentary peers after a myocardial infarction. 
METHODS
Participants
Sixty- ve male participants were included and strati ed into four groups based on 
their lifelong physical activity patterns and cardiac medical history: 1) veteran athletes 
(ATH, n=18), 2) veteran post-MI athletes (ATH+MI, n=20), 3) sedentary controls (SED, 
n=13), and 4) sedentary post-MI controls (SED+MI, n=14). To ensure that pathological LV 
remodelling was stabilized, (7) post-MI participants with a myocardial infarction diagnosis 
>6 months before the start of the study were included. Participants were recruited via local 
newspapers, internet advertisement, and the Nijmegen Exercise Study. (13, 14) Individuals that 
expressed interest in study participation were  rst screened by telephone and received a 
questionnaire regarding their exercise history. Individuals that were more than 20 years 
physically active and performed regular endurance exercise for ≥30 MET-hours per week 
were assigned to the athlete group. Individuals that did not exceed the recommended 
138
Chapter 9
exercise dose of the World Health Organisation (<10 MET-hours/week) with habitual 
physical activities over the past 20 years, were assigned to the sedentary control group. 15) 
Individuals that could not be assigned to the athlete or sedentary group were excluded 
from further study participation. Smokers and diabetics were not included in the study. 
Additional exclusion criteria for the asymptomatic veteran athletes and sedentary 
controls was the use of cardiovascular medication (e.g. antihypertensives, lipid-lowering 
medications). The Local Ethical Committee of the region Arnhem-Nijmegen approved 
the study and all participants gave written consent. All procedures performed in studies 
involving human participants were in accordance with the ethical standards of the 
institutional and/or national research committee and with the 1964 Helsinki declaration 
and its later amendments or comparable ethical standards. Informed consent was obtained 
from all individual participants included in the study.
Study design
Individuals that expressed interest in the study were  rst screened via telephone and 
completed a questionnaire regarding their lifelong exercise history. Participants visited 
our laboratory on two days during this cross-sectional study. On day 1, participants 
were medically screened for eligibility, followed by an incremental maximal cycling test. 
On day  2, participants underwent a comprehensive assessment of LV function using 
transthoracic echocardiography.
Measurements
Medical screening
A physician screened the participants by taking a detailed medical history, physical 
examination, and 12-lead electrocardiogram. Blood samples were obtained, under 
fasting conditions, from an antecubital vein for the analysis of total cholesterol, HDL, LDL, 
triglycerides, glucose, and HbA1c. 
Lifelong physical activity patterns
Lifelong physical activity patterns were queried via an exercise history questionnaire, 
distinguishing  ve age-periods: I) 20-29 years, II) 30-39 years, III) 40-49 years, IV) 50-59 years, 
and V) >60 years. Each category consisted of three queries: 1) type of activity (e.g. running, 
cycling, etc., or nothing), 2) exercise time (hours) per activity per week, and (3) self-
perceived intensity (light, moderate, or vigorous) per activity.  The corresponding metabolic 
equivalent of task (MET) score per exercise activity was determined, (16) and exercise dose 
(MET-hours/week) was calculated by multiplying exercise time with MET scores. Average 
exercise dose was calculated over the last 20 years. For post-MI participants, exercise dose 
before and after the myocardial infarction diagnosis were calculated. 
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Incremental maximal cycling test 
Cardiorespiratory  tness (VO2peak, mLO2/min/kg) was assessed via an incremental 
maximal cycling test. Participants cycled with 60-80 rotations per minute while the 
workload increased with 20 Watt/min for athletes and 10 Watt/min for post-MI controls. 
Heart rate (12 lead-electrocardiogram), oxygen uptake (VO2 [ml/min]), carbon dioxide 
output (VCO2 [ml/min]), and respiratory exchange ratio (RER) were continuously measured 
(CPET, Cosmed v9.1b, Italy). (17) The anaerobic threshold was de ned as a RER above 1.0. (17) 
Participants were verbally encouraged to stimulate maximal exercise performance. Lactate 
concentration (mmol/L) was measured via a capillary blood sample taken one-and-a-half 
minute after exercise cessation (Arkray, type LT-1730, Japan). 
Cardiac medical history
Myocardial infarction characteristics were extracted from medical health records from 
the hospitals at which the patients were admitted. Speci cally, clinical diagnosis of the 
myocardial infarction, cardiac enzyme levels (creatine kinase [CK], creatinine [CREAT], 
aspartate transaminase [ASAT], and lactate dehydrogenase [LDH]), treatment strategy, and 
secondary events were identi ed and used for data analyses. 
Echocardiography
Participants abstained from exercise 24 hours before the echocardiography assessment. 
Two-dimensional Doppler and four-dimensional images were obtained by a single 
experienced cardiologist using an ultrasound system (Vivid E9, General Electric Healthcare, 
Norway) equipped with a M5-S and V4 probe. All measurements were performed according 
to the American Society of Echocardiography (ASE) guidelines (18) with the participant 
in the left lateral recumbent position. Images were taken at end-expiratory breath hold, 
carefully avoiding Valsalva manoeuvre. A continuous three-lead electrocardiogram 
registration was used to detect end-diastole time points (onset of QRS). Data were 
transferred to a workstation for o  ine analysis (EchoPac PC version 113, General Electric 
Healthcare, Norway). Data analysis of the echocardiographic images was performed by an 
independent, blinded expert. 
Left ventricular systolic function. LV ejection fraction (LVEF) was calculated from the LV end-
diastolic volume (LVEDV) and LV end-systolic volume (LVESV) using Simpson’s biplane 
method. Based on ASE guidelines, a LVEF below 52% was de ned as an impaired LVEF. (18) 
Stroke volume was calculated by multiplying the time velocity integral and cross-sectional 
area of the LV out ow tract. Cardiac output was calculated by multiplying stroke volume 
with heart rate. 
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The cardiac index was calculated by dividing cardiac output by body surface area. Body 
surface area was calculated using DuBois’ formula [1]. 
0.007184 ∗ (𝑏𝑏𝑏𝑏𝑏𝑏𝑏𝑏 𝑚𝑚𝑚𝑚𝑚𝑚𝑚𝑚 (𝑘𝑘𝑘𝑘)0.425) ∗ (ℎ𝑒𝑒𝑒𝑒𝑘𝑘ℎ𝑡𝑡 (𝑚𝑚)0.725) [1]
Pulsed-wave tissue Doppler imaging measurements of peak systolic annular tissue 
velocities were obtained at the septal and lateral mitral annulus from apical 4-chamber 
images and an average of both sites is presented.
Left ventricular wall strain. Via the apical window, a 4D full volume R-wave 6 beat gated 
dataset of the LV was acquired. Volume-rate was kept >30 Hz. The dataset was post-
processed using 4D automated LV quanti cation tool available in EchoPac to determine LV 
wall strain. From 4D images, endocardial border detection process was initialized by manual 
alignment of the apex and mitral valves in a long-axis view at both end-diastolic and end-
systolic phase. The endocardial border was automatically generated throughout the cardiac 
cycle. The proposed contour was evaluated via short-axis cut-planes of the 3D volume at 
base, mid, and apex of the LV and cut-planes of the apical 4-, 3-, and 2-chamber views. Only 
major deviations of the expected endocardial borders were operator corrected. Papillary 
muscles and major trabeculae were included in the LV cavity. The epicardial border was 
automatically generated by the software, which created a 3D region of interest of the LV 
wall. Speckle tracking was applied to determine global longitudinal, circumferential, area, 
and radial strain. 
Left ventricular diastolic function. Diastolic function was assessed with LV in ow pulsed-
wave Doppler measurements at the mitral lea et tips, including peak  ow velocity of the 
early rapid  lling wave (E-wave), peak  ow velocity of the late  lling wave due to atrial 
contraction (A-wave) and E/A ratio. Using pulsed-wave tissue Doppler, the tissue velocity of 
the septal and lateral mitral annulus was registered. From these tracings, peak early mitral 
annular tissue velocity (e’-wave), and peak late mitral annular tissue velocity during atrial 
contraction (a’-wave) were measured. The ratio of E-wave and e’ (E/e’) was calculated.
Statistical analysis
Data is reported as mean±standard deviation or median (interquartile range [IQR]). 
Categorical data were analysed using the Fisher’s exact test. Parameters were checked 
for normality using a Shapiro-Wilk test. Skewed variables were loge-transformed before 
analyses. Data that could not be transformed into Gaussian distribution were analysed 
using nonparametric tests. An independent Student’s t or Mann-Whitney-U test were used 
to analyse cardiac enzyme levels between ATH+MI and SED+MI, when appropriate. 
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ANOVA with a Tukey post hoc or Kruskal-Wallis test were performed to determine di erences 
between groups, when appropriate. Statistical analyses were performed using SPSS 21.0. 
software (IBM Corp., Armonk, N.Y., USA). 
RESULTS
Participant characteristics
Participant characteristics of the four study groups are summarized in Table 9.1. Average 
exercise time and dose were signi cantly higher in ATH and ATH+MI compared to SED and 
SED+MI. Exercise time and dose before compared to after myocardial infarction increased 
in the ATH+MI, but did not change in SED+MI. ATH and ATH+MI performed most of the 
time moderate intensity exercise (65%), followed by vigorous intensity exercise (33%) and 
light intensity exercise (2%). VO2peak di ered across groups, with ATH demonstrating the 
highest VO2peak uptake (48.0±8.9 mL/min/kg), followed by ATH+MI (40.9±5.5 mL/min/
kg), SED (31.6±4.8 mL/min/kg) and SED+MI (29.7±6.5 mL/min/kg, P<0.01). VO2peak did 
not di er between SED and SED+MI (Table 9.1).
MEDICAL HISTORY AND MEDICATION USAGE
No di erences were observed between ATH+MI and SED+MI for time between myocardial 
infarction diagnosis and study participation, cardiac enzyme levels (CK, CREAT, ASAT, and 
LDH), and infarct location (Table 9.2). Percutaneous Coronary Intervention (PCI) treatment 
was applied in 94% of the post-MI patients and prevalence did not di er between both 
post-MI groups (Table 9.2). None of the participants received coronary artery bypass 
grafting surgery. 71% of the post-MI participants completed a cardiac rehabilitation 
program and this did not di er between both post-MI groups (Table 9.2). Four post-
MI controls needed an elective PCI and one of them reported a recurrent myocardial 
infarction, whereas none of the post-MI athletes needed an elective PCI or reported a 
recurrent myocardial infarction. Apart from ACE-inhibitors, medication use did not di er 
between post-MI groups (Table 9.2).
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Table 9.1 Participants’ characteristics of the veteran athletes (ATH, n=18), veteran post-MI athletes (ATH+MI, n=20), sedentary controls 
(SED, n=13) and sedentary post-MI controls (SED+MI, n=14). P-value refers to a one-way ANOVA or Kruskal-Wallis test (*).
ATH ATH+MI SED SED+MI P-value
n 18 20 13 14
CHARACTERISTICS
Age (years) 61±7 60±6 58±7 61±6 0.67
Height (cm) 178±8 176±5 181±5 176±5 0.09
Body mass (kg) 74±8 77±7 88±9 1,2 83±14 <0.01
Body Mass Index (kg/m2)* 23.3 (20.6-25.3) 24.5 (23.9-26.0) 26.9 (25.4-27.4) 1 26.6 (22.5-28.8) 1 <0.01
Body Surface Area (m2) 1.91±0.13 1.93±0.11 2.09±0.10 1,2 1.99±0.18 <0.01
Mean arterial pressure (mmHg)* 98 (89-108) 95 (93-100) 105 (94-109) 92 (89-97) 0.14
Resting heart rate (beats/min)* 50 (48-55) 57 (53-62) 61 (54-71) 1 59 (56-60) 1 <0.01
Ever smoked (yes n) 10 (56%) 12 (60%) 11 (85%) 10 (71%) 0.34
Positive family history (yes n) 9 (50%) 15 (75%) 6 (46%) 11 (79%) 0.13
LIFELONG PHYSICAL ACTIVITY PATTERNS
Exercise time
Average (hours/week)* 7.1 (5.8-11.9) 5.7 (4.9-9.4) 0.1 (0.0-0.9) 1,2 0.1 (0.0-0.4) 1,2 <0.001
Pre-MI (hours/week)* 5.7 (4.6-8.6) 0.2 (0.1-1.1) <0.001
Post-MI (hours/week)* 6.2 (5.3-10.3) 0.0 (0.0-0.6) <0.001
Exercise dose
Average (MET-hours/week)* 60 (47-110) 51 (40-93) 1 (0-6) 1,2 0 (0-3) 1,2 <0.001
Pre-MI (MET-hours/week)* 49 (35-84) 1 (0-4) <0.001
Post-MI (MET-hours/week)* 56 (43-93) 0 (0-4) <0.001
INCREMENTAL MAXIMAL CYCLING TEST
VO2peak (mL/min/kg) 48.0±8.9 40.9±5.5 1 31.6±4.8 1,2 29.7±6.5 1,2 <0.01
%VO2peak predicted (%) 164±22 143±16 1 115±19 1,2 111±22 1,2 <0.01
Power Output (Watt) 319±58 274±40 1 213±48 1,2 188±43 1,2 <0.01
Maximal heart rate (beats/min) 165±13 164±15 168±15 147±20 1,2,3 <0.01
Anaerobic threshold (Watt) 224±63 200±44 145±411,2 134±561,2 <0.01
Respiratory Exchange Ratio (VCO2 / VO2) 1.14±0.06 1.12±0.08 1.10±0.07 1.11±0.10 0.56
Lactate (mmol/L)* 11.6 (8.9-12.3) 10.5 (9.2-11.2) 11.3 (10.8-12.4) 11.4 (9.9-12.4) 0.28
FASTING BLOOD LEVELS
HbA1c (mmol/mol)* 35.5 (34.4-39.4) 36.6 (35.5-37.7) 37.2 (35.5-38.8) 37.7 (36.1-39.4) 0.18
Cholesterol (mmol/L) 5.4±0.8 4.5±0.9 1 6.0±0.9 2 4.2±0.7 1,3 <0.01
HDL (mmol/L) 1.8±0.3 1.6±0.4 1.4±0.3 1 1.4±0.2 1 <0.01
LDL (mmol/L) 3.3±0.8 2.6±0.8 1 4.1±0.7 1,2 2.3±0.6 1,3 <0.01
Triglycerides (mmol/L)* 0.9 (0.7-1.3) 0.9 (0.8-1.1) 1.3 (1.0-2.2) 1 1.2 (0.9-1.9) <0.01
Glucose (mmol/L)* 4.6 (4.3-5.0) 4.6 (4.5-5.0) 4.7 (4.4-5.0) 4.7 (4.3-5.0) 0.79
MET: Metabolic Equivalent of Task; HbA1c: Glycated haemoglobin; HDL: High-density lipoprotein; LDL: low-density lipoprotein. 
1Signi cant di erent from ATH; 2Signi cant di erent from ATH+MI; 3Signi cant di erent from SED. 
* non-parametric
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Table 9.2 Cardiac medical history data of the veteran post-MI athletes (ATH+MI, n=20) and sedentary post-MI controls (SED+MI, 
n=14). P-value refers to a Mann-Whitney U (*) or Fisher’s exact test (two-sided).
ATH+MI SED+MI P-value
Post-MI time (years) 5 (3-10) 7 (4-10) 0.73
ENZYME MARKERS¥
CK (u/L) (median [IQR])* n=17 775 (251-2029) n=14 522 (399-2222) 0.45
CREAT (umol/L) (median [IQR])* n=14 87 (78-103) n=13 89 (71-97) 0.49
AST (u/L) (median [IQR])* n=14 38 (26-135) n=12 75 (35-117) 0.44
LDH (u/L) (median [IQR])* n=13 407 (335-638) n=11 382 (176-520) 0.14
INFARCT LOCATION
Anterior (n) 7 (35%) 8 (57%) 0.30
Inferior (n) 7 (35%) 5 (36%) 1.00
Non-STEMI (n) 6 (30%) 1 (7%) 0.20
TREATMENT¥
PCI (n [%]) 18 (95%) 12 (92%)
1.00
Thrombolytic therapy (n [%]) 1 (5%) 1 (8%)
CARDIAC REHABILITATION
Cardiac rehabilitation (n [%]) 13 (65%) 11 (79%) 0.47
POST-MI INCIDENTS
Elective PCI (n) 0 (0%) 4 (29%) 0.022
Recurrent myocardial infarction (n) 0 (0%) 1 (7%) 0.41
MEDICATION
Anticoagulant (n) 19 (95%) 14 (100%) 1.00
Anti-platelet (n) 18 (90%) 12 (86%) 1.00
Vitamin K antagonist (n) 1 (5%) 2 (14%) 0.56
Antihypertensives (n) 14 (70%) 13 (93%) 0.20
ACE-inhibitor (n) 5 (25%) 9 (64%) 0.035
AT2-antagonist (n) 3 (15%) 3 (21%) 0.67
Beta-blocker (n) 8 (40%) 10 (71%) 0.09
Diuretic (n) 1 (5%) 3 (21%) 0.28
CCB (n) 1 (5%) 0 (0%) 1.00
Antihyperlipidemic agents (n) 16 (80%) 14 (100%) 0.13
Statins (n) 16 (80%) 14 (100%) 0.13
¥Based on a sub sample; hospital data were not available. MI: myocardial infarction; PCI: Percutaneous coronary intervention; CK: 
Creatine kinase; CREAT: Creatinine; ASAT: Aspartate transaminase; LDH: Lactate dehydrogenase; NON-STEMI: non-ST elevation 
myocardial infarction; ACE: angiotensin converting enzyme; AT: angiotensin; CCB: calcium channel blocker.
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ECHOCARDIOGRAPHY
Left ventricular systolic function
Due to a low-quality echocardiogram, LVESV, and LVEDV of two ATH and two ATH+MI could 
not be determined and were not included in the statistical analyses. LVESV was signi cantly 
lower in ATH (38 mL [32 to 50]) and SED (39 mL [32 to 44]) compared to SED+MI (50 mL [44 
to 69]) (P<0.01), but did not di er compared to ATH+MI (47 mL [42 to 52], P>0.10). LVEF was 
signi cantly higher in ATH (61% [57 to 62]), ATH+MI (59% [56 to 60]), and SED (58% [52 to 
63]) compared to SED+MI (51% [47 to 55], P<0.01, Figure 9.1). Two (10%) ATH+MI vs. eight 
(57%) SED+MI demonstrated an impaired LVEF (P<0.01). Stroke volume was signi cantly 
higher in ATH (83 mL [73 to 102] compared to SED (71 mL [60 to 79]) and SED+MI (68 mL 
[57 to 82], P<0.05), but stroke volume did not di er between ATH+MI (82 mL [68 to 97]) and 
ATH, SED, and SED+MI (P>0.10). Cardiac output, cardiac index, and peak systolic annular 
tissue velocity did not di er across groups (Table 9.3).
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Figure 9.1 Individual and average values of A) left ventricular end systolic volume (LVESV) and B) left 
ventricular ejection fraction (LVEF) of the veteran athletes (ATH, circles), veteran post-MI athletes 
(ATH+MI, squares), sedentary controls (SED, triangles), and sedentary post-MI controls (SED+MI, 
diamonds). LVESV was signi cantly lower in ATH and SED compared to SED+MI (P<0.01), but did 
not di er compared to ATH+MI (P>0.10). LVEF was signi cantly higher in ATH, ATH+MI, and SED 
compared to SED+MI (P<0.01). Group averages are reported as median and interquartile range.
Left ventricular wall strain
LV longitudinal strain did not di er between ATH+MI (-13% [-18 to -10]), SED (-12% [-15 
to -11]), and SED+MI (-11% [-15 to -6], P>0.05), but LV longitudinal strain was superior (i.e. 
more negative strain) in ATH (-16% [-18 to -14]) compared to SED+MI (Figure 9.2¸P<0.05). 
LV circumferential strain was superior in ATH (-19% [-21 to -17], ATH+MI (-16% [-20 to -12]), 
and SED [-15% [-18 to -14] compared to SED+MI (-13% [-15 to -8], P<0.01). LV area strain 
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was superior in ATH  (-31% [-34 to -26]) and ATH+MI (-26% [-33 to -21]) compared to SED+MI 
(-20% [-26 to -13], P<0.05), whereas LV area strain did not di er between SED (-26% [-29 to 
-22]) and the other three groups (Figure 9.2, P>0.05). LV radial strain did not di er between 
ATH+MI (37% [30 to 52]), SED (38% [31 to 45]), and SED+MI (33% [24 to 38], P>0.05), but 
LV radial strain was superior in ATH (47% [38 to 55]) compared to SED+MI (Figure 9.2, 
P<0.01). LV longitudinal, circumferential, area, and radial strain did not di er between ATH 
and ATH+MI (P>0.10). LV circumferential strain was superior in SED compared to SED+MI 
(P<0.05).
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Figure 9.2 Individual and average values of A) LV longitudinal strain, B) circumferential 
strain, C) area strain, and D) radial strain of the of the veteran athletes (ATH, 
circles), veteran post-MI athletes (ATH+MI, squares), sedentary controls (SED, 
triangles), and sedentary post-MI controls (SED+MI, diamonds). LV longitudinal 
strain did not di er between ATH+MI, SED, and SED+MI, but LV longitudinal 
strain was superior (i.e. more negative strain) in ATH compared to SED+MI. 
LV circumferential strain was superior in ATH, ATH+MI, and SED compared to 
SED+MI. LV area strain was superior in ATH and ATH+MI compared to SED+MI, 
whereas LV area strain did not di er between SED and the other three groups. 
LV radial strain did not di er between ATH+MI, SED, and SED+MI, but LV radial 
strain was superior in ATH compared to SED+MI. Group averages are reported as 
median and interquartile range.
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Left ventricular diastolic function
All diastolic function parameters (i.e. LVEDV, E-wave, A-wave, E/A ratio, e’ LV, a’ LV, and E/e’ 
ratio) did not di er across groups (Table 9.3).
Table 9.3 Left ventricular systolic and diastolic function of the veteran athletes (ATH, n=18), veteran post-MI athletes 
(ATH+MI, n=20), sedentary controls (SED, n=13) and sedentary post-MI controls (SED+MI, n=14). P-value refers to a 
one-way ANOVA. Kruskal-Wallis. or Mann-Whitney U test.
ATH ATH+MI SED SED+MI P-value
SYSTOLIC FUNCTION
SV (mL) * 83 (73-102) 82 (68-97) 71 (60-79) 1 68 (57-82) 1 0.045
CO (L/min) * 4.3 (3.7-5.8) 4.7 (3.9-5.5) 4.4 (4.1-6.1) 3.6 (3.4-5.1) 0.45
CI (L/min/m2) 2.1 (1.9-2.7) 2.4 (2.1-2.8) 2.2 (1.9-2.8) 1.9 (1.7-2.8) 0.33
s’ velocity (cm/s) 9.3±1.9 8.8±1.7 9.0±1.4 8.4±2.0 0.52
DIASTOLIC FUNCTION
LVEDV (mL) 101±24 109±18 92±15 107±22 0.14
E (m/s) 63.0±11.9 62.9±16.3 62.7±15.7 68.9±15.0 0.61
A (m/s) 58 (46-71) 59 (52-75) 69 (54-81) 70 (64-81) 0.07
E/A ratio 1.10 (0.86-1.29) 0.95 (0.80-1.27) 0.92 (0.71-1.18) 0.92 (0.80-1.05) 0.51
e’ LV (cm/s) 11.7 (9.7-13.3) 9.3 (8.0-10.5) 9.0 (7.3-10.5) 10.3 (7.5-12.1) 0.10
a’ LV (cm/s) 11.3±2.5 10.4±1.7 11.2±2.0 10.4±1.2 0.41
E/e’ 5.9 (5.0-6.5) 6.4 (5.6-8.5) 7.5 (6.1-8.7) 6.7 (6.2-7.8) 0.11
SV: Stroke Volume; CO: Cardiac Output; CI: Cardiac Index; s’ velocity: peak systolic annular tissue velocity; LVEDV: left 
ventricular end-diastolic volume; E: peak  ow velocity of the early rapid  lling wave at the mitral lea et tips; A: peak 
 ow velocity of the late  lling wave at the mitral lea et tips; e’ LV: peak annular tissue velocity during early  lling; a’: 
peak annular tissue velocity during late diastolic atrial contraction; E/e’: ratio of peak E velocity with e’. 1Signi cant 
di erent from ATH.
DISCUSSION
The major  nding of this study is that ATH+MI had a better ejection fraction and a superior 
global LV wall strain compared to SED+MI. Ejection fraction and LV wall strain are important 
parameters for LV systolic function. (18) We found no di erences in LV function between ATH 
and ATH+MI, whereas ejection fraction and circumferential strain di ered between SED 
and SED+MI. These  ndings suggest that lifelong exercise training may protect against the 
deleterious e ects of a myocardial infarction and/or minimizes the e ects of pathological 
LV remodelling after a myocardial infarction. 
The magnitude of pathological LV remodelling is dependent on the severity of the 
myocardial infarction, (19) clinical treatment (PCI), (20) medication use, (21, 22) and lifestyle 
changes following diagnosis. (22, 23) We found no di erence in cardiac enzyme levels, PCI 
treatment, infarct location, and medication between both post-MI groups, suggesting that 
myocardial infarction size was comparable between ATH+MI and SED+MI. Interestingly, 
ATH+MI reported an increase in activity levels after the myocardial infarction compared 
to before, whereas the SED+MI did not change their physical activity behaviour. These 
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 ndings suggest that ATH+MI and SED+MI did not di er in clinical characteristics, while 
their habitual exercise levels were signi cantly di erent. 
Before the myocardial infarction, ATH+MI were highly physically active (49 [35-84] MET-
hours/week), whereas SED+MI were inactive (1 [0-4] MET-hours/week). Several studies 
support the hypothesis that exercise training induces preconditioning e ects against 
ischemia and reperfusion, (24, 25) which subsequently protects the myocardium against 
damage produced by ischemia and reperfusion. (9-11) A reduction of the induced cardiac 
damage due to a myocardial infarction will promote the healing process of the infarcted 
area. (9-11) Indeed, evidence from animal studies suggests that exercise training before a 
myocardial infarction attenuates LV remodelling (9-12) and improves cardiac function (9-12) 
after myocardial infarction. Findings from our study support this hypothesis as LV function 
(i.e. LV ejection fraction, global circumferential and area strain) was superior in ATH+MI 
compared to SED+MI. Our results are indicative that lifelong exercise training may improve 
infarct healing after myocardial infarction. 
An alternative explanation for the better LV systolic function in ATH+MI vs. SED+MI may relate 
to their activity patterns after the myocardial infarction. Most cardiovascular professional 
societies recommend post-MI patients to participate in a cardiac rehabilitation program, 
and advise post-MI patients to remain physically active at a low-to-moderate endurance 
intensity level. (22, 26) An early start of cardiac rehabilitation and prolonged exercise training 
(>12 weeks) is associated with larger improvements in LV remodelling. (27) In the present 
study, ATH+MI continued and even increased their high-level physical activity patterns 
after MI, whereas SED+MI maintained their sedentary lifestyle. The VO2peak of our study 
population reinforces these observations; ATH+MI (40.9±5.5 mL/min/kg) showed a 
substantially higher VO2peak uptake compared to SED+MI (29.8±6.1 mL/min/kg). The 
physically active lifestyle after the myocardial infarction may have contributed to the 
better LV systolic function in ATH+MI compared to SED+MI. In fact, these observations may 
represent optimal cardiac rehabilitation, as LV function of ATH+MI was not di erent from 
their non-MI peers. 
In the current study, it is impossible to distinguish the independent e ects of exercise 
training before and after the myocardial infarction on LV function. The combination 
of exercise training before and after myocardial infarction may be superior to exercise 
training before or after myocardial infarction only. One animal study suggests that 
the combination of exercise training before and after myocardial infarction improves 
LV remodelling by reducing the in ammatory response and scar thinning process. (28) 
Another animal study demonstrated that the combination of exercise training before and 
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after myocardial infarction improved infarct healing and post-MI survival compared to no 
exercise training. (11) However, ameliorating e ects on LV remodelling observed in mice 
that either exercised before or after myocardial infarction were lost in mice that exercised 
before and after myocardial infarction. (11) Absence of exercise bene ts on LV remodelling 
in this combination group most likely relate to a very early start of post-MI exercise training 
accompanied with a high exercise intensity (~7 km/day in the  rst week post-MI) in this 
particular study. (11) Indeed, there is evidence that vigorous post-MI exercise may cause 
further deterioration of the injured heart. (29) This negative e ect seems to be dependent 
on the severity of the myocardial infarction and timing of the exercise training.  (30) 
Additional research is warranted to assess the relation between exercise before and after 
the myocardial infarction in relation to LV remodelling in humans.
In contrast to LV systolic function, we did not observe statistical di erences in diastolic 
function between ATH+MI and SED+MI. A potential explanation could relate to the fact 
that not all post-MI patients develop diastolic dysfunction after a myocardial infarction. (31, 32) 
Speci c treatment to improve diastolic function after a myocardial infarction is not available. 
(33) Potentially the long period between myocardial infarction and study participation (Q50: 
6 years [Q25: 3 to Q75: 10]), and adequate cardiac medication use may have contributed 
to the null  ndings of diastolic function between groups. Alternatively, aging has been 
associated with a progressive decline in diastolic function. (34, 35) Aging may lead to an 
impaired diastolic relaxation pattern (34, 35) and lifelong exercise training can only partially 
minimize the age-related decline. (34, 36) Sub analysis of our results, revealed that indeed 
a higher age was associated with a signi cantly lower E/A ratio (r=-0.35; P<0.01) and a 
higher E/e’ ratio (r=0.42; P<0.01). These  ndings indicate that the inclusion of an older 
study population a ected our results on diastolic function. Collectively, the possibility that 
not all post-MI patients develop diastolic dysfunction after a myocardial infarction and 
the in uence of ageing on diastolic function, could have resulted into the null  ndings in 
diastolic function in the present study. 
Clinical implications
In an event when exercise training ‘fails’ to prevent a myocardial infarction, our data 
suggest that veteran athletes may restore and/or maintain their LV systolic function after a 
myocardial infarction. Additional bene ts are improved secondary prevention, since none 
of the ATH+MI had an elective PCI or recurrent myocardial infarction. The information of the 
current study that exercise training improves LV remodelling after myocardial infarction 
might be another reason to motivate sedentary post-MI patients or individuals at risk for 
cardiovascular disease to change their lifestyle and enjoy exercise training to improve 
cardiovascular health. 
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Limitations
Presence of recall bias regarding exercise history of the participants is a potential study 
limitation. To minimize this error, we did not elucidate our study hypothesis to the study 
participants. (37) Moreover, the time span of exercise history was similar between the three 
groups and it is likely that recall bias was similar across groups. This study was cross-
sectional by design and is subject to the inherent limitations of that approach. It is likely 
that over the last 20 years, lifestyle habits have changed, and this might have in uenced 
the risk for a myocardial infarction (e.g. smoking or dietary habits). To avoid such concerns, 
a longitudinal study design is preferred, but such a study would take too much time for 
observations and tests. Ethical concerns would emerge during a longitudinal study design, 
because individuals clearly at risk for myocardial infarction will receive preventative 
measures. These individuals may not endure a myocardial infarction and will have no 
cardiac damage. Consequently, it would be impossible to study the protective e ects 
of lifelong exercise training against pathological LV remodelling after the myocardial 
infarction. Therefore, we used the cross-sectional approach, coupled with great e ort to 
minimize bias. We could not retrieve information about other clinical markers (e.g. ejection 
fraction or troponin I or T) than the reported cardiac enzyme markers, which may have 
limited the comparison of infarct size between post-MI groups. Although previous studies 
demonstrated that the cardiac enzyme markers reported in this study are related to infarct 
size, (38-43) LV ejection fraction directly after the myocardial infarction would have improved 
the comparison between post-MI groups. Unfortunately, these values could not be 
provided by the di erent hospitals of the patients that were included in the present study.
Conclusions
ATH+MI had a better LV systolic function compared to SED+MI and a similar LV systolic 
function compared to ATH. SED+MI had a lower LV ejection fraction and circumferential 
wall strain compared to SED. These  ndings suggest that lifelong exercise training may 
protect against the deleterious e ects of a myocardial infarction and/or minimizes the 
e ects of pathological LV remodelling after a myocardial infarction in veteran athletes. 
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"Those who think they have not time for bodily exercise will sooner or later have to  nd 
time for illness” 
— Edward Stanley, 15th Earl of Derby (1826 – 1893)
 General discussion
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Health bene ts of regular physical activity or exercise training on the cardiovascular system 
are irrefutable. Since the London Transport Workers study by Morris and colleagues in the 
1950s, many studies assessed the e ects of physical activity on changes in (cardiovascular) 
health. However, less is known about the exact dose-response association between 
physical activity and the risk for cardiovascular morbidity/mortality, and which mediators 
contribute to the physical activity-induced improvement of the cardiovascular risk pro le. 
The recent debate on the potential deleterious e ects of extreme forms of exercise on 
cardiovascular health is striking and warrants further exploration. 
National Health and Nutrition Examination Survey (NHANES)
At some parts of the general discussion,  ndings of this thesis are discussed 
and compared to results of the United States National Health and Nutrition 
Examination Survey (NHANES). The NHANES is an ongoing annual survey 
designed to assess the vital status of adults in the U.S. The datasets are available 
to the public and include a wide variety of health factors, such as cardiovascular 
biomarkers (e.g. lipid pro le), physical activity status, and mortality status 
(follow up period till 2011). We pooled the data of the NHANES from 1999 to 
2006 and included 22,511 individuals aged 18 years or older. 
Minimal dose for attenuating cardiovascular risk
Consistent with the vast body of evidence that exercise improves (cardiovascular) health, (1-3) 
our  ndings (chapter 3) demonstrated that exercise is related to a lower prevalence of 
cardiovascular morbidity. Performing exercise at approximately 50% of the recommended 
exercise dose yields signi cant cardiovascular bene ts of 45% and 43% reduction in CVD 
and CVRF prevalence, respectively. Similar bene ts were observed for all-cause mortality 
and cardiovascular mortality in the NHANES (Figure 10.1). These data emphasize that 
exercise is medicine and that even low volumes of this medicine exert great cardiovascular 
health bene ts. Increasing the exercise dose up to the recommended exercise guidelines, 
we observed a further improvement in cardiovascular bene ts with more than 60% 
reduction in CVD/CVRF prevalence. These observations have important clinical and public 
health implications. In 2014, more than 40% of the American population (4) and more than 
30% of the Dutch population (5) did not meet the guidelines for physical activity, despite 
the well-accepted health bene ts of exercise. Lack of time, feeling too tired, and a dislike of 
exercise are examples of perceived personal barriers to participate in physical activity. (6-10) 
The high return of low investment may motivate these sedentary or vulnerable individuals 
to start and continue exercising as an achievable health goal for cardiovascular morbidity 
and mortality bene ts. Lowering physical inactivity on a population-level will also reduce 
the economic burden involved with sedentary-related diseases. (11) 
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Extremes at the exercise continuum
Health e ects of extreme doses of exercise have been described in di erent papers 
with di erent outcomes (Table 10.1). (16-22) Findings of chapter 3 suggest that optimal 
cardiovascular health bene ts were present with 170 to 242 min/wk of moderate intensity 
exercise or 90 to 128 min/wk of vigorous-intensity exercise. Higher exercise doses did not 
further lower CVRFs/CVD prevalence, but seemed to stabilize. This suggests no attenuation 
of the exercise-induced cardiovascular health bene ts at the highest exercise doses in the 
Nijmegen Exercise Study (NES). Our observation that higher exercise doses do not further 
improve cardiovascular health is in agreement with a recent study of Lee and colleagues. (21) 
In a second study of Lee et al., they performed additional analyses to explore the possibility 
that cardiovascular health bene ts may be attenuated in the highest exercise dose 
group.  (18) 
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body mass index.
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Interestingly, the most active individuals within the highest exercise dose group (hazard 
ratio [HR]= 0.80 [95% CI: 0.47 to 1.36) had similar mortality rates as sedentary controls. (18) We 
applied a similar approach to better understand the dose-response association of extreme 
exercise training and cardiovascular morbidity. To ensure adequate statistical power in the 
higher exercise quintiles, we added the NES questionnaires from 2015 and 2016 to the 
original dataset of chapter 3. Individuals of the highest quintile (Q5) were further strati ed 
into tertiles based on their exercise dose and we performed similar statistical analyses as 
within chapter 3. (18)
Metabolic Equivalent of Task
People engage in a variety of exercise activities and at di erent rates of intensity. 
This makes it challenging to quantify how much they exercise during the week. 
Transforming the amount of exercise to a common value signi cantly improves 
the comparability between individuals. (12) The Metabolic Equivalent of Task 
(MET) score is a simple and practical procedure to quantify the energy cost 
of physical activities. (13) MET is an index of the intensity of activities, whereby 
a larger MET value signi es more intense activity. One MET is de ned as the 
amount of oxygen consumed while sitting during rest. (13) The Compendium 
of Physical Activities was developed by Ainsworth et al. (14, 15) and is generally 
accepted to estimate and classify the energy cost of a wide-range of physical 
activities. By multiplying the duration (in minutes or hours) of an activity with 
its MET value, we can calculate the volume or dose of an exercise activity. For 
example, if someone ran at a pace equivalent to 10 METs for 30 minutes per 
week, the exercise dose would be calculated as 10x30 = 300 MET-min/wk.
We found that each tertile of Q5 had a statistically lower risk for cardiovascular morbidity 
compared to the reference group of non-exercisers (Q1, Figure 10.2). Hence, our results 
do not support a U-shaped association between exercise dose and CVD/CVRF morbidity. 
However, it can be argued whether individuals of Q5 (≥1772 MET-min/wk) within the NES 
are truly extremely physically active. A large Taiwanese cohort study (22) and the NHANES 
study reported a similar exercise dose in their highest activity group (2,442 MET-min/wk and 
2,522 MET-min/wk, respectively), and also found no upturn in mortality rates (Table 10.1). 
Arem et al. included a substantially larger study population and created categories that 
re ected multiples of the recommended exercise guidelines. These categories ranged 
from 1 to more than 10 times the recommended exercise levels (≥4,500 MET-min/wk). (20) 
An upper threshold for mortality risk was observed at 3 to 5 times the recommended 
exercise levels (HR=0.58 [0.56 to 0.61]). Although their highest exercise dose group had 
slightly higher HR for mortality (HR=0.71 [95% CI: 0.56 to 0.91]) compared to the optimal 
dose, no evidence of harm was observed. Nonetheless, their results suggest the presence 
an inverse J-shaped curve at 10 times the recommended exercise guidelines. (20) These 
observations suggest that with extreme exercise doses attenuation of the exercise bene ts 
possibly occurs. But also that, at least part of the bene ts associated with regular exercise, 
remain present and is not reversed to a potential health risk.
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Instead of dividing exercise dose into speci c categories, a continuous approach may 
possibly be a better approach to evaluate the dose-dependent fashion. We used a restricted 
cubic spline regression analysis with  ve knots to examine the nature of the dose-response 
relationship between exercise dose and CVD/CVRF. (23) The knots were placed at the 5th, 
27.5th, 50th, 72.5th, and 95th percentile of the exercise dose after excluding the sedentary 
reference group. (24) The restricted cubic spline regression analysis revealed a non-linear 
relation between exercise dose and CVD/CVRFs (Figure 10.3) and indicated that a lifelong 
exercise dose above 5,100 MET-min/wk (i.e. more than 10 times the recommended 
exercise dose) might be associated with attenuated health bene ts of exercise training. 
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Figure 10.2 Odds ratios of cardiovascular diseases (CVD, A) and 
cardiovascular risk factors (CVRFs, B) by average lifelong exercise 
dose of 462 CVD patients, 1,549 CVRFs patients, and 11,510 
controls from the Nijmegen Exercise Study. Participants were 
classi ed into six groups: inactive reference group and quintiles 
of exercise dose, with the last quintile (Q5) further categorized 
into tertiles (Q5-T1, Q5-T2, and Q5-T3). All odds ratios were 
corrected for age, sex, smoking status, level of education (low, 
middle, or high), and CVD family history.
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Figure 10.3 Restricted Cubic Spline Regression analysis of A) cardiovascular 
diseases (CVD) and B) cardiovascular risk factors (CVRFs) by 
average lifelong exercise dose of 462 CVD patients, 1,549 CVRFs 
patients, and 11,510 controls from the Nijmegen Exercise Study. 
During the analysis, we corrected for age, sex, smoking status, 
level of education (low, middle, or high), and CVD family history. 
Data on the x-axis is plotted on log2 scale.
Nonetheless, care should be taken into account when studying the dose-response curve 
at such high exercise doses. The analysis is hindered by the limited number of individuals 
who exercise at such a high exercise level as evidenced by widening of the con dence 
intervals (Figure  10.3). Although it is too premature to conclude that extreme doses 
of exercise increase the risk for cardiovascular events, more exercise may not always be 
better. Considerably larger studies or pooled analyses of several studies will be required to 
determine whether or not cardiovascular risk increases with higher levels of exercise.
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Possible side effects of extreme exercise
Results of chapter 6 may provide some insight whether attenuation of the cardioprotective 
e ects occur at extreme doses. Veteran athletes demonstrated higher levels of advanced 
glycation endproducts (AGEs, i.e. Nε-(carboxymethyl)lysine [CML] and Nε-(carboxyethyl)
lysine [CEL]). An increase in AGEs is suggested to relate with poor health outcomes. (25-27) 
Our  ndings indicated that higher concentrations of CML (r 0.45, P<0.01) and CEL (r 0.36, 
P<0.05) were positively related with higher exercise volume. Possibly these observations 
relate to vigorous exercise intensity over a prolonged period of time, suggesting too much 
exercise with too little recovery. A recent study reinforced our  ndings and found that 
CML concentration was signi cantly higher in non-professional runners (51.9±17.2 ng/ml) 
compared to sedentary controls (35.6±16.2 ng/ml). (28) Furthermore, a signi cant increase 
in CML levels was found directly after completion of a half-marathon (62.6±16.9  ng/
ml), which persisted after a recovery period of 7 days (52.2±16.9 ng/ml). (28) A potential 
explanation could relate to a transient increase in oxidative stress due to vigorous exercise 
intensity, (29, 30) which promotes the formation of AGEs. (31) Once AGEs are formed, they are 
nearly irreversible and accumulate with ageing. (31) The clinical value of high levels of serum 
AGEs, however, is unclear. Through activation with cell surface receptor for AGEs (RAGEs), 
serum AGEs can initiate several responses linked to adverse cardiovascular adaptation, 
such as increased IMT and oxidative stress. High concentrations of circulating AGEs in 
veteran athletes may be a consequence of less accumulation or trapping of AGEs in the 
surrounding (e.g. adipose, endothelial) tissue RAGEs. (32, 33) Possibly prolonged ‘exposure’ to 
high-intensity exercise training accumulates levels of AGEs, but future studies need to be 
undertaken to assess the clinical value of this phenomenon.
Exercise and longevity
Whether extreme doses of exercise attenuate the cardiovascular bene ts is true or not, most 
epidemiological evidence indicates that exercise prolongs the disease-free period.  (34-36) 
Data from the Nijmegen Exercise Study indicates that CVD and CVRFs were diagnosed at a 
later age in exercisers (Q1 to Q5) compared to inactive peers (CVD: +3.3±1.5 years or CVRFs: 
+2.4±0.8 years). Parallels can be drawn to longevity and life expectancy. (35, 37-39) Exercise 
promotes longevity with 2.8 years in former Olympic medallists compared to the general 
population. (35) In the general population, being physically active between 6 to 224 MET-
min/wk was associated with a gain of 1.8 years (95% CI: 1.6 to 2.0) in life expectancy 
compared to inactivity. (36) Whether the improvement in cardiovascular risk is attributable 
to exercise habits, lifestyle habits, superior genetic constitution or a combination of these 
factors remains to be elucidated. (40) Collectively, there is strong evidence that exercise 
reduces cardiovascular and all-cause mortality in elite athletes and the general population.
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Cardiovascular benefits of lifelong exercise training
The bene ts of exercise could relate to various potential mechanisms, including improved 
vascular and cardiac structure/function, (41-44) lower dicarbonyl stress, (45, 46) and better 
cardiovascular risk pro le. (47, 48) Results from chapter 8 indicate that the vascular structure 
of veteran athletes is di erent from their inactive peers, as evidenced by a smaller IMT 
and IMT/diameter ratio in the femoral artery compared to sedentary controls, whilst no 
di erences were observed in the vascular structure of the carotid or brachial artery. Some 
discrepancy is present around the e ects of endurance exercise training on carotid wall 
thickness. (49-55) Some cross-sectional studies found no signi cant di erence in carotid IMT 
between athletes and sedentary controls. (49-52) Similarly, no e ects on carotid IMT were 
observed after 8 to 12 weeks of exercise training in sedentary individuals. (49, 53, 54) However, 
a recent comparison between elite squash players and less active controls revealed a 
signi cant lower carotid IMT. (55) The disparity in outcomes could relate to di erences in 
training intensity (22 hr/wk (55) vs. 3 hr/wk or 5 days/wk (49, 51)), and suggests that changes in 
carotid IMT requires high exercise intensities. 
Studies of the e ects of exercise on IMT in peripheral arteries are sparse. Our observation 
that the femoral artery IMT was lower in veteran athletes compared to sedentary controls 
is in line with previous research. (51, 56, 57) The di erences between the carotid artery IMT and 
femoral artery IMT could relate to the dominant lower limb exercise activities (e.g. running 
and road cycling) performed by our cohort of veteran athletes. Adaptations observed in 
the femoral artery might be a re ection of (local) hemodynamic stimuli, such as increased 
wall stressed due to increased femoral blood  ow during lower limb exercise.  (42,  58) 
Although we did not  nd a lower IMT in the brachial artery in veteran athletes, some 
studies demonstrated that exercise training results in favourable changes in IMT in non-
trained limbs of healthy individuals. (55, 59, 60) Taken into account the e ects of exercise on the 
carotid, brachial, and femoral artery observed in longitudinal studies, these data suggest 
a systemic e ect of exercise training on the arterial wall thickness. Possibly our cross-
sectional design may have hindered the comparability between athletes and sedentary 
controls, as there are many factors (e.g. dietary patterns, heredity) which can potentially 
in uence artery wall thickness. (61)
Interestingly, some, but not all, parameters of vascular function were superior in veteran 
athletes. Veteran athletes had a lower arterial sti ness compared to sedentary controls, 
which is in line with previous work. (62, 63) In contrast, brachial artery endothelial function 
was lower in veteran athletes compared to sedentary controls. Some controversy is 
present about the e ects of regular exercise training on endothelial function measured via 
the  ow-mediated dilation. (64-69) It has been suggested that exercise improves endothelial 
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function in individuals with blunted endothelial function, whereas exercise has little e ect 
on endothelial function in healthy individuals with normal endothelial function. (70) The 
presence of a ‘preserved’ endothelial function after exercise training may be explained 
by the fact that endothelial function re ects an equilibrium between vasodilator and 
vasoconstrictor mechanisms. For example, nitric oxide is an important regulator of basal 
vasodilator tone of the blood vessels, (71) which is believed to inhibit the sympathetic 
vasoconstrictive activity. (72-74) Despite the fact that exercise promotes the bioavailability of 
nitric oxide, (75, 76) athletes do not demonstrate an increase basal limb blood  ow (77) or basal 
coronary  ow. (78) Some evidence suggests that exercise training increases sympathetic 
vasoconstrictor tone, which may be a necessary adaptation to counterbalance the exercise-
induced enhancement in the bioavailability of nitric oxide and vasodilator capacity to 
maintain basal limb blood  ow. (77-79) This interaction may attenuate the conduit artery 
endothelium-dependent responses to elevated shear stress during the  ow-mediated 
dilation, but future studies are needed to explore this hypothesis. 
In contrast to sedentary peers, veteran athletes did not demonstrate a lower endothelial 
function after ischemia-reperfusion exposure (chapter 7). This suggests that athletes 
may have an increased tolerance against ischemia-reperfusion. Although our study was 
limited to the vasoreactivity of the brachial artery, these  ndings may be extrapolated to 
the coronary arteries. In an event when the coronary artery is occluded (i.e. myocardial 
infarction), reperfusion therapy is essential to restore blood  ow to ischemic tissue.  (80) 
However, reperfusion comes with signi cant additional damage (i.e. ischemia-reperfusion 
[IR] injury) to the endothelium, which may limit the prognosis after myocardial infarction. (81) 
Evidence suggests that exercise promotes cardioprotection against ischemia-reperfusion 
and limits the deleterious e ects of ischaemic events on the myocardium.  (82,  83) In 
conjunction with our  ndings of chapter 7, this could contribute to why veteran athletes 
after myocardial infarction demonstrated a preserved left ventricular function compared 
to sedentary controls (chapter 9). Speculating about potential mechanisms for increased 
tolerance against ischemia reperfusion, one could argue that moderate-to-vigorous-
intensity exercise promotes the acute increase of blood  ow and shear stress. (84) This 
improves the nitric oxide bioavailability via an increased activity of endothelial nitric 
oxide synthase and a decreased interaction with reactive oxygen species (ROS). (43, 85, 86) 
An additional e ect of the increased bioavailability of nitric oxide is increased presence 
of endothelial progenitor cells. (85, 87, 88) Endothelial progenitor cells are closely related with 
the vascular capacity to regenerate after injury and restore endothelial function. (87) These 
observations suggest that exercise training may o er cardioprotective e ects, partially 
through increased tolerance against ischemia-reperfusion, which may limit the deleterious 
e ects if ischemic events.
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Additional bene ts of exercise training could relate to lower levels of dicarbonyl stress as 
described in chapter 6. Dicarbonyl stress is abnormal accumulation of α-oxoaldehyde 
(dicarbonyl) metabolites, (89) which are highly reactive and linked to the development of 
diabetes and cardiovascular diseases. (25-27) We described that veteran athletes have lower 
levels of dicarbonyl stress (methylglyoxal [MGO] and 3-deoxyglucose [3-DG]) compared to 
sedentary peers. Whether the observed lower dicarbonyl stress is a re ection of inhibited 
formation or increased detoxi cation of dicarbonyl compounds in veteran athletes remains 
the question. Glucose is most likely one of the most important sources for dicarbonyl 
compounds. (90, 91) Exercise improves insulin sensitivity (92) and thereby lowers blood glucose 
levels, which may inhibit the formation of dicarbonyl components. (91) Alternatively, exercise 
might enhance the glyoxalase system, which lowers dicarbonyl stress. (25, 45, 93) The activity 
of the glyoxalase system depends on concentrations of reduced glutathione (GSH). (25, 93) 
Biosynthesis of GSH is heavily dependent of the antioxidant response element-nuclear 
respiratory factor (ARE-Nrf) pathway. Animal and human studies demonstrated that an 
acute bout of swimming or moderate intensity endurance exercise training upregulates 
the ARE-Nrf pathway and GSH biosynthesis. (45) This led to the hypothesis that exercise 
training enhances the glyoxalase system, which may lower levels of dicarbonyl stress. 
Physically active individuals have a favourable cardiovascular risk pro le compared to 
sedentary controls. (47, 48) In this thesis, we demonstrated that veteran (post-MI) athletes 
had a higher cardiorespiratory  tness and favourable lipid pro le compared to sedentary 
(post-MI) controls, whereas no di erences in blood pressure were observed (chapter 8). 
The Framingham Risk Score (FRS) did not di er between veteran athletes and sedentary 
controls, which may suggest that the FRS might not be the best method to evaluate 
cardiovascular risk in physically active individuals or that the bene ts of exercise cannot 
fully be explained by cardiovascular risk factors. The recently developed lifetime risk 
score (LRS) (94) demonstrated that veteran athletes have a lower cardiovascular risk pro le 
compared to sedentary peers. The discrepancy between FRS and LTR could relate to the 
inclusion of cardiorespiratory  tness in the LTR. Indeed, veteran athletes had a higher 
cardiorespiratory  tness compared to sedentary controls. As indicated in previous studies, 
cardiorespiratory  tness is strongly related with reduced risk for morbidity and mortality, 
independent from traditional CV risk factors (such as included in the FRS). (95, 96) Possibly the 
LTR better re ects cardiovascular risk in physically active individuals. 
While the dose-response association between exercise and morbidity/mortality risk has 
been studied extensively, less is known about the dose-response association between 
exercise dose and cardiovascular risk factors. Therefore, we compared cardiovascular risk 
factors across leisure time moderate-to-vigorous intensity physical activity (MVPA) quintiles 
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Adequate cardiovascular risk assessment is important in primary prevention strategies. 
Conventional measures such as the Body Mass Index (BMI) and waist circumference (WC) 
are popular parameters to estimate an individual’s cardiovascular risk (97, 98). Although an 
increase in BMI or WC is generally associated with an increased CVD risk (98-100), a signi cant 
number of at-risk patients are not detected via these risk factors. (101) A potential explanation 
could relate to the fact that BMI cannot distinguish between adipose tissue and lean body 
mass. (102-106) In contrast, WC is a good predictor for abdominal adipose tissue, (107, 108) but to 
what extent WC depends on body size remains unclear. (109, 110) Novel body indices, such as 
A Body Shape Index (ABSI, greater fraction of abdominal adipose tissue), Body Roundness 
Index, (111) or ultrasound derived parameters (chapter 5) could improve CV risk strati cation 
in the general population. In chapter 4, we found that the body roundness index showed 
very promising results to detect CVD and nearly outperformed the BMI as discriminator for 
CVD/CVRF. This indicates that body roundness index may be a better method to evaluate 
Table 10.2 Association of various cardiovascular risk factors and moderate-to-vigorous physical activity dose in the National Health and 
Nutrition Examination Survey. 
Dose-response association
Sedentary Active P-value Q1 Q2 Q3 Q4 Q5
GLUCOSE METABOLISM
HOMA-IR 4.2±6.7 3.2±4.6 <0.01 3.4±4.0 3.4±5.7 3.3±4.6 3.2±4.9 2.8±3.3
2-hr glucose (OGTT)  mmol/L) 7.28±3.60 6.18±2.41 <0.01 6.49±2.49 6.59±2.64 6.06±2.29 5.96±2.48 5.87±2.10
LIPID PROFILE
Total cholesterol (mmol/L) 5.23±1.14 5.08±1.12 <0.01 5.19±1.13 5.15±1.12 5.13±1.17 5.08±1.12 4.87±1.06
HDL-Cholesterol (mmol/L) 1.36±0.42 1.39±0.41 <0.01 1.39±0.42 1.39±0.40 1.39±0.41 1.40±0.41 1.38±0.40
LDL-cholesterol (mmol/L) 3.09±0.94 2.99±0.94 <0.01 3.05±0.90 3.01±0.89 3.02±0.97 2.99±1.01 2.86±0.91
Triglyceride (mmol/L) 1.76±1.42 1.55±1.42 <0.01 1.69±1.78 1.58±1.12 1.58±1.38 1.47±0.96 1.42±1.70
Apolipoprotein (B) (g/L) 1.04±0.29 0.98±0.28 <0.01 1.03±0.29 0.98±0.27 1.00±0.30 0.97±0.25 0.93±0.26
INFLAMMATORY MARKERS
Fibrinogen (g/L) 3.91±0.87 3.65±0.78 <0.01 3.75±0.82 3.69±0.82 3.61±0.77 3.62±0.71 3.78±0.83
C-reactive protein(mg/dL) 0.58±1.08 0.40±0.79 <0.01 0.49±0.84 0.45±0.94 0.39±0.73 0.36±0.68 0.31±0.73
BLOOD PRESSURE PROFILE
Diastolic pressure (mmHg) 69±15 69±13 0.44 69±14 69±14 70±13 69±13 69±12
Systolic pressure (mmHg) 128±23 122±19 <0.01 123±20 123±20 123±19 122±18 120±17
using the NHANES database (Table 10.2). Physically active individuals had a better glucose 
metabolism (lower HOMA-IR and lower glucose levels) and a more favourable lipid pro le 
(lower LDL, triglyceride and Apo-B levels, but higher HDL levels) compared to sedentary 
controls (Table 10.2). Systolic blood pressure was lower in the active group and diastolic 
blood pressure did not di er between both groups (Table 10.2). In general, there was an 
inverse relation between exercise and cardiovascular risk factors, which suggests more 
exercise leads to a more favourable the cardiovascular risk pro le. 
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Body mass (BM) did not di er across increasing exercise dose quintiles (βz-BM: 0.003, 95% 
CI: -0.004 to 0.011; P=0.41). In contrast, a dose-dependent reduction in BMI (βz-BMI: -0.054, 
95% CI: -0.061 to -0.047; P<0.01), WC (βz-WC: -0.075, 95% CI: -0.082 to -0.067; P<0.01), body 
roundness index (βz-BRI: -0.109, 95% CI: -0.117 to -0.102; P<0.01), and ABSI (βz-ABSI: -0.120, 
95% CI: -0.127 to -0.112; P<0.01) was observed with increasing exercise doses. These body 
indices relate to body fat, and therefore these results indicate that exercise has a larger 
e ect on body fat rather than on BM. Dual Energy X-ray Absorptiometry (DXA)-measured 
trunk fat reinforces this observation, as evidenced by the di erence in percentage trunk 
fat between the inactive reference group (35%±9.3) and Q5 (28%±9.5). There seems to be 
an inverse dose-dependent relation between percentage trunk fat and MVPA quintiles 
(βz-TF:  -0.120, 95% CI: -0.128 to -0.113; P<0.01, Figure 10.4). A growing body of evidence 
suggests that instead of evaluating BM, visceral adipose tissue (VAT) is a better re ection 
of health status. (112) Increase in VAT is strongly related with dyslipidaemia and insulin 
resistance, whereas a reduction in VAT improves cardiovascular and metabolic risk. (113-115)
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Figure 10.4 Associations between the dose (MET-min/wk) of leisure time moderate-to-vigorous intensity 
physical activity (MVPA) and several body indices in the National Health and Nutrition 
Examination Survey (NHANES) database. BM: body mass; BMI: body mass index; WC: waist 
circumference; BRI: body roundness index; ABSI: a body shape index; TF: percentage trunk fat. 
Standardized z-scores were used to make comparison across the six parameters of interest 
possible. P-value refers to linear regression analysis. 
cardiovascular risk in physically active individuals. To evaluate the dose-response relation 
between various CVD risk indicators (i.e. body mass, BMI, WC, body roundness index, ABSI, 
and trunk fat) and exercise doses, we performed additional analyses using the NHANES 
database (Figure 10.4). 
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Implications of the studies and future perspectives
The studies conducted in this thesis mainly focussed on the association between lifelong 
exercise training and occurrence of cardiovascular events as well as cardiovascular 
adaptations. Work derived from this thesis contributes to a better understanding of the 
dose-dependent fashion on how exercise attenuates the risk for CVD or CVRFs. Low 
doses of exercise training result in a markedly lower risk for CVD. This information can 
help to motivate sedentary individuals to start moving. Increasing the exercise dose 
further improves CVD risk until a threshold is reached, thereafter exercise does not yield 
signi cant additional bene ts. Although much of the discussion regarding deleterious 
e ects of exercise is often hijacked by de nitive media-grabbing statements, de nitive 
prove is absent. Athletes and professional athletes live longer compared to sedentary 
controls. More important to realize is the fact that the problem of our Western society is 
not too much exercise, but too little exercise. It is well-known that physical inactivity is one 
of the biggest contributors to various chronic diseases. Still, a large group of individuals 
remains physically inactive, making physical inactivity one of the biggest health problems 
in the world. Future directions would be to implement personalized exercise programs 
to motivate individuals to start moving. These personalized programs could integrate 
wearable with immediate feedback capabilities, so a person can track its own progress. 
Findings of the studies presented in this thesis add to the big puzzle of the exercise bene ts 
on the cardiovascular system. Veteran athletes demonstrated an increased tolerance 
against ischemia-reperfusion and veteran post-MI athletes had a better left ventricular 
function compared to sedentary peers. Secondary events were less prominent in veteran 
post-MI athletes compared to sedentary post-MI controls. This indicates that when 
exercise ‘fails’ to protect against cardiovascular events, physically active individuals still 
bene t from their physically active lifestyle by minimising the functional consequences 
of exposure to a harmful stimulus (e.g. myocardial infarction). Novel cardiovascular risk 
assessment methods, such as the lifetime risk score, may better predict future events in 
physically active individuals. Moreover, re nement of our understanding in the dose-
response associations between cardiovascular markers and the exercise continuum is 
warranted. Throughout this thesis, we did not compare potential di erences in the e ects 
of exercise on the cardiovascular system between males and females. In future research it 
is important to evaluate the potential cardiovascular di erences in exercise responses on 
the cardiovascular system in males vs. females. 
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"The purpose of a storyteller is not to tell you how to think, but to give you questions to 
think upon"
— Hoid (The Way of Kings)
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Summary
Cardiovascular diseases (CVD) are probably as old as mankind and are the leading global 
cause of death. In Chapter 1 we provided an overvie w of the historical work regarding 
the bene cial e ects of regular physical activity or exercise training on CVD risk. Some 
recent studies suggested that extreme volumes of exercise may increase CVD risk. This 
hypothesis warrants further exploration and therefore we explored the e ects of lifelong 
exercise training on cardiovascular health. In Chapter 2 we discussed the relation between 
training volumes and longevity, and whether a U-shape would appropriately re ect this 
association. Given the abundant evidence of superior life expectancy in amateur and 
professional athletes, we could not support this hypothesis. In line with these observations, 
results of Chapter 3 revealed that performing exercise below the recommended exercise 
guidelines yields signi cant health bene ts. Optimal cardiovascular health bene ts were 
present with 170 to 242 min/wk of moderate intensity exercise or 90 to 128 min/wk of 
vigorous-intensity exercise. Higher exercise doses did not yield additional cardiovascular 
bene ts. Most importantly, we could not  nd an increased risk for cardiovascular morbidity 
and therefore our results do not support a U-shaped association between exercise and 
cardiovascular morbidity. 
Traditional measures, such as the body mass index (BMI) and waist circumference (WC), are 
often used to assess cardiovascular risk. In Chapter 4, we evaluated whether novel body 
indices (a body shape index [ABSI] and body roundness index [BRI]) can detect CVD, and 
whether these measures are superior to the body mass index and waist circumference. Our 
 ndings indicated that the prevalence of CVD and CVD risk factors signi cantly increased 
across increasing quintiles for ABSI, BRI, BMI, and WC. However, after adjusting for age, sex, 
and smoking only BRI, BMI, and WC could detect CVD or CVD risk factors and not ABSI. In 
contrast to ABSI, the capacity of the BRI to ‘model’ the human body shape gave an adequate 
impression of the cardiovascular health status, but was not superior to BMI or WC. 
In Chapter 5, we investigated whether compound strain imaging, a technique which 
showed to enable di erentiation between  brous and  bro-atheromatous plaques 
in patient with severe stenosis, can also be applied to measure the local arterial wall 
deformation in subjects with non-stenotic arteries. Furthermore, we compared whether 
strain parameters obtained with compound strain imaging provided incremental 
discriminative power to di erentiate between controls and patients with a history of CVD 
compared to traditional measures of vascular health (i.e. distensibility, central pulse wave 
velocity, and intima-media thickness). We found that a higher strain was associated with 
a higher distensibility and lower central pulse wave velocity. Whilst distensibility, strain, 
and central pulse wave velocity did not signi cantly di er between groups, the intima-
media thickness was signi cantly lower in controls compared to CVD patients. The intima-
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media thickness was able to identify CVD patients, whereas the other measurements did 
not detect any di erences between controls and CVD patients. These results suggest that 
compound strain imaging is a feasible technique to use in non-stenotic arteries, but does 
not seem to provide additional discriminative power to traditional measures of vascular 
health to detect CVD. To understand the e ect of exercise training on cardiovascular 
parameters beyond traditional cardiovascular risk factors (e.g. cholesterol, blood pressure, 
etc.), we also conducted a series of cross-sectional comparisons between veteran athletes 
and sedentary controls. 
High levels of dicarbonyl stress and advanced glycation endproducts (AGEs) relate to poor 
cardiovascular health and increased CVD risk. Exercise training is known to lower the CVD 
risk. In Chapter 6 we assessed whether veteran athletes have lower levels of dicarbonyl 
stress and AGEs compared to sedentary controls. We found that veteran athletes had lower 
levels of dicarbonyl stress (MGO and 3DG) and MGO-derived AGEs (MG-H1) compared to 
sedentary controls. Remarkably, veteran athletes had higher levels of AGEs (CML and CEL) 
compared to sedentary controls. The underlying mechanism and (clinical) relevance of 
higher CML and CEL concentrations among these veteran athletes is unclear and warrants 
further exploration. 
Reperfusion is essential for the survival of ischemic tissue, but causes additional damage 
to the endothelium (ischemia-reperfusion [IR] injury). Ischemic preconditioning (IPC) refers 
to short repetitive episodes of ischemia that can protect against IR, but the e  cacy of IPC 
attenuates with ageing. In Chapter 7, we explored whether lifelong exercise training 
attenuates endothelial IR in the brachial artery and maintains IPC e  cacy in veteran 
athletes. We found that brachial artery endothelial function decreases after forearm IR in 
older sedentary individuals. In marked contrast to the sedentary individuals, we found 
that endothelial function did not decrease after IR in veteran athletes. IPC did not a ect 
endothelial function after ischemia-reperfusion, independently from training in older 
men. These data suggest that lifelong exercise training protects against the detrimental 
e ects of ischemia reperfusion on endothelial function.
Despite athletes have a lower cardiovascular risk compared to sedentary peers, they are 
not exempted from cardiac events (i.e. myocardial infarction [MI]). The presence of a MI 
is associated with increased cardiovascular risk and attenuated cardiovascular function. 
In Chapter 8, we tested the hypothesis that lifelong exercise training in post-MI athletes, 
similar as in healthy controls, is associated with a superior peripheral vascular function 
and structure compared to a sedentary lifestyle in post-MI individuals. We found that 
some markers of vascular function (arterial sti ness) and structure (femoral intima-media 
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thickness) were signi cantly better in asymptomatic veteran athletes compared to their 
sedentary peers. However, we found no di erences in vascular function or structure 
between veteran post-MI athletes and sedentary post-MI controls, which may be a 
consequence of pharmaceutical strategies. Interestingly, veteran post-MI athletes reported 
no secondary cardiovascular events, which contrasts the eight events that occurred in the 
sedentary post-MI controls. 
Evidence from animal studies suggests that exercise training attenuates pathological 
left ventricular (LV) remodelling after myocardial infarction. In Chapter 9, we tested the 
hypothesis that lifelong exercise training is related to a better LV systolic function in veteran 
post-MI athletes compared to sedentary post-MI controls. We found no di erences in LV 
function between asymptomatic veteran athletes and veteran post-MI athletes, whereas 
ejection fraction and LV circumferential wall strain di ered between asymptomatic 
sedentary controls and sedentary post-MI controls. These  ndings may suggest lifelong 
exercise relates to a maintained LV systolic function and suggest that lifelong exercise 
training protects against the deleterious e ects of a MI and/or minimizes the e ects of 
pathological LV remodelling after MI in veteran athletes.
Chapter 10 summarizes, discusses, and explain the  ndings of the studies presented in 
this thesis. Additionally, we compared our data to observations of the American National 
Health and Survey Examination Survey to place the  ndings in a broader perspective. 
"Everything should be made as simple as possible, but not simpler"
— Albert Einstein (1879-1955)
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Samenvatting
Hart- en vaatziekten zijn de belangrijkste doodsoorzaak in de westerse wereld. In 
hoofdstuk 1 zijn verschillende studies beschreven die de gunstige e ecten van bewegen 
en sporten op het risico van hart- en vaatziekten hebben onderzocht. Verreweg de meeste 
onderzoeken hebben aangetoond dat regelmatig sporten en/of bewegen het risico op 
het krijgen van hart- en vaatziekten signi cant laat afnemen. Er zijn echter enkele recente 
studies die suggereren dat sporters die ruim boven de 'norm gezond bewegen' 1 trainen, 
een even groot of zelfs groter risico hebben om vroegtijdig te overlijden aan hart- en 
vaatziekten ten opzichte van niet-sportende personen. Deze bevinding is opmerkelijk 
en daarom hebben we de associatie tussen levenslang sporten en/of bewegen en de 
ontwikkeling van hartvaatziekten in dit proefschrift nader onderzocht. 
In hoofdstuk 2 reageren we op een studie die suggereert dat te veel sporten het risico op 
voortijdig overlijden verhoogt. Er is veel wetenschappelijk bewijs dat zowel amateur- als 
professionele sporters een hogere levensverwachting hebben ten opzichte van mensen die 
geen sport beoefenen. De resultaten van hoofdstuk 3 bekrachtigen deze gedachtegang. 
Onze resultaten laten zien dat zelfs sporten en/of bewegen onder de norm gezond 
bewegen aanzienlijke gezondheidsvoordelen oplevert ten opzichte van niet sporten. De 
meest gunstige e ecten vonden wij rondom deze norm, wat betekent dat men tussen de 
170 en 242 min per week op een matige intensief niveau moet bewegen. Ook sporters die 
ruim boven de norm trainen hadden een lager risico op hart- en vaatziekten ten opzichte 
van niet-sportende personen. Onze studie verwerpt daarmee de hypothese dat te veel 
sporten het risico op hart- en vaatziekten verhoogt.
Om het risicopro el op hart- en vaatziekten te beoordelen wordt regelmatig gebruik 
gemaakt van traditionele lichaamsmaten, zoals de Body Mass Index (BMI) en buikomvang. 
In hoofdstuk 4 hebben we onderzocht of nieuwe lichaamsmaten, zoals 'A Body Shape 
Index' (ABSI) en 'Body Roundness Index' (BRI), beter hartpatiënten kunnen identi ceren 
ten opzichte van de BMI en buikomvang. Onze resultaten laten zien dat alle vier de maten 
een positieve associatie hadden met hart- en vaatziekten en deze patiënten goed konden 
identi ceren. Echter, wanneer we rekening hielden met leeftijd, geslacht en roken, konden 
alleen de BRI, BMI, en buikomvang hartpatiënten identi ceren en de ABSI niet meer. 
In hoofdstuk 5 hebben we een nieuwe echogra sche techniek onderzocht om te bepalen 
of deze beter in staat is hartpatiënten te identi ceren dan traditionele echogra sche 
technieken. De nieuwe echogra sche techniek is gebaseerd op de vervorming ('strain') van 
de bloedvatwand door de pulsaties van de bloedstroom als gevolg van de hartslag. Met de 
traditionele echogra sche technieken hebben wij de mate van uitrekbaarheid, elasticiteit 
en de dikte van de bloedvatwand gemeten. De vervorming van de bloedvatwand, mate 
1 Norm Gezond bewegen: minstens vijf dagen per week 30 minuten matig intensief bewegen 
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van uitrekbaarheid en elasticiteit waren niet verschillend tussen hartpatiënten en gezonde 
controles. Alleen de dikte van de bloedvatwand was een goede maat om hartpatiënten 
en gezonde controles van elkaar te onderscheiden. Deze resultaten suggereren dat de 
vervorming van bloedvatwand kan worden gebruikt bij patiënten, maar mogelijk niet veel 
toevoegt aan de identi catie van hartpatiënten. 
Zoals blijkt uit onze bevindingen in hoofdstuk  3, biedt regelmatig bewegen en/of 
sporten geen volledige bescherming tegen hart- en vaatziekten. Een van de belangrijkste 
risicofactoren voor hart- en vaatziekten is aderverkalking. Studies uit de jaren 60 hebben 
aangetoond dat een actieve leefstijl niet beschermt tegen het ontstaan van aderverkalking. 
Desondanks is het risico op het krijgen van hart- en vaatziekten beduidend lager bij actieve 
personen ten opzichte van inactieve controles. De onderliggende mechanismen van de 
gunstige gezondheidse ecten van sporten en/of bewegen zijn nog niet geheel duidelijk. 
Ongeveer 60% van de gunstige e ecten kan worden toeschreven aan traditionele 
risicofactoren, zoals bloeddruk en lichaamsgewicht. Factoren die verantwoordelijk zijn 
voor de overige 40% zijn onbekend, maar volgens recent onderzoek kan een verbetering 
in de structuur en functie van hart en bloedvaten hieraan bijdragen. In de volgende 
onderzoeken hebben we potentiële nieuwe gezondheidse ecten van de sporten 
bestudeerd. 
Een toename in de bloedconcentratie van dicarbonyl stress en Advanced Glycation 
Endproducts (AGEs) verhoogt het risico op hart- en vaatziekten. AGEs zijn versuikerde 
eiwitten en komen in verhoogde concentraties voor bij mensen met diabetes en hart- en 
vaatziekten. In hoofdstuk 6 hebben we onderzocht of sporters van middelbare leeftijd 
en ouder minder dicarbonyl stress en AGEs hebben in vergelijking met niet-sportende 
personen. Onze resultaten laten zien dat de sporters inderdaad minder dicarbonyl stress 
hadden. Echter, vonden we een onverwacht resultaat; de bloedconcentratie AGEs was 
hoger bij sporters ten opzichte van de niet-sporters. Het onderliggende mechanisme 
waarom deze AGEs hoger zijn bij sporters is niet bekend en meer onderzoek is nodig om 
de (klinische) relevantie hiervan te ontrafelen. 
In de situatie dat een bloedvat is afgesloten (bijvoorbeeld een hartinfarct), is het belangrijk 
dat het bloedvat zo snel mogelijk weer wordt opengemaakt. Het omliggende weefsel 
kan dan weer worden voorzien van zuurstof. Dit wordt reperfusie genoemd. Echter, als 
een bloedvat open wordt gemaakt ontstaat er extra schade aan de binnenste laag van 
de bloedvaten (de zogenoemde endotheellaag). Dit wordt ischemie-reperfusie (IR) 
schade genoemd. IR-schade verslechtert de prognose van de patiënt en veel onderzoek 
is eraan gewijd om deze schade te beperken. Ischemische preconditionering (IPC), korte 
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repetitieve episodes van lokale ischemie, kan mogelijk beschermen tegen IR. Echter, 
met het ouder worden vermindert de e ectiviteit van IPC. In hoofdstuk 7 hebben we 
onderzocht of sporters van middelbare leeftijd en ouder, minder IR-schade ondervinden en 
een verbeterde e ectiviteit van de IPC hebben ten opzichte van niet-sportende personen. 
Onze resultaten laten zien dat bij de controlepersonen de endotheel functie vermindert 
na langdurig afsluiten van de onderarm en dat IPC deze afname niet kon voorkomen. 
Echter, bij de sporters vonden we geen afname van de endotheel functie na langdurige 
afsluiting van de bloedvaten. Deze gegevens suggereren dat sporten beschermt tegen 
de schadelijke gevolgen van een langdurige afsluiting van bloedvaten en IR-schade op de 
endotheel functie.
Het krijgen van een hartinfarct is vaak geassocieerd met een verminderde hart- en 
vaatfunctie. In hoofdstuk 8 hebben we onderzocht of sporters met een hartinfarct een 
betere vaatfunctie en -structuur hebben ten opzichte van niet-sporters met een hartinfarct. 
Onze resultaten tonen aan dat gezonde sporters een verminderde vaatstijfheid en een 
kleinere bloedvatwand hebben ten opzichte van gezonde niet-sporters. We vonden 
echter geen verschillen in vaatfunctie of -structuur tussen sporters en niet-sporters 
met een hartinfarct. Deze bevindingen werden mogelijk beïnvloed door de medicatie 
die in beide patiëntgroepen werd gebruikt. Als toevalsbevinding vonden we dat geen 
enkele sporter met een hartinfarct een tweede keer opgenomen was in het ziekenhuis 
voor hartklachten, terwijl dit wel het geval was bij zes niet-sporters met een hartinfarct. 
Dit suggereert dat het gezondheidse ect van sporten zich niet enkel hoeft te uiten in 
vaatfunctie of -structuur, maar dat het zich ook kan presenteren in een lager risico op 
toekomstige gezondheidsproblemen.
Resultaten van dierstudies doen vermoeden dat de sporten voor en na een hartinfarct 
de mate van blijvende schade van de linkerhartkamer kan verminderen. In hoofdstuk 9 
hebben we onderzocht of sporters van middelbare leeftijd en ouder met een hartinfarct 
een betere linkerkamer functie hebben dan niet-sporters met een hartinfarct. Tussen 
gezonde sporters en sporters met een hartinfarct vonden wij geen verschillen in de 
linkerkamerfunctie. Echter, sporters met een hartinfarct hadden een betere pompfunctie 
en vervorming van de linkerkamerwand ten opzichte van niet-sporters met een 
hartinfarct. Deze bevindingen duiden erop dat sporters, ondanks een hartinfarct, een 
betere linkerkamerfunctie hebben dan niet-sporters. 
Hoofdstuk 10 bespreekt de resultaten van voorgaande hoofdstukken van dit proefschrift 
vanuit een breder perspectief. Daarnaast hebben we onze data vergeleken met een grote 
Amerikaanse studie (National Health and Nutrition Examination Survey [NHANES]) om 
meer inzicht te krijgen in de betekenis van onze resultaten. 
"Do not question the universe, sometimes things just work out"
— William "Bill" Oswalt (Fargo)
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Martijn Maessen werd op 15 januari 1987 geboren te Baexem. Na zijn middelbare 
schoolperiode aan de Philips van Horne college te Weert, startte hij in 2006 met de opleiding 
fysiotherapie aan de hogeschool Zuyd te Heerlen. In het afstudeerjaar van deze opleiding 
heeft hij een half jaar in Australië gestudeerd, gewoond en gewerkt. Aansluitend doorliep 
hij de opleiding Biomedische Wetenschappen aan de Radboud Universiteit Nijmegen, 
welke hij Cum Laude afsloot. Tijdens de eerste onderzoeksstage kwam hij in aanraking 
met de afdeling Integratieve Fysiologie. Onder begeleiding van Dr.  Thijs  Eijsvogels en 
Prof. Dick Thijssen vergeleek hij de verschillen in hartstructuur en -functie tussen sporters 
met en zonder hartinfarct. Deze stage zou uiteindelijk de basis zijn voor zijn fysiologische 
onderzoeken tijdens zijn promotietraject. Tijdens de tweede stage kwam hij in aanraking 
met de afdeling Health Evidence en bestudeerde de cardiovasculaire risicoclassi cering 
van verschillende lichaamsmaten onder begeleiding van Dr.  Femmie  de  Vegt en 
Prof. André Verbeek. In Oktober 2013 startte hij met zijn promotietraject waarbij de focus 
lag op de fysiologische verschillen van het cardiovasculaire systeem tussen sporters en 
niet-sporters met of zonder hartinfarct. Tijdens deze periode werden verschillende studies 
uitgevoerd naar de structuur en functie van hart en bloedvaten bij deze groepen. Later 
verschoof de focus van fysiologisch onderzoek naar epidemiologisch onderzoek. Middels 
de Nijmegen Exercise Study werd de associatie tussen sport en het optreden van hart- en 
vaatziekten bestudeerd. Tijdens zijn periode als promovendus heeft hij meerdere bachelor- 
and masterstudenten begeleid en was betrokken bij onderwijs van Geneeskunde en 
Biomedische Wetenschappen aan de Radboud Unversiteit. Inmiddels is Martijn werkzaam 
bij de afdeling Fysiologie en betrokken bij het INTERREG-project als projectcoördinator/
onderzoeker. Tijdens dit project zal in samenwerking met hartpatiënten, zorgprofessionals, 
en zorgverzekeraars de hartrevalidatie van Nederland en Duitsland in kaart worden 
gebracht.  
"The whole of life is just like watching a movie. Only it is as though you always get in ten 
minutes after the big picture has started, and no-one will tell you the plot, so you have to 
work it out all yourself from the clues"
— Terry Pratchett (Moving Pictures, Discworld)
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Promoveren…hard werken, schrijven, data analyseren, vrije tijd opo eren en op 
familiefeestjes voor de zoveelste keer uitleggen dat het géén afstuderen is. Gelukkig is het 
meer dan dit; het is een echte achtbaan. Op sommige momenten lijkt het niet vooruit te 
gaan, maar op andere momenten vliegt het voorbij. Op dit moment kan ik zeggen dat het 
een fantastische (leer)ervaring was en dat ik er met plezier op terug kijk. Een proefschrift 
a everen en verdedigen is iets wat je niet alleen doet. Zonder de (in)directe hulp van velen 
om mij heen had ik dit traject naar alle waarschijnlijkheid nooit (succesvol) af kunnen 
ronden. In de komende paar zinnen wil ik diegene bedanken voor de steun en bijdrage 
die zij hebben geleverd. 
Allereerst, de personen die hebben deelgenomen aan de verschillende onderzoeken. Mijn 
dank aan al deze enthousiastelingen die altijd klaarstonden om de verschillende metingen 
te ondergaan. Fietsen tot het licht er bijna bij uitging, bloed afstaan, armen laten afknellen 
en vragenlijsten invullen waaraan geen einde leek te komen… niets was te veel voor jullie 
en daarvoor mijn dank. Zonder jullie was het onderzoek nooit mogelijk geweest en hield 
het analyseren en schrijven al snel op. 
Maria, onze eerste ontmoeting was tijdens mijn pre-master jaar. Een van de dia’s van 
je college ging over de London Transportation Study van Prof.  Morris. Dit verhaal had 
mijn interesse voor beweging en hart- en vaatziekten gewekt. Een paar maanden later 
kwamen we elkaar weer tegen tijdens mijn masterstage. Het project dat uiteindelijk 
heeft geleid tot mijn promotietraject. Je enthousiasme voor het onderzoek, de gave om 
overal uitdagingen in te zien (en geen problemen!), de manier waarop jij 'out-of-the-box' 
kunt denken, zijn voor mij een bron van inspiratie. Ondanks jouw overvolle agenda was 
je altijd zeer toegankelijk. Met veel reminders heb ik geprobeerd mezelf iets hoger op 
jouw prioriteitenlijstje te krijgen, als ik graag wilde dat jij naar een nieuwe versie van een 
manuscript keek. Onze werkoverleggen heb ik altijd als prettig ervaren. Het zorgde weer 
voor rust en overzicht in het soms zo chaotische promoveren. Maria, heel erg bedankt dat 
je mij de kans en ondersteuning hebt geboden om bij jou te promoveren. Het was een 
ontzettend gave en leerzame achtbaan.
Dick, in het begin van mijn promotie heb je nog een poging gedaan om mij te leren 
echoën. Ondanks dat ik het een zeer leerzaam traject vond, kwam ik gaandeweg mijn 
promotie erachter dat ik toch meer met 'computerdingen' en datasets heb. Desalniettemin 
heb ik enorm veel van jou geleerd. Jouw manier van schrijven, het reageren op (lastige en 
soms ook wel vervelende) vragen van reviewers, en het gebruik van metaforen hebben mij 
enorm geholpen tijdens mijn promotietraject. Soms heb ik het idee dat jij in je eentje drie 
ploegendiensten draait; het maakt niet uit wanneer ik je een mailtje stuurde binnen zeer 
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korte tijd had ik een (zeer) uitgebreide reactie. Ongeloo ijk hoe jij alles organiseert en voor 
elkaar hebt. Ik kan hier alleen maar bewondering voor hebben. 
Thijs, copromotor, held, en klaagmuur; wat heb ik met ontzettend veel plezier 
samengewerkt met jou (NB…dat doe ik nog steeds!). Je was van begin af aan betrokken 
bij mijn promotietraject. We hadden één keer in de week overleg en dat zorgde ervoor dat 
alles zeer gestroomlijnd liep. Je creatieve gedachtes over de mogelijkheden met de data 
van de Nijmegen Exercise Study leken (lijken…) oneindig. Jammer genoeg kon je mij iets 
minder goed helpen met het programmeren van het algoritme en dat was/is altijd een 
uitdaging voor mij 😉. Je hebt mij nogal vaak horen zeggen “ik moet eerst even nadenken 
over hoe ik dit moet programmeren” of “het algoritme is (een beetje) veranderd, maar het heeft 
nauwelijks invloed op het eindresultaat”. Altijd bleef je positief en die positiviteit heeft enorm 
bijgedragen aan het schrijven van mijn proefschrift. De snelheid en e ectiviteit waarmee 
je mijn stukken hebt gereviseerd waren ongelofelijk en heb ik altijd enorm gewaardeerd 
(ook al hebben wij af-en-toe  ink gediscussieerd). Onlangs ben je samen met Coco de 
trotste ouders geworden van jullie prachtige zoon Floris. Ik wens jullie het allerbeste! In de 
toekomst zullen we nog mooie studies uitvoeren.
Rik, de stille motor van het promotieteam. De nieuwe echomethode staat nog in de 
kinderschoenen en wat hebben we vaak over die data-analyse in Matlab gesproken. 
Het was altijd een 'feest' als we de data opnieuw gingen analyseren. Uiteindelijk hebben 
we toch een mooi stuk opgeschreven. Jouw nuchtere blik op het promoveren was altijd 
lekker relativerend. De treinreizen richting Nijmegen of terug naar het mooie Limburg 
(Roermond/Echt) waren altijd gezellig! Niet alleen praten over werk, maar ook over hoe 
het thuis is, heb ik altijd zeer gewaardeerd. 
André, tijdens mijn stage op de afdeling Health Evidence nam je mij al snel onder je 
vleugels. Je hebt me laten proeven aan de epidemiologie via de Nijmegen Exercise Study. 
Erg bedankt voor jouw (epi)kennis, manier van (kritisch) vragenstellen, gevoel voor humor, 
en corrigerend vermogen qua schrij outen (zowel Nederlands als Duits).
Arie, al tijdens mijn masterstage was je betrokken bij het onderzoeksproject. In de late 
avonduurtjes nog 'snel' even een echo van het hart maken en tussendoor nog even een 
ecg beoordelen. Ondanks dat je een drukbezet persoon bent, maakte je altijd weer tijd. 
Met veel plezier heb ik met jou samengewerkt, dank hiervoor.
Casper, bedankt voor de geboden kans om in samenwerking met jouw laboratorium de 
bloedsamples te analyseren. Dankzij deze samenwerking heb ik mijn wetenschappelijke 
kennis kunnen verbreden en verdiepen in de wondere wereld van AGEs en dicarbonyl 
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stress. Erg bedankt dat je altijd even tijd maakte om te overleggen over de (opmerkelijke) 
resultaten. Het heeft geresulteerd in een prachtige publicatie. 
Promoveren eenzaam? Nee, alles behalve dat! Niet alleen tijdens het werken samen met 
de collega’s lachen (en soms huilen), maar ook erbuiten met de kerstborrels, BBQs, laa es, 
etc. Heerlijk om in zo’n mooi team te mogen promoveren. 
Mister Coen (CB) Bongers, een van onze eerste ontmoetingen was tijdens een onderzoek 
van HM01. En wat voor een onderzoek: op blote voeten sprintend door de 'Mertensgang'! 
Tijdens de Master kwamen we elkaar vaker tegen en vooral tijdens de stage op de afdeling 
Fysiologie, waar we nog een spelletje deden kaarten. Leuk dat we nog steeds bij dezelfde 
afdeling zijn 😊. Met jouw schrijftalent komt het helemaal goed met jouw promotie! Veel 
succes met de laatste loodjes! Rebecca (Becs), wat een vlaag van gezelligheid en humor 
kwam in december 2013 op de afdeling. Je aanstekelijke lach is bewonderenswaardig en 
was altijd welkom tijdens de screening en maximale inspanningstest. Altijd een brede 
lach op het gezicht en alles voor 200% georganiseerd; promoveren is iets wat je erbij doet 
😉. Daarnaast ben je ook nog een superdokter en binnenkort (super)mama! Erg bedankt 
voor al je gezelligheid en succes met je promotie! Dominique (Do), In het begin waren 
we nog even kamergenoten, totdat je naar het andere 'kamp' verhuisde. Altijd  jn dat ik 
een pepermuntje kon krijgen. De Limburgse gezelligheid zit er bij jou wel in (carnaval, 
tentfeesten, etc…). Respect voor de doorzettingskracht om zo een studie van de grond te 
trekken; 10 pallets met ±20,000 pakjes voedingsmiddelen bestickeren is niet niks 😝. Die 
publicaties komen er wel en het komt helemaal goed met jouw promotie. 
Hugo (Boss),  jn om iemand op de afdeling te hebben met wie ik over computerdingen 
kon praten. Ik ben toch wel een beetje blij dat ik jou af en toe nog wat kan 'wijs' maken 
over computers. Jouw kennis en vooral de rust en het concentratievermogen waarmee je 
programmeert en analyseert zijn bewonderenswaardig. Veel succes met het maken van de 
'Loops' en je promotie. Yvonne (Yvon), een mooie aanwinst voor het team 'de Limburgers' 
van de afdeling Fysiologie. Ik zal proberen iets meer te doen aan het 'reduced sitting time' en 
wat vaker te lopen. Veel succes met je prachtige onderzoek en het schrijven van je Matlab/
Excel programmaatjes. Succes met al je (echo)metingen! Vincent (Vincenzo), bedankt 
voor de screeningen die je voor mij hebt gedaan. Je onderzoeken zijn bere-interessant 
en zonder enige twijfel zal jij een prachtig boekje a everen. Succes met je liefdesdriehoek 
tussen, laat maar zeggen, Rome-Nijmegen-Esmée. Esmée (Bakkertje), onlangs gestart 
met je nieuwe uitdaging. Ik ben blij dat je erbij bent gekomen, want je epidemiologische 
kennis is iets waar ik nog vaker een beroep op zal gaan doen. Bedankt voor de tips qua 
broodbakken! Veel succes met je mooie promotieonderzoek. Lando, de spreukmaster, net 
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begonnen op de afdeling en nu al goede ideeën met je bier- en bowlingavond. Dat belooft 
wat tijdens je promotie! Veel succes met al je screeningen en metingen! Eline, ook jij bent 
net begonnen met je ambitieuze project. Al snel veel leuke uitstapjes bedacht, zoals de 
escaperoom en spelletjesavond, dat belooft veel gezelligheid. Als ik nog iets moet weten 
over draadloze koptelefoons weet ik je wel te vinden! Veel succes met je opleiding tot 
huisarts én promotietraject.
Silvie, een diepe buiging voor jouw parate kennis, onderzoeksmentaliteit, kritische houding, 
manier van vragenstellen, en geduld met de CMO. Veel succes met de verschillende mooie 
onderzoeken die je gepland hebt en geniet van het mamaschap! Milène, we waren kort 
roomies en in die korte periode heb ik meerdere malen heel  jn met je kunnen overleggen 
over het onderwijs. Daar heb ik veel van geleerd. Als persoonlijke waterdrager wil ik je 
enorm veel succes wensen met je nieuwe baan bij TNO. We zullen elkaar vast nog eens zien! 
Bregina (Bregien), elke dag sta je (herkenbaar en aanstekelijk) lachend op de werkvloer. 
Voor de proefpersonen was het altijd gezellig als je de echometingen kwam doen. De 
voorkant van dit boekje, die je hebt ontworpen, is prachtig en heel erg bedankt daarvoor! 
Matthijs (Don Juan), tijdens onze promotie hebben we een paar mooie reisjes gemaakt. Je 
hebt mij kennis laten maken met de fotogra e en hebt mij hier veel over kunnen leren. We 
moeten maar snel weer eens ergens naar toegaan om mooie kiekjes te maken! Veel succes 
met je avontuur in Venlo, wat je ook gaat doen (SEH of anesthesiologie): jij komt er wel. 
Pascalle, onze poortwachter (en chocolademonster) van de afdeling. Zeer professioneel 
en altijd bereid om mee te helpen. Erg bedankt voor het inplannen (en veri ëren…) van 
de verschillende afspraken, ik ben erg blij dat je bij het INTERREG-project betrokken bent. 
Marian, bedankt dat je mijn (rommelige) werkplek altijd weet te herorganiseren. Niets is 
 jner om te werken in een opgeruimde kamer. Jos, bedankt voor het meehelpen met de 
verschillende inspanningstesten!
Nathalie, Femke, Tim, Joost, Leonie, Fleur, Madelijn, Linda, Piet, Gerwen, en Thessa 
bedankt voor al jullie gezelligheid op de afdeling! 
Tijdens mijn promotietraject heb ik met verschillende studenten mogen samenwerken. 
Iedereen heel erg bedankt voor zijn/haar bijdrage aan dit boekje. Yaïra (Jaap), jou wil ik 
in het bijzonder bedanken voor je inzet tijdens het IPC/IRI onderzoek. De proefpersonen 
vonden het altijd gezellig met jou en volgens mij vond jij het ook wel gezellig om met hen 
te roddelen praten… 
Maar niet alleen collega’s zijn betrokken bij een promotie… met a eiding van goede 
vrienden wordt promoveren dragelijker. Stijn (Stino), samen zijn we bijna 5 jaar geleden 
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begonnen op de afdeling Fysiologie. Datgene wat wij nu nog steeds doen (koppen-ko  e-
praat) is altijd gezellig. Hopelijk dat jij snel de mogelijkheid geboden krijgt om je mooi 
(sport)onderzoekideeën uit te voeren! Jordi, Randy & Marieke, en Bjorn, we kennen elkaar 
eigenlijk pas net, maar we hebben al een paar prachtige (stap)avonden meegemaakt. 
Volgens mij gaan er nog vele volgen na een potje tennis. Deborah, Geert & Annemieke, 
Jeroen (Frits), Luc, Lisanne, en Dorien altijd als wij bij elkaar zijn is het weer gegarandeerd 
lachen. Met z’n allen een heerlijke vloer eruit tikken, een BBQ’tje met exotische bieren 
proeven, of lekker meeblèren op pinkpop of tijdens de vierdaagse feesten. Die momenten 
zijn ontspannend en zorgen ervoor dat je met frisse moed het promoveren tegenmoet 
gaat. Natasja, dankzij jou heb ik ondertussen de helft van Nederland gezien. De avonden 
samen met Pete waren/zijn legen…dary. Het ging nergens over en het zal nergens over 
gaan en dat is heerlijk. Die Carltondance houden we erin! Marvick (Mav) en Robbert (Bob) 
niets is te gek bij jullie. We kennen elkaar al heel wat jaren en hebben veel meegemaakt. 
Humor staat altijd voorop als we bij elkaar zijn. Er zullen nog vele avonden volgen en ik kijk 
er altijd naar uit! 
Anke! Tijdens de opleiding kwamen we er al achter dat we veel raakvlakken hadden. Het 
is niet gek dat jij vandaag naast me staat: gamen,  lms (Star Wars), “Call me Maybe”, en over 
verschillende beschonken verhalen hebben we regelmatig kunnen lachen. We zijn heel 
lang roomies geweest en dat zijn we gelukkig binnenkort weer (arme Thijs… 😉). Naar 
alle waarschijnlijkheid gaat dit weer nieuwe epische avonturen opleveren. BTW…heb je 
nog steeds een voorraad aan alcoholdoekjes? Veel succes met het afronden van je boek 
over 'the rocks' en je nieuwe baan!
Peter (Pete), sinds de middelbare school hebben we al veel lol gehad. Biertjes proeven, 
door Nederland crossen, (slechte)  lms kijken: altijd leuk! Onze ko  epauzes of lunchbreaks 
duurden altijd iets lang! Ik ken je niet alleen door je eindeloze humor, maar ook als 
'onbewuste Cupido'… Dank hiervoor. Het is een ontzettende eer dat jij vandaag mij ter 
zijde staat. Binnenkort zal jij je prachtige boekje afronden en ik wens je heel veel succes 
met de laatste loodjes. Als je binnenkort weer een biertje in de laaf wilt doen of een poging 
om het record Mario Golf te verbreken, dan weet je mij te vinden.
Lieve Kitty, Rob, Loes & Rene, al een aantal jaren kom ik bij jullie met veel plezier over 
de vloer. Dit betekent veel voor mij en het was altijd leuk als jullie vroegen naar mijn 
onderzoek. Nie t alleen wil ik jullie bedanken voor alle steun tijdens mijn promotie, maar 
ook voor alle verhuizingen en bijkomende verbouwingen, die wij (Maud en ik) hebben 
gehad in de a open jaren (4 keer…!). Loes, extra bedankt voor het lezen van sommige 
stukken in dit proefschrift. 
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Pap & Mam, jullie staan altijd voor mij klaar. Wie had 20 jaar geleden gedacht dat het zo 
zou lopen… De steun en toeverlaat die jullie mij hebben gegeven is meer dan ik hier met 
woorden kan beschrijven. Pap, bedankt dat je mee wilde doen aan het onderzoek! Eric 
en Thijs, broertjes, altijd gezellig als jullie over de vloer komen! Binnenkort weer met zijn 
drieën een biertje drinken! Eric, heel veel succes (en plezier!!) in Nijmegen. Thijs, succes met 
het op-en-neer pendelen van Amsterdam naar Eindhoven en v.v. Het reizen met de trein is 
altijd een feestje (eigen ervaring). Daarnaast alvast veel succes met je nieuwe studie. 
Last, but certainly not least, Maud, sjatje!, door 'Cupido' min of meer aan elkaar gekoppeld 
en dat al 9 jaar. Je hebt altijd achter mij gestaan en je steun tijdens mijn promotietraject 
was (bijna 😉) oneindig. Samen reizen is iets wat ik koester. Ik zeg het misschien niet vaak, 
maar jij bent de allerbelangrijkste voor mij; ik hou van jou en kijk uit naar onze prachtige 
toekomst samen. Kusje!
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Spoon boy: "Do not try and bend the spoon. That's impossible. Instead... only try to realize 
the truth."
Neo: "What truth?"
Spoon boy: "There is no spoon"
— Spoon Boy & Neo (The Matrix)
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TRAINING ACTIVITIES
Courses & Workshop
Radboud lnstitute for Health Sciences lntroduction course for PhD students 2014 1.4
Vascular Function and Angiogenesis in Health and Lifestyle related disease 2014 5.0
Management voor Promovendi 2014 3.0
Advanced Conversation 2014 1.5
BROK (Basiscursus Regelgeving en Organisatie voor Klinisch onderzoekers) 2014 1.4
Scienti c Integrity 2014 0.6
Vena Punctie 2014 0.1
Loopbaanmanagement voor Promovendi 2015 1.5
Seminars & lectures
Radboud Research Rounds 2013-2016 0.1
Prof. Paul Thompson (Lecture: Can [too much] exercise hurt your heart?) 20 15 0.1
Symposia & congresses
European College of Sport Science, Barcelona (Oral) 2013 1.3
Dag van Sport Onderzoek (Oral) 2014 0.3
Nederlandse Fysiologen Vereniging (Poster) 2014 0.6
European College of Sport Science, Malmö (Oral) 2015 1.3
American College of Sport Science, Boston (Poster) 2016 1.3
Nederlandse Fysiologen Vereniging (Oral) 2016 0.6
Other
Vascular Damages meetings 2013-2016 0.2
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2014 1.0
Robert van Wissen (Master Medicine) - In uence of sympathetic activity on periopheral 
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 ness and central arterial sti ness measured by PWV in healthy subjects 2014 1.0
Sylvie-Elise van Schayik (Master Medicine) - Endothelial function in athletes and sedentary 
men with or without a history of myocardial infarction 2014 1.0
Paulien Janssen (Master Medicine) - Di erence in exercise tolerance, measured with the 
maximal oxygen uptake compared to the oxygen uptake e  ciency slope, of physical 
active and inactive people with and without myocardial infarction.
2015 1.0
Nancy Wigman (Master Medicine) - Recovery of systolic and diastolic cardiac function: 
Lifelong physically active and sedentary males with an acute myocardial infarction 2015 1.0
Jesper van den Ouweland (Bachelor Biomedical Sciences) - The role of physical activity in 
ischemic reperfusion injury in elderly men 2015 1.0
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